(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” a “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ~~[ ]~~☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ~~[ ]~~ ☐ No ~~[X]~~ ☒

As of November ~~11, 2020,~~15, 2021, there were ~~89,601,912~~372,814,911 shares of the registrant’s common stock outstanding.

CONSOLIDATED BALANCE SHEETS ~~AS OF SEPTEMBER 30, 2020 AND DECEMBER 31, 2019~~


	September 30,			December 31,			September 30,			December 31,
	2020			2019			2021			2020

ASSETS
Current assets:
Cash	$	1,362,188		$	81,964		$	78,081		$	474,019
Restricted cash		20,000			-			20,000			20,000
Accounts receivable		19,748			149,748			69,806			19,748
Prepaid & other current assets		88,010			41,288			20,946			101,869

Total current assets		1,489,946			273,000			188,833			615,636

Development equipment, net of depreciation of $83,152 and $64,404		19,477			47,554
Intangibles, net of accumulated amortization of $124,133 and $85,608		886,047			924,572
In process R&D, net of accumulated amortization of $206,580 and $0		1,170,620			1,377,200
Development equipment, net of depreciation of $109,419 and $101,810								2,539			10,148
Intangibles, net of accumulated amortization of $175,497 and $136,974								834,683			873,206
In process R&D								1,101,760			1,101,760
Goodwill		21,062,455			21,062,455			21,062,455			21,062,455
Total assets	$	24,628,545		$	23,684,781		$	23,190,270		$	23,663,205

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	2,731,620		$	2,054,983		$	4,406,807		$	2,735,805
Accounts payable to related party		385,002			601,682			425,740			391,631
Contingent consideration		2,625,000			2,625,000
Contingent Consideration								2,625,000			2,625,000
Derivative liability on Notes		776,470			540,517			393,161			777,024
Convertible debt for clinical trial								2,050,409			2,000,000
Convertible debt, net of costs		1,017,868			944,450			1,941,490			1,091,612
Convertible debt, related party, net of costs		330,674			16,474			690,518			297,989
Private placement convertible debt, net of costs		612,892			-
Private placement convertible debt, related party, net of costs		33,274			-
Private Placement convertible note, net of costs								2,073,480			943,586
Private Placement convertible note, related party, net of costs								101,115			67,992
Payroll Protection Plan loan		251,104			-			92,995			251,733

Total current liabilities		8,763,904			6,783,106			14,800,715			11,182,372

Commitments and contingencies (Note 11)
Commitments and contingencies (Note 12)								-

Stockholders’ equity:
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 278,188 and 278,188 shares issued and outstanding		2,782			2,782
Common stock, $.01 par value; 150,000,000 shares authorized; 89,601,912 and 84,069,967 issued and outstanding, respectively		896,020			840,700
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 and 278,188 shares issued and outstanding								-			2,782
Common stock, $.01 par value; 750,000,000 and 150,000,000 shares authorized; 372,564,911 and 90,601,912 issued and outstanding, respectively								3,725,649			906,019
Additional paid-in capital		32,176,064			28,185,599			33,511,091			32,493,086
Accumulated deficit		(18,189,766	)		(12,127,406	)		(29,226,896	)		(21,630,008	)
Total Mateon Therapeutics, Inc stockholders’ equity		14,885,100			16,901,675
Non-controlling interest		979,541			-

Total Oncotelic Therapeutics, Inc. stockholders’ equity								8,009,844			11,771,879
Non-controlling interests								379,711			708,954

Total stockholders’ equity		15,864,641			16,901,675			8,389,555			12,480,833
Total liabilities and stockholders’ equity	$	24,628,545		$	23,684,781		$	23,190,270		$	23,663,205

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

For the Three MONTHS AND NINE MONTHS ended SEPTEMBER 30, ~~2020~~2021 and ~~2019~~2020

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

									Additional					Non-
	Preferred Stock				Common Stock				Paid-in		Accumulated			Controlling		Stockholders’			Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Non controlling			Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Interest		Equity			Shares			Amount			Shares		Amount		Capital			Deficit			Interests			Equity

Balance at January 1, 2020		278,188	$	2,782		84,069,967	$	840,700	$	28,185,599	$	(12,127,406	)	$	-	$	16,901,675
Balance at January 1, 2021																				278,188		$	2,782			90,601,912	$	906,019	$	32,493,086		$	(21,630,008	)	$	708,954		$	12,480,833

Common shares issued upon conversion of Preferred Stock																				(278,188	)		(2,782	)		278,187,847		2,781,878		(2,779,096	)		-			-			-
Common shares issued upon conversion of debt																				-			-			657,200		6,572		203,729			-			-			210,301
Common shares issued upon partial conversion of debt
Common shares issued upon partial conversion of debt, shares
Beneficial Conversion Feature on convertible debt																				-			-			-		-		605,719			-			-			605,719
Warrants issued in connection with private placement																				-			-			-		-		166,575			-			-			166,575
Increase in non-controlling interest from issuance of additional Edgepoint stock																				-			-			-		-		-			-			620,052			620,052
Common shares issued issued in lieu of services
Common shares issued issued in lieu of services, shares
Common shares issued issued for cash
Common shares issued issued for cash, shares
Common shares issued issued in lieu of resctricted stock units
Common shares issued issued in lieu of resctricted stock units, shares
Stock-based compensation		-		-		-		-		2,147,591		-			-		2,147,591
Common shares issued upon partial conversion of debt		-		-		3,962,145		39,621		681,443		-			-		721,064
Net loss		-		-		-		-		-		(4,657,894	)				(4,657,894	)
Balance at March 31, 2020		278,188		2,782		88,032,112		880,321		31,014,633		(16,785,300	)		-		15,112,436

Common shares issued upon partial conversion of debt		-		-		569,800		5,699		97,741		-			-		103,440
Net income		-		-		-		-		-		582,091			-		582,091
Balance as of June 30, 2020		278,188		2,782		88,601,912		886,020		31,112,374		(16,203,209	)		-		15,797,967
															-
Common shares issued upon partial conversion of debt		-		-		1,000,000		10,000		66,065		-			-		76,065
Beneficial conversion feature on convertible debt		-		-		-		-		632,194		-			-		632,194
Warrants issued in connection with private placement		-		-		-		-		365,431		-			-		365,431
Non-controlling interest in Edgepoint		-		-		-		-		-		-			979,541		979,541						-																-
Net loss		-		-		-		-		-		(1,986,557	)		-		(1,986,557	)		-			-			-		-		-			(2,803,080	)		(319,557	)		(3,122,637	)
Balance as of September 30, 2020		278,188	$	2,782		89,601,912	$	896,020	$	32,176,064	$	(18,189,766	)	$	979,541	$	15,864,641
Balance at March 31, 2021																				-			-			369,446,959		3,694,469		30,690,013			(24,433,088	)		1,009,449			10,960,843

Warrants issued in connection with private placement																				-			-			-		-		2,023,552			-			-			2,023,552
Common shares issued in lieu of services																				-			-			250,000		2,500		67,500			-			-			70,000
Common shares issued for cash																										400,000		4,000		95,055									99,055
Net loss																				-			-			-		-		-			(3,231,280	)		(336,737	)		(3,568,017	)
Balance as of June 30, 2021																				-			-			370,096,959	$	3,700,969	$	32,876,120		$	(27,664,368	)		672,712			9,585,433

Common shares issued in lieu of services																				-			-			310,000		3,100		20,541			-			-			23,641
Common shares issued for cash																				-			-			900,000		9,000		100,688			-			-			109,688
Common shares issued in lieu of restricted stock units																				-			-			1,257,952		12,580		213,852			-			-			226,432
Stock Compensation Expense																												-		299,890			-			-			299,890
Net loss																				-			-			-		-		-			(1,562,528	)		(293,001	)		(1,855,529	)
Balance as of September 30, 2021																				-		$	-			372,564,911	$	3,725,649	$	33,511,091		$	(29,226,896	)	$	379,711		$	8,389,555

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.


	For the Nine Months Ended September 30,							For the Nine Months Ended September 30,
	2020			2019				2021				2020
Cash flows from operating activities:
Net loss	$	(6,062,360	)	$	(3,156,299	)		$	(8,546,183	)		$	(6,062,360	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred finance costs		1,591,261			88,479				1,059,525				1,591,261
Amortization of intangible assets		245,104			38,524				38,524				245,104
Stock-based compensation		2,147,591			340,674
Warrants issued in connection with private placement									2,093,552
Common shares issued in lieu of restricted stock units									226,432				-
Stock compensation expense									299,890				2,147,591
Depreciation on development equipment		27,987			-				7,609				27,987
Issuance of common stock in lieu of cash for services		-			418,136
Change in fair value of derivative		(60,504	)		-				(239,278	)			(60,504	)
Loss on debt conversion		254,884			-				27,504				254,884
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		104,071			35,175				30,865				104,071
Accounts payable and accrued expenses		644,329			329,760				1,600,849				644,329
Accounts payable to related party		(216,680	)		569,256				34,109				(216,680	)
Net cash used in operating activities		(1,324,317	)		(1,336,295	)			(3,366,602	)			(1,324,317	)

Cash flows from investing activities:

Cash acquired in mergers		-			182,883
Net cash provided by investing activities		-			182,883

Cash flows from financing activities:
Proceeds from sales of common stock, net of costs		-			83,120
Proceeds from private placement									1,613,200				2,304,541
Proceeds from sales of common stock									118,594				-
Proceeds from convertible debt									300,000				-
Proceeds from convertible notes and short term loans, others									1,020,875				-
Repaid to note holder									(100,000	)			-
Repaid to others									(75,000	)			-
Proceeds from Payroll Protection Plan		250,000			-				92,995				250,000
Proceeds from short term loan, related party		70,000			148,000				-				70,000
Proceeds from private placement		2,304,541			-
Net cash provided by financing activities		2,624,541			1,167,120				2,970,664				2,624,541
Net increase in cash and restricted cash		1,300,224			13,708

Cash - beginning of period		81,964			2,498
Net (decrease) increase in cash									(395,938	)			1,300,224

Cash and restricted cash - beginning of period									494,019				81,964

Cash and restricted cash - end of period	$	1,382,188		$	16,206			$	98,081			$	1,382,188

Supplemental cash flow information:
Non cash investing and financing activities:
Cash paid for:
Interest paid								$	-			$	-
Non-cash investing and financing activities:
Warrants issued in connection with private placement								$	2,190,127			$	-
Common shares issued upon partial conversion of debt	$	900,569		$	-		$	210,301			$	900,569
Recapitalization under reverse merger	$	-		$	3,727,752
Common shares issued in lieu of services								$	93,641			$	-
Common shares issued in lieu of restricted stock units								$	226,432			$	-
Non-cash cost upon sale of common stock								$	39,991			$	-
Beneficial Conversion Feature on convertible debt and restricted common shares	$	-		$	684,140			$	605,719			$	-
Common stock issued for settlement of accounts payable	$	-		$	238,090

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

Oncotelic Therapeutics, Inc. (also d/b/a Mateon Therapeutics, Inc. ~~(f/k/a OXiGENE, Inc.~~) ~~( “~~(“~~Mateon~~Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, ~~and~~ changed its name to Mateon Therapeutics, Inc. in ~~2016. Mateon~~2016, and then Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through ~~both Mateon~~Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc. (“~~Oncotelic~~”), a Delaware corporation ~~and~~(“Oncotelic, Inc.”), PointR Data, Inc. (“PointR”), a Delaware corporation, and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, ~~(Mateon,~~(Oncotelic, Oncotelic Inc., PointR and Edgepoint are collectively called the “Company”). ~~Mateon~~

In February 2020, the Company formed a subsidiary, Edgepoint. Edgepoint is ~~evaluating~~a start-up company that plans to develop technologies and IP related to various unmet issues within the ~~further development of its product candidates OXi4503 as~~pharmaceutical and medical device industries. The Company may spin off Edgepoint into a ~~treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma.~~separate public company.

~~In April 2019, Mateon entered into an Agreement and Plan of Merger with Oncotelic (the “~~~~Merger Agreement~~”), a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications and the Mateon’s wholly-owned subsidiary Oncotelic Acquisition Corporation (the “~~Merger Sub~~~~”). Upon the terms of and subject to the satisfaction of the conditions described in the Merger Agreement, the Merger Sub was merged with and into Oncotelic (the “~~~~Merger~~”), with Oncotelic surviving the Merger as a wholly-owned subsidiary of Mateon. Also, in April 2019, Mateon completed the Merger and Oncotelic became a wholly-owned subsidiary of Mateon. The Merger was treated as a recapitalization and reverse acquisition for financial accounting purposes. Oncotelic is considered the acquirer for accounting purposes, and Mateon’s historical financial statements before the Merger have been replaced with the historical financial statements of Oncotelic prior to the Merger in the financial statements and filings with the Securities and Exchange Commission.

The Company is a cancer immunotherapy company dedicated to the development of first in class self-immunization protocol ~~(SIP™~~(“SIP™”) candidates for difficult to treat cancers. The Company’s proprietary SIP™ candidates offer advantages over other immunotherapies because they do not require extraction of the tumor or isolation of the antigens, and they have the potential for broad-spectrum applicability for multiple cancer types. The Company’s proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The Company aims to translate its unique insights, which span more than three decades of original work using RNA therapeutics, into the deployment of antisense as a RNA therapeutic for diseases which are caused by ~~TGF-beta~~TGF-β overexpression, starting with cancer and expanding to Duchenne Muscular Dystrophy ~~(DMD)~~(“DMD”) and others. ~~Oncotelic’s~~Oncotelic Inc.’s lead product candidate, OT-101, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers. Together, the Company plans to initiate phase 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer, and any other indications that may evolve.

The Company is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma.

The Company is also developing OT-101 for the various epidemics and pandemics, similar to the current ~~corona virus~~coronavirus (“COVID-19”) pandemic. In this connection, ~~Mateon~~the Company entered into an agreement and supplemental agreement with Golden Mountain Partners (“GMP”) for a total of ~~$1.2~~$1.2 million to render services and was paid for the development of OT-101. ~~Such amount was~~The Company recorded $0 and $1.7 million as revenue during the three and nine months ended September 30, 2020 respectively, upon completion of all performance obligations under the agreement. No similar revenues were recorded during the same periods in 2021. Further, Inin June 2020, ~~Mateon~~the Company secured $2$2 million in convertible debt financing ~~evidenced by a one year convertible note (the “~~~~GMP Note”)~~ from GMP to conduct a clinical trial evaluating OT-101 against COVID-19. The Company discontinued enrollment in its OT-101 clinical trial in patients with COVID-19 ~~bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu,~~in June 2021. The trial completed randomization of 32 out of 36 patients planned, on an intent to treat basis. The discontinuance of the ~~Chief Executive Officer of Mateon. The GMP Note liability commenced to accrue when GMP first began to pay for services related~~trial was due to the ~~clinical trial~~continuing rise of more severe variants in Latin America, leading to ~~our third party clinical research organization, upto a maximum~~exhaustion of ~~$2 million. GMP paid an equivalent of approximately $0.5 million to the clinical trial organization~~medical care infrastructure in October 2020. The GMP Note is convertible into Mateon’s Common Stock upon the GMP Note’s maturity one year from the date of the GMP Note, at Mateon’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial.Latin America.

~~In addition, the Company was paid $0.5 million for the completion of a successful in-vivo study of OT-101 in combination with Interluken 2 from Autotelic BIO Co., LTD. (“~~~~ATB~~~~”), an unaffiliated South Korean Company with whom Oncotelic had entered into an agreement in 2018.~~

~~In August 2019, Mateon entered into an Agreement and Plan of Merger (the “~~~~PointR Merger Agreement~~~~”) with PointR. PointR survived the merger as a wholly-owned subsidiary of the Company (the “~~~~PointR Merger~~~~”). The PointR Merger was intended to create a publicly-traded artificial intelligence (“~~AI”) driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. In November 2019, Mateon entered into Amendment No. 1 (the “~~Amendment~~”) to the PointR Merger Agreement with PointR. The Amendment revised certain terms of the PointR Merger Agreement to provide that holders of PointR Common Stock would receive shares of the Mateon’s Series A Preferred Stock in lieu of shares of Mateon’s Common Stock in connection with the PointR Merger, as originally contemplated by the PointR Merger Agreement. The Amendment also revised the terms of the milestones for earn-out payment. Also in November 2019, pursuant to the terms of the PointR Merger Agreement, Mateon completed the PointR Merger.

In February 2020, Mateon formed a subsidiary, Edgepoint. Edgepoint is a start-up company that plans to develop technologies and IP related to various unmet issues within the pharma and medical device industries.

In addition, the Company is developing ~~artemisinin.~~Artemisinin. Artemisinin, purified from a plant Artemisia annua, is able to inhibit TGF-β activity and is able to neutralize SARS-CoV-2 (COVID-19). ~~It has~~The Company’s test results during an in vitro study at Utah State University showed Artemisinin having an EC50 of 0.45 ug/ml, ~~(In an in vitro study Mateon’s test result at Utah State University),~~ and a Safety Index of 140. Artemisinin can target multiple viral threats including COVID-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. Viral replication cannot occur without TGF-β. Artemisinin also has been reported to have antiviral activities against hepatitis B and C viruses, human herpes viruses, HIV-1, influenza virus A, and bovine viral diarrhea virus in the low micromolar range. TGF-β surge and cytokine storm cannot occur without TGF-β. Clinical consequences related to the TGF-β surge, including ARDS and cytokine storm, are suppressed by targeting TGF-β with Artemisinin. ~~This is~~The ARTI-19 Clinical Study (“ARTI-19”) was a global study with India to contribute at least 120 ~~pts~~patients up to the total potential aggregate of 3000 ~~pts.~~patients. ARTI-19 in India ~~is being~~was conducted by Windlas Biotech Private Limited (“Windlas”), business partner in India, as part of ~~Mateon’s~~the plan for the Company’s global effort at deploying ~~ArtiShield~~Pulmoheal^TMacross India, Africa, and Latin America. We continue to evaluate to seek approval, and subsequently launch Pulmoheal^TM, with or without local partners, in various countries within the regions planned. Pulmoheal^TMis a combination of ARTIVeda^TM, our artificial intelligence (“AI”) cough application and our AI post marketing survey (“PMS”).

In January 2021 and subsequently in February 2021, the Company announced preliminary results for ARTIVeda^™, or PulmoHeal^™, which is the Company’s lead Ayurvedic drug against COVID-19 in India and being developed by the Company in partnership with Windlas. These interim results were based on 120 randomized patients across 3 sites in India. The ARTI-19 India trial completed enrollment of 120 randomized individuals, we reported positive topline results in April 2021 and we expect final data as soon as available. Upon completion of the trial results and obtaining regulatory approval for the use in India, it is the Company’s objective to file for Emergency Use Authorization (“EUA”) with regulatory authorities around the world, including India, the United States, the United Kingdom, countries in Africa and Latin America; discussions regarding EUA with several of these authorities have commenced. On August 24, 2021, the Company announced that PulmoHeal^TMand ArtiVeda^TM have proven to be effective against mild and moderate COVID-19 following the preplanned prospective analysis of the Company’s ARTI-19 clinical trial. As previously announced, the study report would serve as the basis for the Company’s regulatory submission for marketing approval of ArtiVeda^TM.

~~In June 2020, Mateon secured $2 million~~ Purchase Agreements with Autotelic Inc., the Company’s Chief Financial Officer (“CFO”), and certain other accredited investors. Under the terms of the Note Purchase Agreements, the Company issued an aggregate of $698,500 (the “Principal Amount”) in debt ~~financing, evidenced~~in the form of unsecured convertible promissory notes (collectively, the “Notes”). The Notes are unsecured, and provide for interest at the rate of 5% per annum. Such Notes were issued against some of the short-term debt due as of June 30, 2021. All amounts outstanding under the Notes become due and payable at such time as determined by the holders of a majority of the Principal Amount of the Notes (the “Majority Holders”), on or after (a) the one year ~~convertible note~~anniversary of the Notes ,or (b) the occurrence of an Event of Default (as defined in the Note Purchase Agreements) (the ~~“GMP Note”~~“Maturity Date”) ~~from GMP,~~. The Company may prepay the Notes at any time. Events of Default under the Notes include, without limitation, (i) failure to ~~conduct~~make payments under the Notes within thirty (30) days of the Maturity Date, (ii) breaches of the Note Purchase Agreement or Notes by the Company which is not cured within thirty (30) days of notice of the breach, (iii) bankruptcy, or (iv) a ~~clinical trial evaluating OT-101 against COVID-19 bearing 2% annual~~change in control of the Company (as defined in the Note Purchase Agreements). The Majority Holders have the right, at any time not more than five days following the Maturity Date, to elect to convert all, and not less than all, of the outstanding accrued and unpaid interest and ~~is personally guaranteed by Dr. Vuong Trieu,~~principal on the Notes. The Notes may be converted, at the election of the Majority Holders, into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a fixed conversion price of $0.18 per share.

In August 2021 the Company, the Company’s Chief Executive Officer (the “CEO”), and GMP executed a letter of ~~Mateon.~~intent and a non-binding term sheet (the “Term Sheet”), which Term Sheet included certain binding terms relating to a standstill agreement and the issuance of a convertible promissory note (as more fully described below). The Term Sheet sets forth the terms and conditions pursuant to which the Company and GMP will, subject to shareholder approval, form a joint venture (the “JV”) with the objective to develop the Company’s product portfolio. Pursuant to the Term Sheet, the Company will contribute its product portfolio to the JV in consideration for a 35% ownership stake in the JV. As set forth above, the Term Sheet sets forth certain binding terms regarding (i) a 45-day standstill by the Company, and (ii) the issuance by the Company of a convertible note for $1.5 million to GMP to fund the OT-101 clinical trial study close-out. Although no assurances can be given, the Company and GMP currently intend to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. The formation of the JV is not assured as the formation of the JV is subject to approval of the Company’s shareholders and the execution of definitive agreements, among other conditions.

In September 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $1.5 million (the “September 2021 Note”), which September 2021 Note is convertible into ~~Mateon’s~~shares of the Company’s Common ~~Stock upon~~Stock.

The September 2021 Note carries an interest rate of 2% per annum and matures on the ~~GMP Note’s maturity~~earlier of (a) the one year ~~from~~anniversary of the date of the ~~GMP Note, at Mateon’s Common Stock price on the date~~Agreement, (b) early termination of ~~conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial.~~

~~The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the~~that certain clinical trial ~~to our third-party clinical research organization, up to~~known as “A Randomized, Controlled, Multi - Center Study of OT-101 in COVID-19 Patients (Investigational New Drug (IND) Application #149299)” (the “Clinical Trial”), or any termination of the Clinical Trial, or (c) the acceleration of the maturity of the September 2021 Note by GMP upon occurrence of an Event of Default (as defined below). The September 2021 Note contains a ~~maximum of $2 million. In October 2020,~~voluntary conversion mechanism whereby GMP may convert the ~~GMP paid approximately $0.5 million to the clinical trial organization, which~~outstanding principal and accrued ~~as a liability to the Company~~interest under the terms of the ~~GMP Note.~~

~~JH Darbie & Co.~~September 2021 Note into shares of Common Stock (the “Conversion Shares”), ~~Inc. Private Placement~~

~~During~~at the ~~three months ended September 30, 2020,~~consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company ~~raised net~~receives a Notice of Conversion (as defined in the September 2021 Note) from GMP. Prepayment of the September 2021 Note may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. The September 2021 Note contains customary events of default (each an “Event of Default”). If an Event of Default occurs, at GMP’s election, the outstanding principal amount of the September 2021 Note, plus accrued but unpaid interest, will become immediately due and payable in cash.

In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “October Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million (the “October 2021 Note”), which October 2021 Note is convertible into shares of the Company’s Common Stock.

The October 2021 Note carries an interest rate of 2% per annum and matures on the earlier of (a) the one-year anniversary of the date of the October Purchase Agreement, or (b) the acceleration of the maturity of the October 2021 Note by GMP upon occurrence of an Event of Default (as defined below). The October 2021 Note contains a voluntary conversion mechanism whereby GMP may convert the outstanding principal and accrued interest under the terms of the October 2021 Note into shares of Common Stock (the “Conversion Shares”), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion (as defined in the October 2021 Note) from GMP. Prepayment of the October 2021 Note may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. The October Note contains customary events of default (each an “Event of Default”). If an Event of Default occurs, at GMP’s election, the outstanding principal amount of the October 2021 Note, plus accrued but unpaid interest, will become immediately due and payable in cash. The October Purchase Agreement requires the Company to use of the proceeds received under the October 2021 Note to support the clinical development of OT-101, including payroll and has been made in continuation of the relationship between the Company and GMP.

In May 2021, the Company entered into an Equity Purchase Agreement (the “EPL”) and Registration Rights Agreement (the “Registration Rights Agreement”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company shall have the right, but not the obligation, to direct Peak One, to purchase up to $10.0 million (the “Maximum Commitment Amount”) in shares of the common stock, par value $0.01 per share (“Common Stock”) in multiple tranches. The Company has directed Peak One, on four occasions, since to the Company entered into the EPL for an aggregate of 1.3 million shares of Common Stock for aggregate cash proceeds of approximately ~~$2.3 million, between July~~ $169,000 and ~~September 2020, through JH Darbie & Co., Inc. (“~~~~JH Darbie~~~~”) through~~incurred a cost of approximately $40,000 against the sale of the Common Stock.

In May 2021, the Company consummated the closing of a private placement transaction whereby, pursuant to a Securities Purchase Agreement (the “Geneva Agreement”) entered into with Geneva Roth Remark (“Geneva”), the Company issued a convertible promissory note in the aggregate principal amount of $203,750 (the “Note 1”). Further on June 28, 2021, the Company issued an additional convertible promissory note in the aggregate principal amount of $103,750 (“Note 2”, and collectively with Note 1, the “Notes”). The Notes are convertible into shares of the Company’s Common Stock. Additional convertible promissory notes may be issued under the Geneva Agreement for up to $1.2 million in the aggregate principal amount subject to further agreement by and between the Company and Geneva.

Extension of Maturity Date for J.H. Darbie Financing Notes & Issuance of Oncotelic Warrants

The Company issued and sold a total of 100 units (“Units”), with each Unit consisting of (i) 25,000 shares of Edgepoint common stock, par value $0.01 per share (“Edgepoint Common Stock”), for a price of ~~$1.00~~$1.00 per share of Edgepoint Common Stock; (ii) one convertible promissory note issued by the Company (the “Unit Note”), convertible into up to 25,000 shares of EdgePoint Common Stock at a conversion price of ~~$1.00~~$1.00 per share, or up to 138,889 shares of the Company’s Common Stock, at a conversion price of ~~$0.18~~$0.18 per share; and (iii) 100,000 warrants, ~~(the “~~~~Warrants~~~~”),~~ consisting of (a) 50,000 warrants to purchase an equivalent number of shares of EdgePoint Common Stock at ~~$1.00~~$1.00 per share (“Edgepoint Warrant”), and (b) 50,000 warrants to purchase an equivalent number of shares of Company Common Stock at ~~$0.20~~$0.20 per share (“~~Mateon~~Oncotelic Warrant”) ~~(the~~(collectively, the “JH Darbie Financing”).

~~The~~In June 2021, the Company ~~incurred $0.4 million~~and the Investors agreed to extend the maturity date of ~~costs associated with~~ the Notes from June 30, 2021, to March 31, 2022. In addition, the Company and JHDarbie identified an error in the Oncotelic Warrants and JH Darbie Financing ofdocuments which ~~$0.3 million was paid as direct placement fees~~intended to ~~JH Darbie, pursuant~~have the investors to ~~that certain Placement Agent Agreement, dated February 25, 2020 (the “~~~~Darbie Placement Agreement~~”). Under the Darbie Placement Agreement, JH Darbie has the right to sell a minimum of 40 Units, as described in Note 6 below, and a maximum of 100 Units on a best-efforts basis. The issuance and sale of the 53 Units in July, August and September 2020 represented the first three tranches of the JH Darbie Financing. JH Darbie also earned the right to 5.3 Units as their fees. For more information on the financing, see Note 6 below.

~~On June 25, 2020, the Company commenced a solicitation of shareholder consents (the “~~~~Consent Solicitation~~~~”), pursuant to a consent solicitation statement (the “~~~~Consent Solicitation Statement~~~~”), to the holders (the “~~~~Stockholders~~~~”) of its Common Stock and Preferred Stock, to approve the following actions:~~

~~(1) changing the name of the Company to “Oncotelic, Inc.” and to changing the Company’s ticker symbol (the “~~~~Name Change~~~~”);~~

~~(2) amending the Company’s Amended and Restated 2015 Equity Incentive Plan (the “~~~~2015 Plan~~~~”) to increase the number~~purchase $50,000 of shares of Common Stock ~~available~~or Edgepoint Common Stock. However, the Company only issued 50,000 Oncotelic Warrants, with an aggregate exercise price of $10,000. The error was corrected by the Company and the Company issued to the Investors an aggregate of 20.0 million additional Oncotelic Warrants, and 2.0 million additional Oncotelic Warrants to J.H. Darbie., as placement agent. Each Investor was entitled to receive 200,000 additional Oncotelic Warrants for each Unit purchased. The issuance ~~from 7.25 million shares to 27.25 million shares, and increasing~~of the ~~maximum number~~additional warrants resulted in the Company recording an expense of ~~stock awards that may be issued~~$2,023,552 in ~~any fiscal year from 500,000 to 1,000,000 shares~~the Company’s statement of operations during the three months ended June 30, 2021. No similar expense was recorded in the same period in 2020.

In September 2021, the Company entered into an exclusive License Agreement (the “~~Plan Amendment~~~~”);~~

~~(3) increasing the authorized number of shares of Common Stock from 150,000,000 to 750,000,000 (the “~~~~Capital Increase~~~~”); and~~

~~(4) amending and restating the certificate of incorporation for the Company (the “~~~~Amended and Restated Certificate~~~~”) to give effect to the Name Change, Capital Increase and forum selection provision.~~

The Stockholders approved the Name Change, the Plan Amendment, the Capital Increase, and the Amended and Restated Certificate. On November 5, 2020, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State for the State of Delaware changing its name from “Mateon Therapeutics, Inc.” to “Oncotelic Therapeutics, Inc.” A notice of corporate action has been filed with the Financial Industry Regulatory Authority (FINRA), requesting approval to change its name and ticker symbol. The Company is still awaiting FINRA’s approval on its notice of corporate action, and upon receipt of acceptance, the Company’s ticker symbol will be changed to reflect the Company’s name change.

~~On August 19, 2020 the Company executed a memorandum of understanding (the “~~~~MOU~~”) with ~~Windlas Biotech Private Limited (~~Autotelic, Inc. (“~~“Windlas~~Autotelic”), pursuant to which Autotelic granted Oncotelic, among other things: (i) the exclusive right and license to certain Autotelic Patents (as defined in the Agreement) and Autotelic Know-How (as defined in the Agreement); and (ii) a right of first refusal to acquire at least a majority of the outstanding capital stock of Autotelic prior to Autotelic entering into any transaction that is a financing collaboration, distribution revenues, earn-outs, sales, out-licensing, purchases, debt, royalties, merger acquisition, change of control, transfer of cash or non-cash assets, disposition of capital stock by way of tender or exchange offer, partnership or any other joint or collaborative venture, research collaboration, material transfer, sponsored research or similar transaction or agreements. In exchange for the rights granted to Oncotelic, Autotelic will be entitled to earn the milestone payments of up to $50 million upon achievement of certain financial, development and commercialization of Artemisinin as a therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19. The development of Artemisinin against COVID-19 is dependent on the successful completion of ARTI-19 clinical trial “Artemisinin Intervention trial against COVID-19”, which is being initiated globally in Africa, India, and South America. Windlas will be our manufacturing partner for the clinical trial batches as well as commercial batches.

On September 1, 2020 the Company executed the final MOU with Windlas regarding the development and commercialization of Artemisinin as therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19.

~~The ARTI-19 trial has been cleared by India~~ regulatory authorities for initiation. The trial is now registered under CTRI and three sites have been selected, their IRB approval obtained, their staffs have been trained into the protocol/EDC. Additional sites will be added as the trial progressed. Enrollment of patients has already commenced for the trial.

~~The Company and Windlas entered into a License, Development and Commercialization Agreement, dated November 10, 2020 (the “~~~~Commercialization Agreement~~~~”), which formalized the terms set forth in the MOU. Pursuant~~milestones. In addition to the ~~Commercialization Agreement, Windlas shall~~milestone payments, Autotelic would be responsible for developing, manufacturing, and supplying Artemisinin within India and eventually expanding worldwide, excluding China, and its territories and the Americas. Windlas will also be responsibleentitled to ~~market Artemisinin and its variants in India. Under the terms~~earn royalties equal to 15% of the ~~Commercialization~~net sales of any products that incorporate the Autotelic Patents or Autotelic Know-How. The Agreement ~~Windlas~~contains representations, warranties and indemnification provisions of each of the ~~Company will evenly split all profits derived from commercialization~~parties thereto that are customary for transactions of ~~Artemisinin within India. For all other territories, which excludes China and its territories and the Americas, the profit-split ratio is to be determined and negotiated on a country-by-country basis.~~this type.

~~Please review Note 12 – Subsequent events for more information on updates since September 30, 2020.~~

The consolidated financial statements include the accounts of ~~Mateon and~~Oncotelic, its wholly owned subsidiaries, Oncotelic Inc. and ~~PointR;~~PointR, and Edgepoint ~~for which there are non-controlling interests.~~our non-controlled interest entity. Intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission including Form 10-Q and Regulation S-X. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly state the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been omitted pursuant to such rules and regulations.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net accumulated losses of approximately ~~$18.2~~ $29.2 million since inception of Oncotelic Inc., as ~~Mateon’s~~the Company’s historical financial statements ~~before~~of the ~~Merger~~Company with Oncotelic Inc. have been replaced with the historical financial statements of Oncotelic ~~prior~~Inc. due to the ~~Merger in the financial statements and filings.~~reverse merger with Oncotelic Inc. The Company ~~also~~ has a negative working capital of ~~$7.3~~ $14.6 million at September 30, ~~2020,~~2021 of which ~~approximately $1.3 million is attributable to assumed negative working capital of Mateon and $2.6~~ $2.6million contingent liability of issuance of common shares of ~~Mateon~~the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR ~~Merger Agreement. The~~merger agreement. In addition, the Company ~~continues to have~~has negative cash flows from operations ~~through~~for the nine months ended September 30, ~~2020.~~2021 of $3.4 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to incur additional losses in the foreseeable future and recognizes the need to raise capital to remain viable. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

The Company’s long-term plans include continued development of its current pipeline of products to generate sufficient revenues, ~~to cover its anticipated expenses,~~either through ~~either~~ technology transfer or product sales, ~~as well as develop AI technologies either directly or through~~to cover its ~~subsidiaries.~~anticipated expenses. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments.

Between ~~April 2019~~July 2020 and ~~December 2019, the Company entered into various securities purchase agreements (each individually, a “~~~~SPA~~~~”, and collectively, the “~~~~SPA~~~~s”) and notes payable (each individual, a “~~~~Note~~~~”, and collectively, the “~~~~Notes~~”), including a SPA and two notes payable with the Company’s CEO. In total, the Company raised a gross total of $2 million through such SPAs and Notes. For more details on the SPAs and the Notes, see Note 5 below.

~~In July 2019, the Company entered into a convertible note purchase agreement with PointR. Such convertible note was converted into shares of Mateon upon the completion of the PointR Merger.~~

~~During the three months ended September 30, 2020,~~March 2021, the Company raised gross proceeds of ~~$2.65~~$5 million, ~~between July and September 2020,~~ through the JH Darbie ~~& Co., Inc. (“~~~~JH Darbie~~~~”).~~Financing. The Company incurred ~~$0.4~~$0.7 million of costs associated with the raise, of which ~~$0.3~~$0.65 million was paid as direct placement fees to JH Darbie. JH Darbie and the Company are parties to a placement agent agreement, dated February 25, 2020 pursuant to which DHJH Darbie ~~has~~had the right to sell a minimum of 40 ~~units, as described in Note 6 below,~~ Units and a maximum of 100 ~~units~~ Units on a best-efforts basis. ~~The issuance and~~Concurrently with the sale of the 53 Units, ~~in July, August and September 2020 represented~~JH Darbie was granted, a warrant, exercisable over a five-year period, to purchase 10% of the ~~first three tranches~~number of Units sold in the JH Darbie Financing. As such, the Company granted 10 Units to JH Darbie ~~also earned~~pursuant to the ~~right~~JH Darbie Placement Agreement.

In addition to ~~5.3 Units as their fees. For more information on~~ the ~~financing, see Note 6 below.~~JH Darbie Financing, the Company raised approximately $0.2 million from the Equity Purchase Agreement with Peak One, $0.3 million from Geneva, an approximately $1.0 million from various bridge financiers, including $0.3 million from Autotelic Inc., a related party and approximately $0.1 million from the Paycheck Protection Plan of 2021 for PointR.

During the nine months ended September 30, 2020, the Company recorded a total of approximately ~~$1.7~~$1.2 million in service revenues from GMP and ~~ATB.~~$0.5 million in licensing milestone revenue from Autotelic BIO (“ATB”), an unrelated party. No similar revenues were recorded during the similar periods in 2021. There are no assurances that the Company would be able to generate revenues for services and/or ~~outlicensing~~out-licensing fees in the near future.

~~During the nine months ended September 30, 2020, the Company’s CEO provided short term funding of $70,000 to the Company.~~

Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for 12 months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates.

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.

As of September 30, ~~2020,~~2021, and December 31, ~~2019,~~2020 the Company held all its cash in ~~banks in the United States of America.~~banks. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of September 30, ~~2020~~2021 and December 31, ~~2019.~~2020, respectively. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes.

~~Prior to the Merger, Oncotelic received Series E Preferred Shares of Adhera Therapeutics, Inc. (“~~~~Adhera~~”) in consideration for the issuance of Oncotelic’s Common Stock under various Securities Purchase Agreements. The Company records its investments in equity securities initially at cost in accordance with Accounting Standards Codification (“~~ASC~~~~”) 321, Investments –Equity Securities (“~~~~ASC 321~~”). The Company subsequently marks the investments to market at each reporting period and, in accordance with Accounting Standard Update (“ASU”) 2016-01, Financial Instruments – (Overall), records the unrealized gains or losses in the Consolidated Statement of Operations. During the three months ended December 31, 2019, the Company evaluated the fair value of the investment based on filings by Adhera, in which Adhera describes their current financial condition including the potential to file for bankruptcy, the Company believed that the long term investment in Adhera was impaired and therefore, determined to write off the entire investment.

Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument should be offset against the associated proceeds in the determination of the instrument’s initial net carrying amount.

Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying condensed balance sheets if related to the issuance of debt or presented as a reduction of Additional Paid in capital if related to the issuance of an equity instrument.

~~The Company applied the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction.~~

The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.

~~Other than the restricted cash of $20,000, the~~The Company did not have any Level 1 or Level 2 assets and liabilities at September 30, 2021 and December 31, 2020.

The derivative liabilities associated with its 2019 ~~convertible note debt /financing~~bridge financing Convertible Notes (see Note 5), consisted of conversion feature derivatives at September 30, 2021 and December 31, 2020, ~~hence~~ are ~~classified as~~ Level 3 fair value measurements.

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2021 and 2020:

	Conversion Feature			September 30, 2021 Conversion Feature			September 30, 2020 Conversion Feature
Balance at December 31, 2019	$	540,517
Balance at January 1, 2021 and 2020				$	777,024		$	540,517
New derivative liability		870,268			-			870,268
Reclassification to additional paid in capital from conversion of debt to common stock		(573,811	)		(144,585	)		(573,811	)
Change in fair value		(60,504	)		(239,278	)		(60,504	)

Balance at September 30, 2020	$	776,470
Balance at September 30, 2021 and 2020				$	393,161		$	776,470

As of September 30, ~~2020,~~2021 and ~~December 31, 2019,~~2020, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a ~~risk free~~risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2021 and 2020:

	September 30, 2020 Key Assumptions for fair value of conversions			Sept. 30, 2021 Key Assumptions for fair value of conversions			Sept. 30, 2020 Key Assumptions for fair value of conversions
Risk free interest		0.13	%		0.05	%		0.13	%
Market price of share	$	0.18		$	0.14		$	0.18
Life of instrument in years		1.56 – 1.85			0.56 - 0.85			1.56 -1.85
Volatility		150.77	%		108.96	%		150.77	%
Dividend yield		0	%		0	%		0	%

When the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the ~~period~~periods ended September 30, 2021 and 2020, respectively, there were no transfers of financial assets or financial liabilities between the hierarchy levels.

As of the closing of the Company’s first three rounds of offering under a private placement memorandum with JH Darbie, the estimated grant date fair value of approximately $0.2 per share associated with the warrants to purchase up to 2,915,000 shares of common stock issued in this offering, or a total of approximately $0.4 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive:

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

	Three and Nine Months Ended September 30,				Three and Nine Months Ended Sept. 30,
	2020		2019		2021		2020

Convertible notes		20,237,084		10,000,000		41,522,204		20,237,084
Stock options		6,130,004		6,145,044		16,594,062		6,130,004
Warrants		18,152,500		19,515,787		42,737,500		18,152,500
Potentially dilutive securities		44,519,588		35,660,831		100,853,766		44,519,588

The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations.

For stock options issued to employees and members of the Board of Directors (the “Board”) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.

Pursuant to ASU 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.

For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital.

The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and nine months ended September 30, ~~2020~~2021 and ~~year ended December 31, 2019,~~2020, there were no0 impairment losses recognized for long-lived assets.

The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, there were no0 impairment losses recognized for intangible assets.

Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach.

The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, there were no0 impairment losses recognized for Goodwill.

We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Consolidated Statement of Operations.

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.”

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“~~OID~~”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event ~~occurs that~~ is not within the entity’s control could or ~~would~~ require net cash settlement, then the contract shall be classified as an asset or a liability.

The Company recognizes revenue in accordance with ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606).

Under ASU 2014-9, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following ~~five-step process:~~five-step: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.

At contract inception, once the contract is determined to be within the scope of ASU 2014-09, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company anticipates generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either ~~(i)~~ upon achievement of certain pre-defined milestones, when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or ~~(ii)~~ upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations.

The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.

Research Service Agreement between GMP and ~~Mateon Therapeutics Inc./~~Oncotelic /Oncotelic Inc. (“~~Mateon~~Oncotelic Entities”).

In February 2020, Oncotelic Inc. and GMP entered into a research and services agreement (the “Agreement”) memorializing their collaborative efforts to develop and test COVID-19 antisense therapeutics. In March 2020, the Company reported the positive anti-viral activity results of OT-101 (the “Product”) in an in vitro antiviral testing performed by an independent laboratory to GMP, at which time, the ~~Mateon~~Oncotelic Entities and GMP entered into a supplement to the Agreement (the “Supplement”) to confirm the inclusion of the Product within the scope of the Agreement, pending positive confirmatory testing against COVID-19. In consideration for the financial support provided by GMP for the research, pursuant to the terms of the Agreement (as amended by the Supplement) GMP was entitled to obtain certain exclusive rights to the use of the Product in the COVID field on a global basis, and an economic interest in the use of the Product in the COVID field including 50/50 profit sharing. GMP paid the Company total fees of ~~$0.3~~$1.2 million ~~during the three months ended March 31, 2020 and $0.9 million during the three months ended June 30, 2020~~ for ~~the services rendered under~~ the Agreement and Supplement ~~respectively.~~during the nine months ended September 30, 2020. The Company also recorded approximately ~~$40~~$40 thousand for reimbursement of actual costs incurred. ~~The Company received the cash for the services rendered during the nine months September 30, 2020.~~

Oncotelic Inc. had entered into a license agreement in February 2018 (the “ATB Agreement”) with ATB. The ATB Agreement licensed the use of OT-101 in combination with Interleukin-2 (the “Combined Product”), and granted to ATB an exclusive license under the Oncotelic Inc. technology to develop, make, have made, use, sell, offer for sale, import and export the Combined Product, and the Combination Product only, in the field, throughout the entire world (excluding the United States of America and Canada) as the territory, on the terms and subject to the conditions of the ATB Agreement. The ATB Agreement requires ATB to be responsible for the development of the Combination Product. Oncotelic Inc. was responsible to provide to ATB the technical know-how and other pertinent information on the development of the Combination Product. ATB paid Oncotelic Inc. a non-refundable milestone payment in consideration for the rights and licenses granted to ATB under the ATB Agreement, and ATB was to pay Oncotelic ~~$500,000~~Inc. $500,000 within sixty days from the successful completion of the in vivo efficacy studies. This payment was made ~~in June 2020~~ after the successful completion of the in-vivo study and, as such, the Company recorded the ~~revenue during the three months ended June 30, 2020.~~revenue. In addition, ATB is to pay ~~Oncotelic:~~Oncotelic Inc.: (i) ~~$500,000~~$500,000 upon ~~Oncotelic’s~~Oncotelic Inc.’s completion of the technology know how and ~~Oncotelic’s~~Oncotelic Inc.’s technical assistance and regulatory consultation to ATB, as determined by the preparation of a Current Good Regulation Practices audit or certification by the Food and Drug Administration, with a mutual goal to obtain marketing approval of the Combined Product developed by ATB in the aforementioned territory; (ii) ~~$1,000,000~~$1,000,000 upon receiving marketing approval of the Combined Product in Japan, China, Brazil, Mexico, Russia, or Korea; and (iii) ~~$2,000,000~~$2,000,000 from receiving marketing approval of the Combined Product in Germany, France, Spain, Italy, or the United Kingdom. ~~For the nine months ended September 30, 2020, the~~The Company recorded ~~$500,000~~$500,000 as revenue under the ATB Agreement for the successful completion of the in-vivo ~~study.~~study during the nine months ended September 30, 2020.

In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

Certain amounts in prior periods may have been reclassified to conform with current period presentation.

In January 2017, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance requires only a one-step quantitative impairment test, whereby a goodwill impairment loss will be measured as the excess of a reporting period unit’s carrying amount over its fair value (not to exceed the total goodwill allocated to that reporting unit). It eliminates Step 2 of the current two-step goodwill impairment test, under which a goodwill impairment loss is measured by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 had no material impact on the Company’s consolidated financial statements and related disclosures.

In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09 became effective on January 1, 2018. The ASU also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company adopted ASU 2015-14 during the ~~nine~~three months ended ~~September 30,~~March 31, 2020 as till then, no revenue was earned by the Company.

In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December 15, 2020. The Company is currently evaluating the potential impact of the ~~Update~~update on its consolidated financial ~~statements~~statements.

All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

~~Mateon~~The Company completed ~~the Merger~~a merger with Oncotelic, which gave rise to Goodwill of ~~$4,879,999.~~$4,879,999. Further, ~~Mateon~~the Company added goodwill of ~~$16,182,456~~ $16,182,456 upon the completion of the ~~Merger~~merger with PointR. In general, the goodwill is tested on an annual impairment date of December 31. However, since both ~~mergers were completed in 2019 and both~~ assets are currently being developed for various cancer and COVID-19 therapies, and the Company is contemplating other collaboration efforts for both products and the other products that the Company owns, the Company does not believe the there are any factors or indications that the goodwill is impaired.

In April 2018, Oncotelic Inc. entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Autotelic Inc., an affiliate company, and Autotelic LLC, an affiliate company, pursuant to which Oncotelic acquired the rights to all intellectual property (“IP”) related to a patented product. As consideration for the Assignment Agreement, Oncotelic Inc. issued 204,798 shares of its Common Stock for a value of ~~$819,191.~~$819,191. The Assignment Agreement also provides that Oncotelic Inc. shall be responsible for all costs related to the IP, including development and maintenance, going forward.

The following table summarizes the balances as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, of the intangible assets acquired, their useful life, and annual amortization:

	September 30, 2020			Remaining Estimated Useful Life (Years)		Sept 30, 2021			Remaining Estimated Useful Life (Years)
Intangible asset – Intellectual Property	$	819,191			18.26	$	819,191			16.25
Intangible asset – Capitalization of license cost		190,989			18.26		190,989			16.25
		1,010,180					1,010,180
Less Accumulated Amortization		(124,133	)				(175,497	)
Total	$	886,047				$	834,683

	December 31, 2019			Remaining Estimated Useful Life (Years)		December 31, 2020			Remaining Estimated Useful Life (Years)
Intangible asset – Intellectual Property	$	819,191			18.68	$	819,191			18.00
Intangible asset – Capitalization of license cost		190,989			18.68		190,989			18.00
		1,010,180					1,010,180
Less Accumulated Amortization		(85,608	)				(136,974	)
Total	$	924,572				$	873,206

Amortization of identifiable intangible assets for the three months ended September 30, 2021 and 2020 was $12,841and ~~2019 was $12,841 and $12,841,~~$12,841, respectively. Amortization of identifiable intangible assets for the nine months ended September 30, 2021 and 2020 was $38,524and ~~2019 was $38,524 and $38,524,~~$38,524, respectively.

The future yearly amortization expense over the next five years and thereafter are as follows:

For the years ended December 31,
For the three months and years ending December 31,			For the three months and years ending December 31,

Remainder of 2020	$	12,841
2021		51,365
Remainder of 2021				$	12,841
2022		51,365			51,365
2023		51,365			51,365
2024		51,365			51,365
2025					51,365
Thereafter		667,746			616,382
	$	886,047		$	834,683

The ~~following table summarizes the balances as of September 30, 2020 of the~~ IPR&D assets were acquired in the PointR acquisition during the ~~three months~~year ended December 31, 2019. ~~The~~Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. ~~No similar balances were present in 2019:~~

~~Amortization~~The balance of ~~identifiable intangible assets for the three months ended~~IPR&D as of September 30, 2021 and December 31, 2020 ~~and 2019~~ was ~~$68,860 and $0, respectively. Amortization of identifiable intangible assets for the nine months ended September 30, 2020 and 2019 was $206,580 and $0, respectively.~~$1,101,760.

~~The future yearly amortization expense over the next five years and thereafter are as follows:~~

	September 30, 2020		December 31, 2019		September 30, 2021		December 31, 2020

Accounts payable	$	2,024,261	$	1,793,033	$	3,360,233	$	1,937,419
Accrued expense		707,359		261,950		1,046,574		798,386
	$	2,731,620	$	2,054,983
Accounts payable and accrued liabilities					$	4,406,807	$	2,735,805

As of September 30, 2021 special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts:

As of December 31, 2020, ~~SPAs with~~ convertible debentures and notes, net of debt discount, consist of the following amounts:

	September 30, 2020		December 31, 2020
Convertible debentures
10% Convertible note payable, due June 12, 2022 – Peak One	$	11,183
10% Convertible note payable, due April 23, 2022 - TFK		33,823		39,065
10% Convertible note payable, due April 23, 2022 – Related Party		10,197		14,256
10% Convertible note payable, due April 23, 2022 – Bridge Investor		51,817		69,848
10% Convertible note payable, due August 6, 2022 – Bridge Investor		163,485		168,421
		270,505		291,590
Fall 2019 Notes
5% Convertible note payable – Stephen Boesch		250,648		213,046
5% Convertible note payable – Related Party		250,477		263,733
5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)		249,997		263,253
5% Convertible note payable – CEO, CTO & CFO		84,268		86,257
5% Convertible note payable – Bridge Investors		172,647		176,722
		1,008,037		1,003,011
Other Debt
Short term debt from CFO				25,000
Short term debt from CEO		70,000		20,000
Other short term debt – Bridge Investor				50,000
				95,000
Total of debentures, notes and other debt	$	1,348,542	$	1,389,601

~~As of December 31, 2019, convertible debentures and notes, net of debt discount, consist of the following amounts:~~

The gross principal balances on the convertible debentures listed above totaled ~~$1,000,000~~$1,000,000 and ~~originally~~ included an initial debt ~~discounts~~discount totaling ~~$800,140,~~$800,140, resulting from the recording of the original issue discount, the related financing costs, the beneficial conversion feature for the intrinsic value of the non-bifurcated conversion option and the restricted shares issued contemporaneously with the convertible notes.

Total amortization expense related to these debt discounts ~~related to the convertible debentures~~ was ~~$611,681~~$110,528 and ~~$88,479~~$611,681 for the nine months ended September 30, ~~2020~~2021, and ~~2019,~~2020, respectively. In addition, during the nine months ended September 30, 2021 and 2020, we recorded additional and accelerated amortization of debt discounts, which was created from the bifurcation of the conversion option related the host hybrid instruments, of ~~$262,556~~$24,491 and $262,556, respectively upon the partial and/or full conversion of debt by Peak One and TFK to shares of the Company’s common stock. The total unamortized debt discount at September 30, 2021 and December 31, 2020, was approximately ~~$321,290.~~$64,452, respectively.

All the above notes issued to Peak One, TFK, our CEO and the bridge investors reached the 180 days ~~prior to~~during the ~~end of the three months~~year ended ~~March~~December 31, 2020. As such, all the note holders had the ability to convert that debt into equity at the variable conversion price of 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument.

As of December 31, ~~2019,~~2020, we had a derivative liability of approximately ~~$541,000.~~ $777,000. The Company decrease the fair value of the derivative liability by approximately $241,000 during the nine months ended September 30, 2021. The Company also extinguished approximately $145,000 of derivative liability following the conversion of certain notes to the Company’s common stock in the nine months ended September 30, 2021.

The Company recorded additional derivative liability of approximately ~~$870,000~~$870,000 during the nine months ended September 30, 2020 since the conversion option attached to certain notes became convertible into a variable number of shares of our common stock. The Company also extinguished approximately ~~$574,000~~$574,000 of derivative liability following the conversion of certain notes to the Company’s common stock in the nine months ended September 30, 2020.

Following the recognition as derivative liability of the embedded conversion options, the Company fully amortized the remaining unamortized beneficial conversion feature for approximately ~~$232,000,~~$232,000, recorded an initial ~~$258,070~~$258,070 from the initial recognition of the debt discount following the bifurcation of the embedded conversion option. As of September 30, 2020, the Company had a derivative liability of approximately ~~$776,000~~$776,000 and a change in fair value of approximately ~~$60,500.~~$60,500.

On April 17, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Peak One Opportunity Fund, L.P. (the “Buyer”, “Peak One”), for a commitment to purchase convertible notes in the aggregate amount of ~~$400,000,~~$400,000, pursuant to which, for an aggregate purchase price of ~~$400,000,~~$400,000, the Buyer purchased (a) Tranche #1 in the form of a Convertible Promissory Note in the principal amount of ~~$200,000~~$200,000 (the “Convertible Note”) and (b) 350,000 restricted shares of the Company’s Common Stock (the “Shares”) (the “Purchase and Sale Transaction”). The Company used the net proceeds from the Purchase and Sale Transaction for working capital and general corporate purposes.

The Convertible Note has a principal balance of ~~$200,000,~~$200,000, including a ~~10%~~10%$ OID of ~~$20,000~~$20,000 and ~~$5,000~~$5,000 in debt issuance costs, receiving net proceeds of ~~$175,000,~~$175,000, with a maturity date of April 23, ~~2022.~~ 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under the Convertible Note may also be converted into shares (the “Tranche #1 Conversion Shares”) of the Company’s Common Stock at any time, at the option of the holder, at (i) a conversion price, during the first 180 days, of $0.10 per share (the “~~Fixed Price~~”“Fixed Price”), and then (2) at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company has agreed to at all times, reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of the Tranche #1 Conversion Shares. The Company may redeem the Convertible Note at rates of ~~110%~~110% to ~~140%~~140% over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

The issuance of the Convertible Note resulted in a discount from the beneficial conversion feature totaling ~~$84,570,~~$84,570, including ~~$52,285~~$52,285 related to the beneficial conversion feature and a discount from the issuance of restricted stock of 350,000 shares for ~~$32,285.~~$32,285. Total amortization of these OID and debt issuance cost discounts totaled ~~$84,376~~$0 for the ~~nine~~3 months ended September 30, ~~2020.~~2021. Total unamortized discount on this note was ~~$0 as of~~$0 and $0 at September 30, ~~2020.~~2021 and December 31, 2020, respectively.

On June 12, 2019, the Company entered into an amendment of the Purchase Agreement (“Amendment #1”) in connection with the draw-down of the second tranche, and to provide for additional borrowing capacity under that agreement. Amendment #1 increased the borrowing amount up to ~~$600,000,~~$600,000, adding the ability to borrow an additional ~~$200,000~~$200,000 in a third tranche.

On June 12, 2019, the Buyer purchased Convertible Note Tranche #2 (“Tranche #2”) totaling ~~$200,000,~~$200,000, including a ~~10%~~10% OID of ~~$20,000~~$20,000 and a ~~$1,000~~$1,000 debt issuance cost, receiving net proceeds of ~~$179,000~~$179,000 against the April 17, 2019, Purchase Agreement with Peak One, with a maturity date of June 12, 2022. Amounts due under Tranche #2 are convertible at the same terms as Tranche #1 above.

The issuance of Tranche #2 resulted in a discount from the beneficial conversion feature totaling ~~$180,000,~~$180,000, including ~~$132,091~~$132,091 related to the conversion feature and a discount from the issuance of restricted stock of 350,000 shares for ~~$47,909.~~$47,909. Total amortization of these OID and debt issuance cost discounts totaled ~~$36,187~~$0 for the ~~nine~~3 months ended September 30, ~~2020.~~2021. Total unamortized discount on this note was ~~$127,768~~$0 as of September 30, ~~2020.~~2021.

On November 5, 2019, the Company and Peak One amended the Convertible Note under Tranche #1 to extend the date of conversion of the Convertible Note into Common Stock of the Company at ~~65%~~65% of the traded price of the Company’s Common Stock until January 8, 2020. This amendment put a temporary hold on Peak One to convert the debt under Tranche 1. This restriction did not apply if Peak One opted to convert the Convertible Note at ~~$0.10.~~$0.10. The Company compensated Peak One 300,000 shares of the Company’s Common Stock for delaying the conversion until January 18, 2020. Such shares were issued to Peak One on November 14, 2019. Non-cash compensation expense of ~~$60,000~~$60,000 was recorded for such issuance.

Peak One converted ~~$200,000~~$200,000 of Tranche 1#1 out of their total debt into 2,581,945 shares of ~~Mateon~~the Company during the ~~nine months~~year ended ~~September 30,~~December 31, 2020.

Further, Peak One converted ~~$100,000~~$200,000 of Tranche 2#2 of their total debt into ~~1,000,000~~2,000,000 shares of ~~Mateon~~the Company during the ~~nine months~~year ended ~~September 30,~~December 31, 2020. As such, the total outstanding debt for Peak One was ~~$100,000~~$0 as of September 30, ~~2020.~~2021.

On April 23, 2019, the Company, entered into a Convertible Note (the “TFK Note”) with TFK Investments, LLC (“TFK”). The TFK Note has a principal balance of ~~$200,000,~~$200,000, including a ~~10%~~10% OID of ~~$20,000~~ $20,000 and ~~$5,000~~ $5,000 in debt issuance costs, receiving net proceeds of ~~$175,000,~~$175,000, with a maturity date of April 23, ~~2022.~~ 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event.Amounts due under the Convertible Note may also be converted into shares (the “TFK Conversion Shares”) of the Company’s Common Stock at any time, at (i) a conversion price, during the first 180 days, of $0.10 per share (the “Fixed Price”), and then (2) at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company has agreed to at all times reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of the TFK Conversion Shares. The Company may redeem the Convertible Note at rates of ~~110%~~110% to ~~140%~~140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

The issuance of the TFK Note resulted in a discount from the beneficial conversion feature totaling ~~$84,570,~~$84,570, including ~~$52,285~~$52,285 related to the beneficial conversion feature and a discount from the issuance of restricted, stock of 350,000 shares for ~~$32,285.~~$32,285. Total amortization of these OID and debt issuance cost discounts totaled ~~$80,788~~$0 for the ~~nine~~three months ended September 30, ~~2020.~~2021. Total unamortized discount on this note was ~~$3,589~~$0 and $3,589 as of September 30, ~~2020.~~2021 and September 30, 2020 respectively.

On November 5, 2019, the Company and TFK amended the TFK Convertible Note to extend the date of conversion of the Convertible Note into Common Stock of the Company at ~~65%~~65% of the traded price of the Company’s Common Stock until January 8, 2020. This restriction did not apply if TFK wished to convert the Convertible Note at ~~$0.10~~$0.10 per share. The Company compensated TFK 300,000 shares of the Company’s Common Stock for delaying the conversion until January 8, 2020. Such shares were issued to TFK on November 14, 2019. Non-cash compensation expense of ~~$60,000~~$60,000 was recorded for such issuance.

TFK converted ~~$133,430~~$133,430 of their total debt into 1,950,000 shares of ~~Mateon~~common stock of the Company during the year ended December 31, 2020. As such, the total gross outstanding debt for TFK was approximately $67,000 as of December 31, 2020. TFK had a balance of approximately $109,000 related to the derivative liability as of December 31, 2020. The Company recorded approximately $38,000 as an increase in fair value for the derivative liability, and hence the TFK had a balance of approximately $145,000 of derivative liability. The Company extinguished the $145,000 of derivative liability and approximately $67,000 of the value of the debt, totaling approximately $210,000 following the conversion of the notes to the Company’s common stock during the nine months ended September 30, ~~2020.~~2021 for a total of 657,200 shares of common stock of the Company and recorded a loss on the conversion of approximately $2,000 for the nine months ended September 30, 2021. As such, ~~the total outstanding~~TFK’s debt ~~for TFK was $66,570~~ as of September 30, ~~2020.~~2021 was $0.

On April 17, 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO and the Bridge Investor with a commitment to purchase convertible notes in the aggregate of ~~$400,000.~~$400,000.

On April 23, 2019, the Company entered into a convertible note with our Chief Executive Officer, Vuong Trieu, Ph. D. (the “Trieu Note”). The Trieu Note has a principal balance of ~~$164,444,~~$164,444, including a ~~10%~~10% OID of ~~$16,444,~~$16,444, resulting in net proceeds of ~~$148,000,~~$148,000, with a maturity date of April 23, ~~2022.~~ 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event.Amounts due under the Convertible Note may also be converted into shares (the “~~Trieu~~“Trieu Conversion ~~Shares~~”Shares”) of the Company’s Common Stock at any time, at the option of the holder, at a conversion price of $0.10 per share (the “~~Fixed Price~~”“Fixed Price”), at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the 180^th day or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company has agreed to at all times reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of Conversion Shares. The Company may redeem the Convertible Note at rates of ~~110%~~110% to ~~140%~~140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

The issuance of the Trieu Note resulted in a discount from the beneficial conversion feature totaling ~~$131,555~~$131,555 related to the conversion feature. Total amortization of the 10% OID discount and beneficial conversion feature totaled ~~$4,095~~$2,743 and $5,486 for the nine months ended September 30, ~~2020.~~2021, and 2020, respectively. Total unamortized discount on this note was ~~$8,568~~$1,713 as of September 30, ~~2020.~~2021.

On April 23, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. Tranche #1 has a principal balance of ~~$35,556,~~$35,556, an OID of ~~$3,556,~~$3,556, resulting in net proceeds of ~~$32,000,~~$32,000, with a maturity date of April 23, ~~2022.~~ 2022. Upon the occurrence of certain events of default, the Buyer, among other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under Tranche #1 may also be converted into shares (the “Bridge SPA Conversion Shares”) of the Company’s Common Stock at any time, at (i) a conversion price, during the first 180 days, of $0.10 per share (the “~~Fixed Price~~”“Fixed Price”), and then (2) at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

The issuance of the note resulted in a discount from the beneficial conversion feature totaling ~~$28,445.~~$28,445. Total amortization of the OID and discount totaled ~~$888~~$1,407 for the nine months ended September 30, ~~2019.~~2021. Total unamortized discount on this note was ~~$1,849~~$14 as of September 30, ~~2020.~~2021.

On August 6, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. Tranche #2 has a principal balance of ~~$200,000,~~$200,000, an OID of ~~$20,000~~$20,000 and debt issuance costs of ~~$5,000,~~$5,000, resulting in net proceeds of ~~$175,000,~~$175,000, with a maturity date of August 6, ~~2022.~~ 2022. Upon the occurrence of certain events of default, the Buyer, among other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default ~~event.~~ event. Amounts due under Tranche #1 may also be converted into Bridge Conversion Shares of the Company’s Common Stock at any time, at the option of the holder, at a conversion price equal to the Fixed Price, at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the 180^th day or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of ~~110%~~110% to ~~140%~~140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

The issuance of the note resulted in a discount from the beneficial conversion feature totaling ~~$175,000.~~$175,000. Total amortization of the OID and discount totaled ~~$157,779 for the nine months ended~~$6,279 at September 30, ~~2020.~~2021. Total unamortized discount on this note was ~~$15,396~~$7,036 as of September 30, ~~2020.~~2021.

All the above notes issued to ~~Peak One,~~ TFK, our CEO and the bridge investors reached the 180 days prior to the end of the ~~nine~~three months ended ~~September 30,~~March 31, 2020. As such, all the note holders had the ability to convert that debt into equity at the variable conversion price of 65% % of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument.

As of December 31, 2019, we had a derivative liability of approximately $541,000. Following the initial bifurcation of the conversion features related to certain hybrid convertible notes instruments, the Company recorded an initial fair value of such derivative of $870,268. Following conversion of certain notes to the Company’s common stock, the Company reversed such derivative liability by approximately $573,800. This resulted in a change in fair value of $60,504. As of September 30, ~~2020, the derivative liability~~2021, Peak One and TFK had ~~a fair value of approximately $776,000. During the nine months ended September 30, 2020, the Company~~ fully amortized for $232,054 the remaining unamortized beneficial conversion feature since the conversion feature of certain hybrid instruments were separated and accounted for as derivative liability. The Company recorded an initial debt discount of $258,070 resulting from the bifurcation of the conversion feature representing the net carrying amount of the underlyingconverted their notes ~~since the fair value of the initial derivative liability exceeds the net carrying amount of the underlying notes.~~.

In July 2019, the Company entered into a Note Purchase Agreement with PointR (the “PointR Note Purchase Agreement”). Pursuant to the PointR Note Purchase Agreement, Mateon issued a Convertible Promissory Note to PointR in the principal amount of $200,000 (the “~~PointR Convertible Note~~”). The PointR Convertible Note bore interest at a rate of 8% per annum. Interest payments were due monthly on the 15th day of each calendar month (or the next business day thereafter), and were payable, at the option of PointR, either in cash or in shares of Mateon’s Common Stock, valued at the closing price of the Common Stock on the principal market on which the Common Stock is either traded or quoted at such time. The PointR Convertible Note was due and payable on demand by PointR (a) at any time after January 1, 2020 or (b) upon the occurrence of an Event of Default (as defined in the PointR Convertible Note and the PointR Note Purchase Agreement). All amounts outstanding under the PointR Convertible Note would be automatically converted into the Company’s securities issued in next equity financing raising gross proceeds of $10,000,000 or more (a “~~Qualified Financing~~”) at the price per share paid by investors in the Qualified Financing. As the conversion feature is contingent upon a future event, the conversion feature will be evaluated under ASC 470-20 and ASC 815 when and if the Qualified Financing occurred.

In November 2019, the PointR Convertible Note, with accrued interest of $4,603 thereon, was converted into Company’s Series A Preferred Stock and is a part of the total consideration of 84,475 shares of Mateon’s Series A Preferred Stock issued to the PointR shareholders upon the completion of the PointR Merger. Since the conversion occurred prior to the Qualified Financing, the Company did not have to evaluate the conversion feature under ASC 470-20 and ASC 815.

In December 2019, ~~Mateon~~the Company closed its Fall 2019 Debt Financing, raising an additional ~~$500,000~~$500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to ~~$1,000,000.~~$1,000,000. The Company entered into those certain Note Purchase Agreements (the “Fall 2019 Note Purchase Agreements”) with certain accredited investors and the officers of the Company for the sale of convertible promissory notes (the “Fall 2019 Notes”). ~~Mateon~~The Company completed the initial closing under the Fall 2019 Note Purchase Agreements in November 2019. ~~Mateon~~The Company issued Fall 2019 Notes in the principal amount of ~~$250,000~~$250,000 to each of Dr. Vuong Trieu, the ~~Mateon’s~~Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of ~~$500,000.~~$500,000. In connection with the second and final closing of the Fall 2019 Debt Financing, ~~Mateon~~the Company issued Fall 2019 Notes to additional investors including ~~$250,000~~$250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer and converted such amounts due into the Fall 2019 Notes. ~~$35,000~~$35,000 due to Dr. Vuong Trieu, ~~$27,000~~$27,000 due to Chulho Park and ~~$20,000~~$20,000 due to Amit Shah were converted into debt. The Company also issued the Fall 2019 Notes of ~~$168,000~~$168,000 to two unaffiliated accredited investors. The balance of the Fall 2019 Notes was $850,000 and $950,000 as of September 30, 2021, and December 31, 2020, respectively.

All the Fall 2019 Notes ~~provide~~provided for interest at the rate of 5%5% per annum and ~~are~~were unsecured. All amounts outstanding under the Fall 2019 Notes ~~become~~became due and payable upon the approval of the holders of a majority of the principal amount of outstanding Fall 2019 Notes (the “Majority Holders”) on or after (a) November 23, 2020, or (b) the occurrence of an event of default (either, the “Maturity Date”). The Company may prepay the Fall 2019 Notes at any time. Events of default under the Fall 2019 Notes include failure to make payments of any part of the principal or unpaid accrued interest under the Fall 2019 Notes ~~within~~for more than thirty (30) days ofafter the maturity date, ~~due,~~ failure to observe of the Fall 2019 Note Purchase Agreement or Fall 2019 Notes which is not cured within thirty (30) days of notice of the breach, bankruptcy, or a change in control of the Company (as defined in the Fall 2019 Note Purchase Agreement).

The Majority Holders have the right, at any time not more than five (5) days following the Maturity Date, to elect to convert all, and not less than all, of the outstanding accrued and unpaid interest and principal on the Fall 2019 Notes. The Fall 2019 Notes may be converted, at the election of the Majority Holders, either (a) into shares of the Company’s Common Stock at a conversion price of $0.18 per share, or (b) into shares of common stock of the Edgepoint, at a conversion price of $5.00 (based on a $5.0 million pre-money valuation) of Edgepoint and 1,000,000 shares ~~outstanding.~~outstanding.

The issuance of the Fall 2019 ~~Notes~~notes resulted in a discount from the ~~beneficial conversion feature~~BCF totaling ~~$222,222~~$222,222 related to the conversion feature. Total amortization of the discount totaled ~~$111,112~~$0 and $0$111,112 for the nine months ended September 30, 2021, and 2020, respectively. Total unamortized discount on this note was $0 as of September 30, 2021.

Further, the Company recorded interest expense of $10,625and $12,500 on these Fall 2019 ~~respectively; and $55,556 and $0~~Notes for the three months ended September 30, 2021, and 2020, ~~and 2019,~~ respectively. ~~As of September 30, 2020, the total unamortized discount on these notes was $88,888.~~

~~Further, the~~The Company recorded interest expense of ~~$12,500~~$32,787 and ~~$37,500~~$37,500 on these Fall 2019 Notes for the ~~three and~~ nine months ended September 30, 2021, and 2020, ~~on these Fall 2019 Notes.~~ respectively.

The total amount outstanding under the Fall 2019 Notes, net of discounts and including accrued interest thereon, ~~and net of discounts,~~ as of September 30, ~~2020~~2021, and December 31, ~~2019~~2020, was ~~$1,008,037~~$935,799 and ~~$1,003,870,~~$1,003,011, respectively.

In May and June 2021, the Company entered into Securities Purchase Agreement with Geneva Roth Remark Holdings Inc. (“Geneva”), whereby the Company issued two convertible notes in the aggregate principal amount of $307,500 convertible into shares of common stock of the Company with additional tranches of financing of up to $1,200,000 in the aggregate term of the note. The convertible notes carry a six (6%) percent coupon and a default coupon of 22%, and both mature one year from issuance. Geneva has the right from time to time, and at any time during the period beginning on the date which is one hundred eighty (180) days following issuance date and ending on the maturity date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at sixty five (65%) percent multiplied by the lowest two (2) daily volume weighted average price over the fifteen (15) consecutive trading days. The convertible notes carry a put feature, at the option of Geneva, whereby upon the occurrence of certain events of default, the convertible notes repayment should be accelerated, in the amount of principal plus accrued but unpaid interest plus default interest, in cash with premium.

The total amount outstanding under the Geneva Notes, including accrued interest thereon, as of September 30, 2021, and December 31, 2020, was $313,472 and $0, respectively.

In April 2020, the Company ~~entered into a Paycheck Protection Program Promissory Note (the “~~~~PPP Note~~~~”) with respect to a~~received loan proceeds in the amount of ~~$250,000 (the “~~~~PPP Loan~~~~”) from Silicon Valley Bank (the “~~~~Lender~~~~”). The PPP Loan was obtained pursuant to~~$250,000 under the Paycheck Protection Program ~~(the “~~(“1^stPPP”) ofwhich was established under the Coronavirus Aid, Relief and Economic Security ~~Act (the “~~(“CARES ~~Act~~”) Act and is administered by the ~~U.S.~~ Small Business Administration (“SBA”). The 1^stPPP Lo

provides loans to qualifying businesses in amounts up to 2.5 times the average monthly payroll expenses and was designed to provide direct financial incentive to qualifying businesses to keep their workforce employed during the Coronavirus crisis. The Payment Protection Plan loans (“PPP ~~Loan matures on April 21, 2022~~Loans”) are uncollateralized and bears interest at a rate of 1.00% per annum. The PPP Loan is payable in 17 equal monthly payments commencing November 21, 2020. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties.

~~All or a portion of the PPP Loan may be forgiven~~guaranteed by the SBA and forgivable after a “covered period” (8 weeks or 24 weeks) as long as the ~~Lender~~borrower maintained its payroll levels and uses the loan proceeds for eligible expenses, including payroll, benefits, mortgage interest, rent and utilities. The forgiveness amount would be reduced if the borrower terminated employees or reduced salaries and wages more than 25% during the covered period. Any unforgiven portion was payable over 2 years if issued before, or 5 years if issued after, June 5, 2020 at an interest rate of 1% with payments deferred until the SBA remits the borrowers loan forgiveness amount to the lender, or if the borrower did not apply for forgiveness, 10 months after the covered period. PPP loans provide for customary events of default, including payment defaults, breach of representations and warranties, and insolvency events and may be accelerated upon ~~application by~~occurrence of one or more of these events of default. Additionally, the PPP Loans do not include prepayment penalties.

The Company met the 1^st PPP loan forgiveness requirements and on August 7, 2021 applied for forgiveness. On Aug 17, 2021, the Company ~~not later than~~received the 1^st PPP loan forgiveness approval from the lender and wrote off the loan outstanding amount inclusive of interest accrued, in the amount of $253,347. The Company recorded the amount forgiven as forgiveness income within the other income (expense) section of its statement of operations.

The SBA reserves the right to audit any PPP loan, regardless of size. These audits may occur after the forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain their PPP loan documentation for six years after the loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.

The balance outstanding on 1^st PPP loan, inclusive of accrued interest, was $0 and $251,733 on September 30, 2021 and December 31, 2020, respectively.

In July 2021, the Company’s wholly owned subsidiary, PointR, received loan proceeds in the amount of $92,995 under the PPP (“2^ndPPP”). The 2^nd PPP was at terms similar to the 1^st PPP. The balance outstanding on the 2^nd PPP loan was $92,995 and $0 on September 30, 2021 and December 30, 2020, respectively.

In June 2020, the Company secured $2 million in debt financing, evidenced by a one-year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of the Company. The GMP Note is convertible into the Company’s Common Stock upon ~~documentation~~the GMP Note’s maturity one year from the date of ~~expenditures~~the GMP Note, at the Company’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial.

The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $2 million. As of September 30, 2021, GMP has been invoiced by the clinical research organization for the full $2 million and as such the Company has recognized the liability as a convertible debt.

The balance outstanding on the GMP Note, inclusive of accrued interest, was $2,050,411 and $2,000,000 on September 30, 2021 and December 31, 2020, respectively.

In September 2021, the Company secured a further $1.5 million in ~~accordance~~debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest. The GMP Note is convertible into the Company’s Common Stock upon the GMP Note 2’s maturity one year from the date of the GMP Note 2, at the Company’s Common Stock price on the date of conversion with no discount. GMP does not have the ~~SBA requirements.~~option to convert prior to the GMP Note 2’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial.

As of September 30, 2021, GMP was invoiced by the clinical research organization for $0.5 million. GMP paid the clinical trial organization the first tranche of $0.5 million in October 2021.

In August 2021, the Company entered into Note Purchase Agreements with related party, affiliate entity, and accredited investors (the “August 2021 investors”), whereby the Company issued four convertible notes in the aggregate principal amount of $698,500 convertible into shares of common stock of the Company for net proceeds of $690,825. The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Company’s common stock, at a conversion price of $0.18. The Company determined that the economic characteristics and risks of the embedded conversion option are not clearly and closely related to the economic characteristics and risks of the debt host instrument. Further, the Company determined that the embedded conversion feature meets the definition of a derivative but met the scope exception to the derivative accounting required under ASC 815 for certain contracts involving a reporting entity’s own equity.

As of September 30, 2021, and December 31, 2020, convertible notes, net of debt discount, consist of the following amounts:

As of September 30, 2021, other short term notes consist of the following amounts:

During the fourth quarter of the year ended December 31, 2020, the Company’s CFO and the Bridge Investor provided short term loans of $25,000 and $50,000, respectively to the Company. Such loans were repaid as of March 31, 2021. During the nine months ended September 30, ~~2020,~~2021, the ~~Company’s CEO~~CFO provided ~~additional funding~~a total of ~~$70,000 to~~approximately $120,000, of which $75,000 was converted into the ~~Company.~~August 2021 Notes. As such, a balance of approximately $45,000 remained outstanding as a short-term loan as of September 30, 2021.

During the nine months ended September 30, 2021, the Company received approximately $630,000 primarily from two bridge investors, of which $373,500 was converted into the August 2021 Notes, and approximately $258,000 was outstanding as a short-term loan as of September 30, 2021.

During the ~~three months ended~~period from July 2020 to September 30, ~~2020,~~2021, the Company entered into subscription agreements with certain accredited investors pursuant to the JH Darbie Financing, whereby the Company issued and sold a total of 53100 Units, for total gross proceeds of approximately ~~$2.65~~$5 million, ~~or $2.31 million, net of fees paid to JH Darbie~~ pursuant to the JH Darbie Placement Agreement, with each Unit consisting of:

As ~~of September 30, 2020,~~September30, 2021, funds received under the JH Darbie Financing, net of debt discount, consist of the following amounts:

	September 30, 2020		September 30, 2021
Convertible promissory notes
Subscription agreements - accredited investors	$	612,892	$	2,073,480
Subscription agreements – related party		33,274		101,115
Total convertible promissory notes	$	646,166	$	2,174,595

The Company incurred approximately ~~$0.4~~$0.64 million of issuance costs, including legal costs of approximately ~~$39,000,~~$39,000, that are incremental costs directly related to the issuance of the various instruments bundled in the offering.

Concurrently with the sale of the Units, JH Darbie iswas granted ~~for nominal consideration,~~ a warrant, exercisable over a five-year period, to purchase ~~such number of Units equal 10%~~10% of the number of Units sold in the JH Darbie Financing. ~~The~~As such, the Company granted ~~5.3~~10 Units to JH Darbie pursuant to the JH Darbie Placement Agreement.

The Company allocated the proceeds among the freestanding financial instruments that were issued in the single transaction using the relative fair value method, which affects the determination of each financial instrument initial carrying amount. The Company utilized the relative fair value method as none of the freestanding financial instruments issued as part of the single transaction are measured at fair value. Under the relative fair value method, the Company ~~makes~~made separate estimates of the fair value of each freestanding financial instrument and then ~~allocates~~allocated the proceeds in proportion to those fair value amounts. The Company recorded non-controlling interests of approximately $1$1 million in Edgepoint. Non-controlling interests represent the portion of net assets in consolidated entities that are not owned by the Company and are reported as a component of equity in the ~~unaudited condensed~~ consolidated balance sheets.

As of the multiple closings of the Company during the three months ended March 31, 2021, under the private placement memorandum with JH Darbie, the estimated volume weighted grant date fair value of approximately $0.23 per share associated with the warrants to purchase up to 2,035,000 shares of common stock issued in this offering, or a total of approximately $ 0.5 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values:

As of the multiple closings of the Company through December 31, 2020, under the private placement memorandum with JH Darbie, the estimated grant date fair value of approximately $0.18 per share associated with the warrants to purchase up to 3,465,000 shares of common stock issued in this offering, or a total of approximately $0.6 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values.

The Company recorded an initial debt discount of approximately ~~$0.6~~ $0.7 million representing the intrinsic value of the non-bifurcated conversion option embedded in the convertible debt instrument based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion ~~price embedded in the note.~~price.

The Company recognized amortization expense related to the debt discount and debt issuance costs of ~~$162,267~~$942,160 and $162,267 for the ~~three and~~ nine months ended ~~September~~June 30, ~~2020 respectively,~~2021, and ~~$0 for the three and nine months ended September~~June 30, ~~2019,~~2020, respectively, which is included in interest expense in the ~~condensed~~ statements of operations.

In June 2021, the Company executed amendment #4 to the private placement memorandum. At the time of the original PPM, the Company had inadvertently made an error in the PPM. Originally, the investor was granted 50,000 of the Company’s warrants to purchase an equivalent number of shares of the Company’s common stock at a strike price of $0.20 or 50,000 warrants to purchase an equivalent number of Edgepoint’s common share at strike price of $1.00. However, the PPM was incorrectly written in that the investor could only invest in $10,000 (50,000 shares of common stock at $0.20 per share) of common stock of the Company) or $50,000 (50,000 shares of common stock in Edgepoint AI, Inc. at $1.00 per share). In conjunction with amendment #4 and to correct the error in the PPM, the Company approved the issuance of further 20,000,000 warrants to purchase shares of common stock of the Company to the investors in the 100 Units and 2,000,000 warrants to purchase shares of common stock of the Company to the Placement Agent at the same terms and conditions of the PPM. To clarify further, each unit will receive additional 200,000warrants to purchase an equivalent number of shares of the Company’s common stock at $0.20 per share, so as to make it overall 250,000 warrants to buy an equivalent number of shares of the Company’s common stock, for which the investor would pay a total of $50,000 per unit invested upon exercise.

In connection with the additional warrants issued by the Company in connection with the amendment #4, the Company recorded a stock-based compensation fair value expense of $2,023,522 during the nine months ended September 30, 2021. No similar expense was recorded during the same period of 2020. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values.

In October 2015, Oncotelic entered into a Master Service Agreement (the “MSA”) with Autotelic Inc., a related party that is ~~partly owned~~partly-owned by ~~Dr. Trieu.~~the Company’s CEO Vuong Trieu, Ph.D. Dr. Trieu, a related party, is a control person in Autotelic Inc. Autotelic Inc. currently owns less than ~~10%~~10% of ~~Mateon.~~the Company. The MSA stated that Autotelic Inc. will provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services.

Expenses related to the MSA were ~~$6,011 and $291,887~~$15,801 for the three ~~and~~months ended September 30, 2021 as compared to $6,011 for the same period of 2020. Expenses related to the MSA were $51,039 for the nine months ended September 30, ~~2020, respectively,~~2021 as compared to ~~$309,194 and $1,004,315~~$291,887 for the same ~~periods~~period of ~~2019~~2020.

In ~~January 2019,~~September 2021, the Company entered into an exclusive License Agreement (the “Agreement”) with Autotelic, Inc. (“Autotelic”), pursuant to which Autotelic granted Oncotelic, ~~issued~~among other things: (i) the exclusive right and license to certain Autotelic Patents (as defined in the Agreement) and Autotelic Know-How (as defined in the Agreement); and (ii) a ~~total~~right of ~~80,772 shares~~first refusal to acquire at least a majority of ~~its common~~the outstanding capital stock ~~with a fair value~~ of ~~$4.00 per share~~Autotelic prior to Autotelic ~~Inc. in lieu~~entering into any transaction that is a financing collaboration, distribution revenues, earn-outs, sales, out-licensing, purchases, debt, royalties, merger acquisition, change of control, transfer of cash or non-cash assets, disposition of capital stock by way of tender or exchange offer, partnership or any other joint or collaborative venture, research collaboration, material transfer, sponsored research or similar transaction or agreements. In exchange for the ~~settlement~~rights granted to Oncotelic, Autotelic would be entitled to earn the following milestone payments (collectively, the “Milestone Payments”).

In addition to the Milestone Payments, Autotelic will be entitled to royalties equal to 15% of ~~outstanding accounts payable.~~the net sales of any products that incorporate the Autotelic Patents or Autotelic Know-How. The Agreement contains representations, warranties and indemnification provisions of each of the parties thereto that are customary for transactions of this type.

~~Notes~~Note Payable and ~~Short-Term~~Short Term Loan – Related ~~Party~~Parties

In April 2019, ~~Mateon~~the Company issued a convertible note to Dr. Trieu totaling ~~$164,444,~~$164,444, including OID of ~~$16,444,~~$16,444, receiving net proceeds of ~~$148,000,~~$148,000, which was used by the Company for working capital and general corporate ~~purposes (See Note 5).~~purposes. The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of ~~$250,000, which~~$250,000. Dr. Trieu also offset certain amounts due ~~Dr. Trieu~~to him in the amount of ~~$35,000 due to him~~$35,000 and was converted into the Fall 2019 debt. During the ~~nine months~~year ended ~~September 30,~~December 31, 2020, Dr. Trieu provided additional short-term funding of ~~$70,000~~$70,000 to the ~~Company.~~Company, of which the Company repaid $50,000 prior to December 31, 2020. During the ~~three months~~year ended ~~September 30,~~December 31, 2020, Dr. Trieu purchased 3a total of 5 Units under the private placement for a gross total of ~~$150,000.~~$250,000.

During the three months ended March 31, 2021, Autotelic Inc, provided a short-term loan of $120,000 to the Company, which was repaid in April 2021. During the three months ended June 30, 2021, Autotelic Inc. provided a short-term loan of $250,000 to the Company, which was converted into a August 2021 Convertible Note. And a short term loan of $20,000.

On March 9, 2020, the Company and Artius Bioconsulting, LLC (“Artius”), for which Mr. ~~Steven~~ King ~~our Board and Committee member,~~ is the Managing Member, entered into an amendment to ~~that certain~~the Consulting Agreement dated December 1, 2018, ~~(the “~~~~Artius Agreement~~~~”),~~ under which Artius agreed to serve as a consultant to the Company for services related to the Company’s business from time to time, effective December 1, 2019 (the “Effective Date”) (the “Artius Agreement ~~Effective Date~~”). In connection with the Artius Agreement, Mr. King also agreed to assist the Company with strategic advisory services with respect to transactional and operational contracts, budgetary input, among other matters in connection with the ~~development EdgePoint AI’s Artificial Intelligence~~formation of a new business unit to develop AI and Blockchain Driven Vision Systems (“EdgePoint AI”), for which Mr. King ~~serves as~~is Chief Executive Officer.

Under the terms of the Artius Agreement, the Company agreed to grant to Artius, subject to approval by the ~~Mateon’s~~Company’s Board of Directors and pursuant to the Company’s 2017 Equity Incentive Plan, 148,837 restricted shares of ~~Mateon’s~~the Company’s Common Stock, in addition to a ~~30%~~30% pre-financing ownership stake in EdgePoint AI. The Artius Agreement contemplates that Mr. King will generally provide his services at a rate of $237 per hour, not to exceed 44 hours per month and payable monthly, and to reimburse Mr. King for reasonable and necessary expenses incurred by him or Artius in connection with providing services to the Company.

Either the Company or Artius may terminate the Artius Agreement at any time, for any reason following the ~~Artius Agreement~~ Effective Date. The Artius Agreement will automatically renew one year from the ~~Artius Agreement~~ Effective Date, unless the Parties agree to terminate the Artius Agreement at that time.

The Company recorded ~~$106,712 as~~an expense of $0 and $106,712 during the nine months ended September 30, 2021 and 2020, respectively, related to this Agreement. ~~No similar expense was recorded in 2019.~~

Effective May 5, 2020, the Company and Dr. ~~Anthony~~ Maida ~~one of our Board and Committee members,~~ entered into an independent consulting agreement, commencing April 1, 2020 (the “~~Maida Agreement~~”“Maida Agreement”), under which Dr. Maida will assist the Company in providing medical expertise and advice from time to time in the design, conduct and oversight of the Company’s existing and future clinical trials.

Pursuant to the terms of the Maida Agreement, the Company will grant to Dr. Maida 400,000 restricted shares ~~or stock options~~ of ~~Mateon’s~~the Company’s Common Stock corresponding to ~~$80,000~~$80,000 at the stock value of ~~$0.20~~$0.20 per share, to vest on May 5, 2021. The Company will also pay Dr. Maida $15,000 per month for a minimum of 20 hours per week, in in addition to reimbursement of reasonable and necessary expenses incurred by Dr. Maida in connection with his services to the Company.

Either the Company or Dr. Maida may terminate the Maida Agreement, for any reason, upon 30 days advance written notice.

Dr. Maida was appointed the Chief Clinical Director for Mateon effective July 7, 2020. As of the date of this Quarterly Report, Dr. Maida continues to provide his services under the consulting agreement.

The Company recorded ~~$45,000 and $90,000 as~~an expense ~~under the consulting agreement~~of $45,000 each during the three ~~and nine~~ months ended September 30, ~~2020. No similar~~2021 and 2020 respectively. The Company recorded an expense ~~was recorded~~of $135,000 during ~~the same periods in 2019.~~

~~During~~ the nine months ended September 30, ~~2020, the Company reimbursed~~2021 related to ~~Autotelic Inc. $261,246 for healthcare insurance and 401K services at cost. No similar reimbursements were recorded~~ this Agreement as compared to $90,000 during the same period in ~~2019.~~2020.

On May 3, 2021, the Company entered into an Equity Purchase Agreement (“EPL”) and Registration Rights Agreement with Peak One Opportunity Fund LP (“Peak One” or the “Investor”). Under the terms of the EPL, the Company issued 250,000 shares of Common Stock to Peak One. Further, under the terms of the EPL, Peak One agreed to purchase from the Company up to $10,000,000 of the Company’s Common Stock upon effectiveness of a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission and subject to certain limitations and conditions set forth in the Equity Purchase Agreement. The Registration Rights Agreement provided that the Company would (i) file the Registration Statement with the SEC by July 2, 2021; and (ii) use its best efforts to have the Registration Statement declared effective by the Commission at the earliest possible date (in any event, within 90 days after the execution date of the definitive agreements). The Company filed a Registration Statement on Form S-1 with the Commission on May 24, 2021, and the Form S-1 was declared effective on June 2, 2021.

Following effectiveness of the Registration Statement, and subject to certain limitations and conditions set forth in the Equity Purchase Agreement, the Company shall have the discretion to deliver put notices to the Investor and the Investor will be obligated to purchase shares of the Company’s Common Stock based on the investment amount specified in each put notice. The minimum amount that the Company shall be entitled to put to the Investor in each put notice is $20,000 and the maximum amount is up to the lesser of $1.0 million or two hundred fifty percent (250%) of the average daily trading volume of the Company’s Common Stock defined as the average trading volume of the Company’s Common Stock in the ten (10) days preceding the date on the put notice multiplied by the lowest closing bid price in the ten (10) immediately preceding the date of the put notice. Pursuant to the Equity Purchase Agreement, the Investor will not be permitted to purchase, and the Company may not put shares of the Company’s Common Stock to the Investor that would result in the Investor’s beneficial ownership of the Company’s outstanding Common Stock exceeding 4.99%. The price of each put share shall be equal to ninety one percent (91%) of the market price, which is defined as the lesser of (i) closing bid price of the Common stock on the trading date immediately preceding the respective put date, or (ii) the lowest closing bid price of the Common Stock during the seven (7) trading days immediately following the clearing date associated with the applicable put notice.

In connection with the EPL, the Company recorded a non-cash cost of approximately $40,000 during the nine months ended September 30, 2021.

During the three months ended June 30, 2021, the Company sold a total of 400,000 shares of Common Stock at prices ranging from $0.15 and $0.23 for total gross proceeds of approximately $99,000, including issuance costs of approximately $29,000. In addition, the Company sold a total of 900,000 shares of Common Stock at prices at prices ranging from $0.11 to $0.12 for total gross proceeds of $110,000, including issuance costs of $11,000. Approximately $50,000 of the total net proceeds was received by the Company subsequent to September 30, 2021 and is included in the accounts receivable as of September 30, 2021.

~~In January 2019, Oncotelic issued 11,250 shares of Common Stock with a fair value of $4.00 per share to an employee in lieu of cash for compensation.~~

In January 2019, Oncotelic issued a total of 80,772 shares of Common Stock with a fair value of $4.00 per share to Autotelic, Inc. in lieu of cash for the settlement of outstanding accounts payable and services received.

~~In January 2019, Oncotelic issued a total of 20,750 shares of Common Stock with a fair value of $4.00 per share to two separates investors for $83,000 in cash.~~

~~In March 2019, Oncotelic issued 80,594 shares of Common Stock with a fair value of $4.00 per share to various employees in lieu of cash for accrued compensation.~~

~~In April 2019, Oncotelic issued a total of 150,000 shares of Common Stock to two investors as a result of the conversion of warrants for $120 in cash.~~

In April 2019, pursuant to the ~~Merger, Mateon~~Oncotelic merger the Company issued 193,713 shares of Series A Preferred ~~Stock~~ in exchange for 77,154 shares of Oncotelic Common Stock.

In Further, in November 2019 ~~Mateon~~the Company issued 84,475 shares of Series A Preferred ~~Stock~~ to PointR in exchange of 11,135,935 shares of PointR Common Stock upon the consummation of the PointR merger. In March 2021, 278,188 shares of the Company’s preferred stock converted to 278,187,847 shares of its Common Stock, effective March 31, 2021.

Issuance of Common Stock during the ~~three~~nine months ended September 30, 2021

In January 2021, the Company issued 657,200 shares of its Common Stock to TFK in connection with the part conversion of their convertible notes payable.

In March 2021, the Company converted 278,188 shares of our Series A Preferred Stock to 278,187,847 shares of its Common Stock.

In May 2021, the Company issued 250,000 shares of its Common Stock to Peak One in connection with the EPL and recorded a stock compensation expense of approximately $70,000.

In June 2021, the Company sold a total of 400,000 registered shares of Common Stock at prices ranging from $0.15 and $0.23 in connection with the EPL. The Company received net cash of approximately $70,000 against such sale.

In July 2021, the Company issued 1,257,952 shares of Common Stock to its employees in lieu of fully vested restricted stock units under the 2015 Equity Incentive Plan. The Company recorded a stock-based compensation cost of $226,431 related to such issuance.

In September 2021, the Company issued 310,000 shares of Common Stock to Equity NY in connection with certain services rendered by them and recorded a non-cash expense of $23,641.

In September 2021, the Company sold a total of 900,000 registered shares of Common Stock at prices ranging from $0.11 and $0.12 in connection with the EPL. The Company received net cash of approximately $110,000 against such sale.

In February 2020, ~~Mateon~~the Company issued 500,000 shares of its Common Stock to Peak One in connection with the part conversion of one of their convertible notes payable. ~~(See Note 5).~~

In ~~February~~March 2020, ~~Mateon~~the Company issued ~~1,200,000~~750,000 shares of its Common Stock to TFK in connection with the part conversion of their convertible notes payable.

In March 2020, the Company issued 500,000 shares of its Common Stock to Peak One in connection with the part conversion of one of their convertible notes payable. ~~(See Note 5)~~

In March 2020, ~~Mateon~~the Company issued ~~750,000~~1,012,145 shares of its Common Stock to TFK in connection with the part conversion of their convertible notes payable.

~~In March 2020, Mateon~~Company issued ~~500,000~~1,200,000 shares of its Common Stock to Peak One in connection with the part conversion of one of their convertible notes payable. ~~(See Note 5)~~

~~In March 2020, Mateon issued 1,012,145 shares of its Common Stock to TFK in connection with the part conversion of the TFK Note. (See Note 5).~~

In June 2020, ~~Mateon~~the Company issued 569,800 shares of its Common Stock to Peak One in connection with the full conversion of one of their convertible notes payable. ~~(See Note 5)~~

In July 2020, ~~Mateon~~the Company issued 1,000,000 shares of its Common Stock to Peak One in connection with the partial conversion of Tranche 2 of their convertible notes payable. ~~(See Note 5)~~

~~In April, 2019, pursuant to the Merger, Mateon issued 41,000,033 shares of Common Stock in exchange for 10,318,746 shares of Oncotelic common stock. (See Note 3)~~

~~In April 2019, Mateon issued 700,000 restricted shares of its Common Stock with a fair value of $0.11 per share to two noteholders in connection with convertible notes payable. (See Note 5)~~

~~In June 2019, Mateon issued 350,000 restricted shares of its Common Stock with a fair value of $0.18 per share in connection with a convertible note payable. (See Note 5)~~

In June 2019, Mateon issued 300,000 restricted shares of its Common Stock to Peak One with a fair value of $0.20 to extend the date of conversion of the Peak One Tranche #1 Note into Common Stock of Mateon at 65% of the traded price of Mateon’s Common Stock until January 18, 2020. This restriction did not apply if Peak One wished to convert the Peak One Tranche #1 Note at $0.10. The Company recorded a cost of $60,000 in lieu of such issuance.

In November 2019, Mateon issued 300,000 restricted shares of its Common Stock to TFK with a fair value of $0.20 to extend the date of conversion of the TFK Note into Common Stock of Mateon at 65% of the traded price of Mateon’s Common Stock until January 8, 2020. This restriction did not apply if TFK wished to convert the TFK Note at $0.10 per share. The Company recorded a cost of $60,000 in lieu of such issuance.

Pursuant to the ~~Merger, Mateon’s~~Oncotelic merger, the Company’s Common Stock and corresponding outstanding options survived. The below information details ~~Mateon’s~~the Company’s associated option ~~activity pre and post merger.~~activity.

As of September 30, ~~2020,~~2021, options to purchase ~~Mateon’s~~ Common Stock were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). Under the 2017 Plan, up to 2,000,000 shares of ~~Mateon’s~~the Company’s Common Stock may be issued pursuant to awards granted in the form of nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to 7,250,000 shares of ~~Mateon’s~~the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards.

Employees, consultants, and directors are eligible for awards granted under the 2017 and 2015 Plans. The Company registered an additional total of 20,000,000 shares of its Common Stock, which may be issued pursuant to the Registrant’s Amended and Restated 2015 Equity Incentive Plan (the “Plan”). Such additional shares were approved by the shareholders of the Company on August 10, 2020 and as reported to the Securities and Exchange Commission (the “SEC”) vide a Current Report on Form 8-K on August 14, 2020. As such, the total number of shares of the Company’s Common Stock available for issuance under the 2015 plan is 27,250,000. After June 30, 2021, the Company issued 1,257,952 of its common shares in lieu of fully vested restricted stock units and 4,244,809 incentive and non-qualified stock options to purchase its Common Stock to its employees. All these grants had been approved by the Board of Directors of the Company under the 2015 Plan.

Since the adoption of the 2015 Plan, no0 further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms.

Compensation based stock option activity for qualified and unqualified stock options are summarized as follows:

The following table summarizes information about options to purchase shares of ~~Mateon’s~~the Company’s Common Stock outstanding and exercisable at September 30, ~~2020:~~2021:

SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE

				Weighted-		Weighted-									Weighted-
				Average		Average							Weighted-		Average
		Outstanding		Remaining Life		Exercise		Number			Outstanding		Average		Exercise		Number
Exercise prices	Exercise prices	Options		In Years		Price		Exercisable		Exercise prices	Options		Remaining Life		Price		Exercisable

$	0.22		2,524,513		7.73	$	0.22		2,524,513	0.14		7,150,000		9.92	$	0.14		265,000
	0.38		1,162,500		6.29		0.38		1,162,500	0.16		4,244,809		9.77		0.16		4,244,809
	0.51		242,966		6.70		0.51		242,966	0.22		1,750,000		4.84		0.22		1,750,000
	0.58		271,224		6.07		0.58		271,224	0.38		900,000		4.16		0.38		900,000
	0.73		1,025,000		5.48		0.73		1,025,000	0.73		762,500		3.78		0.73		762,500
	1.37		150,000		4.81		1.37		150,000	1.37		150,000		2.00		1.37		150,000
	1.43		525,000		4.66		1.43		525,000	1.43		300,000		3.91		1.43		300,000
	2.95		150,000		3.62		2.95		150,000	11.88		2,359		0.51		11.88		2,359
	11.88		2,359		1.26		11.88		2,359	15.00		75,000		3.91		15.00		75,000
	15.00		75,000		4.66		15.00		75,000	19.80		1,442		0.34		19.80		1,442
	19.80		1,442		1.08		19.80		1,442			15,336,110		8.37	$	0.31		8,451,110
			6,130,004		6.49	$	0.75		6,130,004

The compensation expense attributed to the issuance of the options is recognized as they are vested.

The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years.

The aggregate intrinsic value totaled $0$0 and was based on ~~Mateon’s~~the Company’s closing stock price of ~~$0.18~~$0.14 as of September 30, 2021, which would have been received by the option holders had all option holders exercised their options as of that date. Correspondingly, the aggregate intrinsic value totaled $0 and was based on the Company’s closing stock price of $0.22 as of December 31, 2020, which would have been received by the option holders had all option holders exercised their options as of that date.

As of September 30, ~~2020,~~2021, there was no future compensation cost as all stock options vested asprior to December 31, 2019 and the compensation was fully expensed prior to the ~~Merger and no new options have been granted since then.~~

~~In April~~ 2019 ~~and in conjunction with the close of the Merger,~~merger between the Company ~~recorded approximately $341,000 in compensation cost as a result of the acceleration of the vesting schedule of approximately 328,000~~and Oncotelic, ~~options. Pursuant to the Merger these options were converted into Common Stock and Series A Preferred Shares in the Company.~~

Inc. In August 2019, the Company had entered into Employment Agreements and incentive compensation arrangements with each of its executive officers, including Dr. Vuong Trieu, the Chief Executive ~~Officer; Dr. Fatih Uckun, the Chief Medical Officer;~~Officer (“CEO”); Dr. Chulho Park, its prior Chief Technology ~~Officer;~~Officer (“CTO’); and Mr. Amit Shah, the Chief Financial ~~Officer. Details of the agreements and the incentive compensation is described in detail in Note 11 – Commitments & Contingencies under “Employment Agreements”~~Officer (“CFO”). The incentive stock options orand the restricted stock awards ~~granted to~~approved for the Company’s executive officers were granted and issued in July 2021. The Company issued an aggregate of 1,257,952 of its common shares in lieu of fully vested restricted stock units and 4,244,809 incentive and non-qualified stock options to purchase its Common Stock to all its employees, including the awards due to the CEO, CFO, the prior CTO and Saran Saund, the Chief Business Officer of the Company. Further, the Company issued all its employees, including the CEO and CBO, 4,325,000 performance-based stock options that would vest over two tranches subject to certain corporate goals being achieved, none of which have ~~not~~vested as of September 30, 2021. In addition, the Company granted its Board of Directors and certain consultants 2,825,000 stock options, which for the Board of Directors vest over 5 quarters commencing the quarter ended September 30, 2021 and for the consultants on the same basis as the Company’s employees. Of the options granted to the Board members, 265,000 have vested as of September 30, 2021.

The Company recorded a fair value stock-based compensation of $299,890 for the vested stock options during the three and nine months ended September 30,2021. NaN similar expense was recorded during the same periods in 2020. The fair value of the stock compensation expense, using a Black Scholes valuation model, was calculated using the following input values.

In addition, the Company recorded a fair value stock-based compensation of $226,431 for the fully vested restricted stock units issued during the three and nine months ended September 30,2021, and which had been granted asto the employees in August 2019. No similar expense was recorded during the same periods in 2020. The fair value of the stock compensation expense was calculated using the stock price of the restricted stock units on the date of ~~this filing.~~the grant as they were fully vested.

Pursuant to the ~~Merger, Mateon’s~~Oncotelic merger, the Company’s Common Stock and corresponding outstanding warrants survived. The below information represents ~~Mateon’s~~the Company’s associated warrant ~~activity pre-merger~~activity.

During the three months ended March 31, 2021, 2,035,000 warrants were issued related to private placement. The fair value of these warrants on issue date amounted to $467,637 with an expected life of 1.5 years, as calculated using Black Scholes valuation model. Further, during the three months ended June 30, 2021, and ~~post-merger.~~as disclosed in Note 6 above, the Company issued 20,000,000 warrants were issued related to private placement. The fair value of these warrants on issue date amounted to $2,023,552 with an expected life of 1-2 years, as calculated using Black Scholes valuation model.

In February 2020, ~~Mateon~~the Company offered to cancel to all the prior warrants of the warrant holders from the 2018 debt financing and offered to reissue new warrants to such warrant holders. Out of all the warrant holders, holders of 13,750,000 warrants opted to participate in the ~~reissuance. In addition,~~reissuance during the ~~Company issued 2,915,000 new~~same period in 2020. The company recognized stock-based compensation of $2.1 million as the fair value of the warrants ~~to certain accredited investors in connection with~~using a Black Scholes valuation model. NaN similar expense was recorded for the ~~financing through JH Darbie (See note 6).~~ three months ended March 31, 2021.

The issuance of warrants to purchase shares of ~~Mateon’s~~the Company’s Common Stock, including those attributed to debt issuances, as of September 30, ~~2020~~2021 and December 31, ~~2019~~2020 are summarized as follows:

The following table summarizes information about warrants outstanding and exercisable at September 30, ~~2020:~~2021:

The Company issued 24,035,000 warrants during the nine months ended September 30, 2021, of which 22,000,000 warrants issued during the three months ended June 30, 2021. The Company recorded stock-based compensation of approximately $2.0 million, as fair value of the warrants, using a Black Scholes valuation model using the following input values. The expense attributed to the issuances of the warrants was recognized as they vested/earned. These warrants ~~were~~are exercisable for three to five years from the grant date. ~~There were no~~All the warrants are currently exercisable.

The Company issued 13,750,000 warrants issued during the ~~year ended December 31, 2019. 13,750,000 warrants were issued during the three~~nine months ended ~~March 31,~~September 30, 2020 ~~and Mateon~~were as recorded stock-based compensation of ~~$2,100,000~~$2.1 million as the fair value of the warrants using a Black Scholes valuation model using the following input values. The expense attributed to the issuances of the warrants was recognized as they vested/earned. These warrants are exercisable for three to five years from the grant date. All the warrants are currently exercisable.

~~Expected Term~~		~~3 years~~
Expected ~~volatility~~Term	3 years		~~140.5~~	%
Expected volatility		140.5	%
Risk-free interest rates		1.40	%
Dividend yields		0.00	%

Significant components of the Company’s ~~July through September private placement offering, the estimated grant date fair value~~deferred tax assets and liabilities for federal and state income taxes as of approximately $0.20 per share associated with the warrants to purchase up to 2,915,000 shares of common stock issued in this offering, or a total of approximately $0.4 million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $0.20 per share of the Company stock or $1.00 per share of Edge Point, subject to adjustment, are exercisable immediately and expire three years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation model using the following input values:

The Company recorded an initial debt discount of approximately $0.6 million representing the intrinsic value of the conversion option embedded in the convertible debt instrument based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. The Company recognized amortization expense related to the debt discount and debt issuance costs of $162,267 for the three and nine months ended September 30, 2021 and December 31, 2020 ~~respectively, which is included~~are as follows in ~~interest expense in the condensed statements of operations. No similar expense was recorded for the same periods in 2019.~~thousands:

The Company had gross deferred tax assets of approximately ~~$66,100,000~~$68.0 million and ~~$65,000,000~~$66.9 million as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively, which primarily relate to net operating loss carryforwards. ~~The increase during the nine months ended~~

As of September 30, 2021 and December 31, 2020, ~~relates~~the Company had gross federal net operating loss carryforwards of approximately $236.3 million and $237.7 million, respectively, which are available to ~~the operations of the Company.~~

offset future taxable income, if any. The Company ~~records~~recorded a valuation allowance in the full amount of ~~our~~its net deferred tax assets since realization of such tax benefits has been determined by ~~the Company’s~~our management to be less likely than not.

At September 30, 2021 and December 31, 2020, the Company had California state gross operating loss carry-forwards of approximately $76.6 million and $69.8 million which will expire in various amounts from 2028 through 2040.At December 31, 2020, the Company had federal research and development tax credits of approximately $3.3 million which will expire in 2021and California state research and development tax credits of approximately $1.4 million which have no expiration date.

The Company ~~has~~ identified ~~our~~its federal and California state tax returns as “major” tax jurisdictions. ~~Currently, the~~The periods ~~the Company’s~~out income tax returns are subject to examination for these jurisdictions are ~~2015~~2017 through ~~2018, until such time the Company files the 2019 tax return. The Company believes its~~2020. We believe our income tax filing positions and deductions will be sustained on audit, and ~~the Company~~we do not anticipate any adjustments that would result in a material change to ~~its~~our financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. The Company filed its 2020 federal and state corporate tax returns in October 2021.

At September 30, 2020, the Company had available net operating loss carry forwards for federal income tax reporting purposes of approximately $251,700,000, including net operating losses of $3,700,000 recorded through the nine months ended September 30, 2020. At December 31, 2019, the Company had available net operating loss carry-forwards for federal income tax reporting purposes of approximately $248,000,000 which are available to offset future taxable income. Portions of these ~~carry-forwards~~carryforwards will expire through 2038, if not otherwise utilized. The ~~Company has~~Company’s utilization of net operating loss carryforwards could be subject to an annual limitation. as a result of certain past or future events, such as stock sales or other equity events constituting a “change in ownership” under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations could result in the expiration of net operating loss carryforwards and tax credits before they can be utilized. We have not performed a formal analysis, but ~~the Company believes its~~we believe our ability to use such net operating losses and tax credit ~~carry-forwards is~~carryforwards will be subject to annual limitations, due to change of ownership control provisions under ~~Sections~~Section 382 and 383 of the Internal Revenue Code, which would significantly ~~impacts the Company’s~~impact our ability to realize these deferred tax assets.

~~As of the date of this filing, the Company has not filed its 2019 federal and state corporate income tax returns. The Company expects to file these documents as soon as practicable.~~

Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. The Company believes the office is sufficient for its current operations.

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is not presently a party to any legal proceedings that it currently believes, if determined adversely to the Company, would individually or taken together have a material adverse effect on the Company’s business, operating results, financial condition or cash flows.

In August 2019, Mateon entered into Employment Agreements and incentive compensation arrangements with each of its then executive officers, including Dr. Vuong Trieu, the Chief Executive Officer; Dr. Fatih Uckun, the Chief Medical Officer; Dr. Chulho Park, the Chief Technology Officer; and Mr. Amit Shah, the Chief Financial Officer. In November 2019, upon review of the said employment agreement with Dr. Uckun, it was observed that the agreement submitted for Dr. Uckun was the incorrect document and the Company filed the correct document.

~~The Employment Agreements provide for annual base salaries for each year of the term, subject to review and adjustment by Mateon’s Board or the Compensation Committee of the Board (the “~~~~Compensation Committee~~”) from time to time. Each Employment Agreement provides that the executive shall be eligible for an annual discretionary cash bonus expressed as a percentage the executive’s base salary, subject to their achievement of performance targets and goals established by the Board or the Compensation Committee.

The Employment Agreements provide for equity awards to each executive under the terms of Mateon’s stock option plans. Each Employment Agreement provides that the executive will receive a restricted stock grant of the Mateon’s Common Stock. Mateon will compensate Messrs. Trieu, Park and Shah for the taxes actually incurred on grant of the restricted shares. The restricted stock will vest fully on the one-year anniversary of employment. As of December 31, 2019, the restricted shares have yet to be issued. The Employment Agreements also provide for grants of incentive stock options to purchase shares of Mateon’s Common Stock under the Stock Plans. Such options shall vest and become exercisable after one year of employment. As of December 31, 2019, these options had yet to be granted. Thereafter, each Employment Agreement contemplates that the executive will be eligible to receive a comparable annual grant of restricted shares or stock options as approved by the Board or Compensation Committee and which shall contain the customary terms and provisions of such grants generally to key executives under the 2017 Stock Plan.

~~The initial restricted stock grants and stock option grants have been set for the executives as follows:~~

~~The incentive stock options or the restricted stock awards granted to the Mateon’s officers have not been issued as of the date of this filing.~~

The total purchase price of ~~$17,831,427~~ $17,831,427 represented the consideration transferred from Mateon in the PointR ~~Merger~~merger and was calculated based on the number of shares of Common Stock plus the preferred shares outstanding but convertible into Common Stock outstanding at the date of the ~~PointR~~ Merger and includes ~~$2,625,000~~ $2,625,000 of contingent consideration of shares issuable to PointR shareholders upon achievement of certain milestones.

~~On November 5, 2020,~~In September 2021, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State for the State of Delaware changing its name from “Mateon Therapeutics, Inc.” to “Oncotelic Therapeutics, Inc.” A notice of corporate action has been filed with the Financial Industry Regulatory Authority (FINRA), requesting approval to change its name and ticker symbol. The Company is still awaiting FINRA’s approval on its notice of corporate action, and upon receipt of acceptance, the Company’s ticker symbol will be changed to reflect the Company’s name change.

~~In June 2020, Mateon~~ secured $2$1.5 million in debt financing ~~evidenced by a one year convertible note (the “GMP Note”) from GMP,~~ to ~~conduct a~~fund the clinical trial evaluating OT-101 against COVID-19 bearing 2% annual ~~interest,~~interest. As of September 30, 2021, GMP was invoiced by the clinical research organization for $0.5 million. GMP paid the clinical trial organization the first tranche of $0.5 million in October 2021.

In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million and ~~is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of Mateon. The GMP~~which October 2021 Note is convertible into ~~Mateon’s Common Stock upon the GMP Note’s maturity one year from the date~~shares of the ~~GMP Note, at Mateon’s~~Company’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial.

The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $2 million. In October 2020, theStock. GMP paid ~~approximately $0.5 million to the clinical trial organization, which accrued as a liability to~~ the Company ~~under~~ the ~~terms of the GMP Note.~~$0.5 million in October 2021.

~~(1) changing the name of the Company to “Oncotelic, Inc.” and to changing the Company’s ticker symbol (the “~~~~Name Change~~~~”);~~

~~(2) amending the Company’s Amended and Restated 2015 Equity Incentive Plan (the “~~~~2015 Plan~~”) to increase the number of shares of Common Stock available for issuance from 7.25 million shares to 27.25 million shares, and increasing the maximum number of stock awards that may be issued in any fiscal year from 500,000 to 1,000,000 shares (the “~~Plan Amendment~~~~”);~~

~~(3) increasing the authorized number of shares of Common Stock from 150,000,000 to 750,000,000 (the “~~~~Capital Increase~~~~”); and~~

~~The Stockholders approved the Name Change, the Plan Amendment, the Capital Increase, and the Amended and Restated Certificate. The State of Delaware approved the name change on November 5, 2020.~~

~~On August 19, 2020 the Company executed a memorandum of understanding (the “~~~~MOU~~~~”) with Windlas Biotech Private Limited (~~~~“Windlas~~”) for the development and commercialization of Artemisinin as a therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19. The development of Artemisinin against COVID-19 is dependent on the successful completion of ARTI-19 clinical trial “Artemisinin Intervention trial against COVID-19”, which is being initiated globally in Africa, India, and South America. Windlas will be our manufacturing partner for the clinical trial batches as well as commercial batches.

The ARTI-19 trial has been cleared by India regulatory authorities for initiation. The trial is now registered under CTRI and three sites have been selected, their IRB approval obtained, their staffs have been trained into the protocol/EDC. Additional sites will be added as the trial progressed. Enrollment of patients has already commenced for the trial.

~~The Company and Windlas entered into a License, Development and Commercialization Agreement, dated November 10, 2020 (the “~~~~Commercialization Agreement~~”), which formalized the terms set forth in the MOU. Pursuant to the Commercialization Agreement, Windlas shall be responsible for developing, manufacturing, and supplying Artemisinin within India and eventually expanding worldwide, excluding China and its territories and the Americas. Windlas will also be responsible to market Artemisinin and its variants in India. Under the terms of the Commercialization Agreement, Windlas and the Company will evenly split all profits derived from commercialization of Artemisinin within India. For all other territories, which excludes China and its territories and the Americas, the profit-split ratio is to be determined and negotiated on a country-by-country basis.

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q (the “Quarterly Report” or “Report”) includes a number of forward-looking statements that reflect management’s current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Some of these risks are included in the section entitled “Risk Factors” set forth in this Quarterly Report and in other reports that we file with the ~~SEC.~~Securities and Exchange Commission (“SEC”). The occurrence of any of these risks, or others of which we are currently unaware, may cause our company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks include, by way of example and without limitation:

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the ~~SEC, including our Form 10-K filed with the SEC on May 14, 2020, which includes the audited financial statements for our subsidiary, Oncotelic, as of and for the years ended December 31, 2018.~~SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that the actual results of operations or the results of our future activities will not differ materially from our assumptions.

Oncotelic Therapeutics, Inc. (also d/b/a Mateon Therapeutics, Inc. ~~(f/k/a OXiGENE, Inc.~~) ~~( “~~(“~~Mateon~~Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, ~~and~~ changed its name to Mateon Therapeutics, Inc. in ~~2016. Mateon~~2016, and then Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through ~~both Mateon~~Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc. (“~~Oncotelic~~”), a Delaware corporation, ~~and~~ PointR Data, Inc. (“PointR”), a Delaware corporation, and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which ~~we have~~there are non-controlling interests, ~~(Mateon,~~(Oncotelic, Oncotelic Inc., PointR and Edgepoint are collectively called the “Company”). ~~Mateon~~The Company is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma.

~~In April 2019, Mateon~~”) entered into an ~~Agreement and Plan of Merger with Oncotelic (the “~~~~Merger Agreement~~~~”),~~ ~~a clinical-stage biopharmaceutical company focused on the treatment of cancer using TGF-b RNA, and Oncotelic Acquisition Corporation (the “~~~~Merger Sub~~”, a newly formed wholly-owned subsidiary of the Company). Meteon and Oncotelic entered into the Merger Agreement in order to create a publicly traded company with a pipeline of immunotherapies that target several cancer markets which currently lack adequate treatment options. Following the satisfaction of closing conditions contained in the Mergerexclusive License Agreement (the “~~Merger~~~~”), the Merger Sub was merged with and into Oncotelic, with Oncotelic surviving the Merger as a wholly-owned subsidiary of the Company.~~

~~In August 2019, Mateon entered into an Agreement and Plan of Merger (the “~~~~PointR Merger~~License Agreement”) with ~~PointR (the~~Autotelic, Inc. (“Autotelic”), pursuant to which Autotelic granted Oncotelic, among other things: (i) the exclusive right and license to certain Autotelic Patents (as defined in the Agreement) and Autotelic Know-How (as defined in the License Agreement); and (ii) a right of first refusal to acquire at least a majority of the outstanding capital stock of Autotelic prior to Autotelic entering into any transaction that is a financing collaboration, distribution revenues, earn-outs, sales, out-licensing, purchases, debt, royalties, merger acquisition, change of control, transfer of cash or non-cash assets, disposition of capital stock by way of tender or exchange offer, partnership or any other joint or collaborative venture, research collaboration, material transfer, sponsored research or similar transaction or agreements. In exchange for the rights granted to Oncotelic, Autotelic will be entitled to earn certain milestone payments (collectively, the “~~PointR Merger~~Milestone Payments”), ~~a privately-held developer of high-performance cluster computer and AI applications. The PointR Merger Agreement provided, that subject~~. In addition to the ~~satisfaction of certain conditions, PointR would~~Milestone Payments, Autotelic will be ~~merged with and into a newly formed subsidiary~~entitled to royalties equal to 15% of the ~~Company, with PointR surviving~~net sales of any products that incorporate the ~~PointR Merger as a wholly-owned subsidiary of the Company.~~Autotelic Patents or Autotelic Know-How.

On May 3, 2021, the Company entered into ~~Amendment No. 1 to the PointR Merger~~an Equity Purchase Agreement (the “~~Amendment~~EPL”) and Registration Rights Agreement (the “Registration Rights Agreement”) with ~~PointR~~Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company shall have the right, but not the obligation, to direct Peak One, to purchase up to $10.0 million (the “Maximum Commitment Amount”) in shares of the Company’s Common Stock. Under the EPL and ~~consummated~~subject to the ~~PointR Merger.~~Maximum Commitment Amount, the Company has the right, but not the obligation, to submit Put Notices (as defined in the EPL) to Peak One (i) in a minimum amount not less than $20,000.00, and (ii) in a maximum amount up to the lesser of (a) $1.0 million or (b) 250% of the Average Daily Trading Value (as defined in the EPL). In exchange for Peak One entering into the EPL, the Company agreed, among other things, to (A) issue Peak One and Peak One Investments, LLC, an aggregate of 250,000 shares of Common Stock, and (B) file a registration statement registering the Common Stock issued or issuable to Peak One under the EPL for resale (the “Registration Statement”) with the SEC within 60 calendar days of the date of the EPL, as more specifically set forth in the Registration Rights Agreement. The ~~PointR Merger~~obligation of Peak One to purchase the Company’s Common Stock shall begin on the date of the EPL, and ending on the earlier of (i) the date on which Peak One shall have purchased Common Stock pursuant to the EPL equal to the Maximum Commitment Amount, (ii) twenty four (24) months after the initial effectiveness of the Registration Statement , (iii) written notice of termination by the Company to Peak One (subject to certain restrictions set forth in the EPL), (iv) the Registration Statement is no longer effective after the initial effective date of the Registration Statement, or (v) the date that the Company commences a voluntary case or any person commences a proceeding against the Company, a custodian is appointed for the Company or for all or substantially all of its property or the Company makes a general assignment for the benefit of its creditors (the “Commitment Period”). During the Commitment Period, the purchase price to be paid by Peak One for the Common Stock under the EPL shall be 91% of the Market Price, which is defined as the lesser of the (i) closing bid price of the Common Stock on the trading day immediately preceding the respective Put Date (as defined in the EPL), or (ii) lowest closing bid price of the Common Stock during the Valuation Period (as defined in the EPL), in each case as reported by Bloomberg Finance L.P or other reputable source designated by Peak One.

Between July 2020 and March 2021, the Company offered and sold certain units (“Units”) in a private placement through JH Darbie & Co., Inc. (“JH Darbie”), with each unit consisting of: (i) 25,000 shares of Edgepoint common stock, par value $0.01 per share (“Edgepoint Common Stock”), for a price of $1.00 per share of Edgepoint Common Stock; (ii) one convertible promissory note issued by the Company (the “Unit Note”), convertible into up to 25,000 shares of EdgePoint Common Stock at a conversion price of $1.00 per share, or up to 138,889 shares of the Company’s Common Stock, at a conversion price of $0.18 per share; and (iii) 100,000 warrants (the “Warrants”), consisting of (a) 50,000 warrants to purchase an equivalent number of shares of EdgePoint Common Stock at $1.00 per share (“Edgepoint Warrant”), and (b) 50,000 warrants to purchase an equivalent number of shares of Company Common Stock at $0.20 per share (“Oncotelic Warrant”) (the sale of Units is hereinafter, the “JH Darbie Financing”). In total, as of December 31, 2020, the Company had issued and sold a total of 63 Units. In addition, 6.3 Units were issued to JH Darbie as fees. Subsequent to December 31, 2020 and through the date of this report, the Company sold the remaining 37 Units and JH Darbie earned an additional 3.7 Units as fees.

The JH Darbie Financing resulted in gross proceeds of $5 million to the Company. Placement agent fees of $0.65 million were paid to JH Darbie pursuant to that certain Placement Agent Agreement, dated February 25, 2020 between the Company and JH Darbie (the “Darbie Placement Agreement”). In addition, the Company paid approximately $39,000 as legal costs for the transaction. Under the Darbie Placement Agreement, JH Darbie had the right to sell a minimum of 40 Units and a maximum of 100 Units on a best-efforts basis. The Company has had nine tranches under the JH Darbie Financing between July and March 31, 2021. Subsequent to December 31, 2020, the Company received gross funds of $1.85 million through 4 tranches under the JH Darbie Financing. Placement fees of $0.2 million were paid to JH Darbie in connection with such financing.

In June 2021, the Company and the Investors agreed to extend the maturity date of the Notes from June 30, 2021, to March 31, 2022. In addition, the Company and JHDarbie identified an error in the Oncotelic Warrants and JH Darbie Financing documents which intended to ~~create~~have the investors to purchase $50,000 of shares of Common Stock or Edgepoint Common Stock. However, the Company only issued 50,000 Oncotelic Warrants, with an aggregate exercise price of $10,000. The error was corrected by the Company and the Company issued to the Investors an aggregate of 20.0 million additional Oncotelic Warrants, and 2.0 million additional Oncotelic Warrants to J.H. Darbie, as placement agent. Each Investor was entitled to receive 200,000 additional Oncotelic Warrants for each Unit purchased.

In May and June 2021, the Company entered into Securities Purchase Agreement (the “Geneva Agreement”) with Geneva Roth Remark Holdings Inc. (“Geneva”), whereby the Company issued two convertible notes (collectively, the “Geneva Notes”) in the aggregate principal amount of $307,500, convertible into shares of Common Stock. Under the terms of the Geneva Agreement, the Company will receive additional tranches of convertible note financing of up to $1.2 million throughout the term of the Geneva Agreement. The Geneva Notes have an interest rate of six percent (6%), which increases to twenty-two percent (22%) in the event of a ~~publicly traded AI driven immuno-oncology company~~default under each respective Note, and both mature one year from issuance (the “Maturity Date”). Geneva has the right from time to time, and at any time during the period beginning on the date which is one hundred eighty (180) days following issuance date and ending on the Maturity Date to convert all or any part of the outstanding and unpaid amount of the applicable Geneva Note into the Company’s Common Stock at a conversion price established at sixty five (65%) percent multiplied by the lowest two (2) daily volume weighted average price over the fifteen (15) consecutive trading days. The Geneva Notes include a clause accelerating the Company’s payment obligations upon the occurrence of certain events of default whereby, at the option of Geneva, the Company will become immediately obligated to repay Geneva in an amount equal to the principal of the applicable Geneva Loan plus both accrued but unpaid interest and default interest, in cash, with premium.

The total amount outstanding under the Geneva Notes, including accrued interest thereon, as of September 30, 2021, and December 31, 2020, was $313,472 and $0, respectively.

In August 2021, the Company issued Note Purchase Agreements with Autotelic the CFO, and certain other accredited investors. Under the terms of the Note Purchase Agreements, the Company issued an aggregate of $698,500 (the “Principal Amount”) in debt in the form of unsecured convertible promissory notes (collectively, the “August 2021 Notes”). The August 2021 Notes are unsecured, and provide for interest at the rate of 5% per annum. Such August 2021 Notes were issued against some of the short-term debt due as of June 30, 2021. All amounts outstanding under the August 2021 Notes become due and payable at such time as determined by the holders of a ~~robust pipeline~~majority of ~~first~~the Principal Amount of the August 2021 Notes (the “Majority Holders”), on or after (a) the one year anniversary of the August 2021 Notes ,or (b) the occurrence of an Event of Default (as defined in ~~class TGF-β immunotherapies for late stage cancers~~the Note Purchase Agreements) (the “Maturity Date”). The Company may prepay the August 2021 Notes at any time. Events of Default under the August 2021 Notes include, without limitation, (i) failure to make payments under the August 2021 Notes within thirty (30) days of the Maturity Date, (ii) breaches of the Note Purchase Agreement or August 2021 Notes by the Company which is not cured within thirty (30) days of notice of the breach, (iii) bankruptcy, or (iv) a change in control of the Company (as defined in the Note Purchase Agreements). The Majority Holders have the right, at any time not more than five days following the Maturity Date, to elect to convert all, and not less than all, of the outstanding accrued and unpaid interest and principal on the August 2021 Notes. The August 2021 Notes may be converted, at the election of the Majority Holders, into shares of the Company’s common stock, par value $0.01 per share, at a fixed conversion price of $0.18 per share.

The Company’s CEO had provided a short term loan of $70,000 to the Company during the year ended December 31, 2020, of which $50,000 was repaid. As such, $20,000 was outstanding at September 30, 2021. During the three months ended March 31, 2021, Autotelic Inc. provided a short-term funding of $120,000 to the Company, which was repaid after the three months ended March 31, 2021. On May 18, 2021, Autotelic provided an additional short-term funding of $250,000 to the Company, which was converted into a promissory note in the August 2021 Notes. Autotelic provided an additional $20,000 short-term loan to the Company, and as ~~gliomas, pancreatic cancer~~such, $20,000 was outstanding and ~~melanoma.~~payable to Autotelic at September 30, 2021. During the fourth quarter of the year ended December 31, 2020, the Company’s CFO and the Bridge Investor provided short term loans of $25,000 and $50,000, respectively to the Company. Such loans were repaid as of March 31, 2021. During the nine months ended September 30, 2021, the CFO provided a total of approximately $120,000, of which $75,000 was converted into the August 2021 Notes. As such, a balance of approximately $45,000 remained outstanding as a short-term loan as of September 30, 2021. During the nine months ended September 30, 2021, the Company received approximately $630,000 primarily from two bridge investors, of which $373,500 was converted into the August 2021 Notes, and approximately $258,000 was outstanding as a short-term loan as of September 30, 2021.

The Company consummated mergers with Oncotelic Inc. and PointR Data Inc. (“Mergers”) in 2019. For additional information on ~~both mergers,~~the Mergers, refer to our Annual Report on ~~form~~Form 10-K filed with the SEC on ~~May 14, 2020.~~April 15, 2021.

We are a clinical stage biopharmaceutical company developing drugs for the treatment of cancer. Our goal is to advance our drug candidates into late stage pivotal clinical trials and either sell marketing rights to a larger pharmaceutical company or seek ~~FDA~~ approval from the United States Food and Drug Administration (“FDA”) ourselves.

~~Oncotelic’s~~The Company’s lead product candidate, OT-101, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers. Together, we plan to initiate phase 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer. During ~~phase~~Phase 2 clinical trials in pancreatic cancer, melanoma, and colorectal cancers ~~(Study P001)~~(“Study P001”) and in high-grade gliomas ~~(Study G004)~~(“Study G004”), meaningful clinical benefits were observed and OT-101 exhibited a favorable safety profile. These clinical benefits included long-term survival and meaningful tumor reduction. Both partial and complete responses have been observed in the Study G004 Phase 2 clinical trial of OT-101 as a single agent in patients with aggressive brain tumors.

~~Oncotelic’s~~The Company’s self-immunization protocol ~~(SIP™~~(“SIP™”) is based on novel and proprietary sequential treatment of cancers with OT-101 (an antisense against TGF-ß2) and chemotherapies. This sequential treatment strategy is aimed at achieving effective self-immunization against a patients’ own cancer, resulting in robust therapeutic immune response and consequently better control of the cancer and improved survival. Prolonged states of being cancer-free have been observed in some patients with the most aggressive forms of cancer, raising a renewed hope for a potential cure. The use of OT-101 lifts the suppression of the patient’s immune cells around the cancer tissue, providing the foundation for an effective initial priming, which is critical for a successful immune response. The subsequent chemotherapy results in the release of neoantigens that result in a robust boost of the immune response. We believe that a rational combination of the ~~Oncotelic~~company’s SIP™ platform with immune-modulatory drugs like interleukin 2 ~~(IL-2)~~(“IL-2”) and/or immune checkpoint inhibitors has the potential to help achieve sustained and robust immune responses in patients with the most difficult-to-treat forms of cancer.

~~Oncotelic~~The Company is also working on developing OT-101 as a possible drug candidate that can be deployed in various epidemic and pandemic diseases, such as Severe Acute Respiratory Syndrome (“SARS”) and specifically for the current COVID-19. As of the date of this report, the Company has filed an Investigational New Drug Application (“IND”) with the FDA to permit the Company to conduct clinical trials to prove the efficacy of OT-101 against COVID-19. The Company has initiated clinical trials in Latin America to evaluate the efficacy of OT-101 against COVID-19 and expects preliminary results ~~in Q2,~~before the end of the fiscal year 2021. The Company plans to initiate the Company’s Phase 2 clinical trial of OT-101, a TGF-β antisense, for the treatment of patients with mild to severe COVID-19 infection. ~~Argentina now has the fifth highest tally of confirmed coronavirus cases worldwide, with the latest additions taking it past Colombia in a global ranking compiled by John Hopkins University. This~~The multi-center, double blind, randomized, placebo-control study ~~will~~was planned to evaluate the safety and efficacy of OT-101 in combination with standard of care on two ~~(2)~~ patient ~~cohorts~~groups – 1)(1) mild or moderate disease, and 2)(2) severe disease requiring mechanical ventilation or intubation. The ~~study will enroll approximately 24~~Company discontinued enrollment in its OT-101 clinical trial in patients with COVID-19 in ~~Argentina with~~June 2021. The trial completed randomization of 32 out of 36 patients planned, on an ~~aggregate total~~intent to treat basis. The discontinuance of ~~72 pts study wide.~~the trial was due to the continuing rise of more severe variants in Latin America, leading to exhaustion of medical care infrastructure in Latin America. We are awaiting topline results for this study.

In addition, the Company is developing ~~artemisinin.~~Artemisinin as an Ayurvedic therapeutic under the product names ARTIVeda^TM (when marketed within India), and ArtiShield^TM (when marketed outside of India) (ARTIVeda^TM and ArtiShield^TMare collectively referred to herein as “ARTIVeda^TM”). Artemisinin, purified from a plant Artemisia ~~annua~~Annua, ~~is able~~has exhibited an ability to inhibit TGF-β activity and ~~is able to~~ neutralize ~~SARS-CoV-2 (COVID-19). It has~~COVID-19. The Company’s test results during an in vitro study at Utah State University showed Artemisinin having an EC50 of 0.45 ug/ml, ~~(In an in vitro study Mateon’s test result at Utah State University),~~ and a Safety Index of 140. Artemisinin can target multiple viral threats including COVID-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. Viral replication cannot occur without TGF-β. Artemisinin also has been reported to have antiviral activities against hepatitis B and C viruses, human herpes viruses, HIV-1, influenza virus A, and bovine viral diarrhea virus in the low micromolar range. TGF-β surge and cytokine storm cannot occur without TGF-β. ~~Clinical~~In a clinical study undertaken in India, clinical consequences related to the TGF-β surge, including ARDS and cytokine storm, ~~are~~were suppressed by targeting TGF-β with Artemisinin. ~~This is~~The clinical study (“ARTI-19”) showing these results was a global study, ~~with India to contribute~~enrolling at least 120 ~~pts~~patients. The number of patients planned to be enrolled in the ARTI-19 trial increases the total aggregate number of ~~3000 pts.~~patients using ARTIVeda^TMto 3,000. The ARTI-19 trials were conducted by Windlas Biotech Private Limited (“Windlas”), the Company’s business partner in India, as part of the Company’s global effort at deploying ARTIVeda^TMacross India, Africa, and Latin America. The Windlas study evaluates the safety and efficacy of Artemisia ~~absinthium~~Absinthium Powder 500mg capsule ~~(ArtiShield~~of ARTIVeda^TM) in the treatment of adults with COVID-19. ~~Top-line data~~Data from ARTI-19 is expected by end of ~~4Q20.~~the fourth quarter of the fiscal year 2021. The ARTI-19 trial was ~~recently cleared by Indian regulatory authorities and is~~ registered under the Clinical Trials Registry India ~~(CTRI)~~(“CTRI”) with three active sites and additional sites to be added as the trial progresses and expands. ARTI-19 ~~in India is being~~was conducted bywith Windlas ~~Biotech Private Limited,~~ as part of ~~Mateon’s~~the plan for the Company’s global effort at deploying ~~ArtiShield~~Pulmoheal^TM, a product package of ARTIVeda^TM, our artificial intelligence (“AI”) cough application (“ArtiHealth”), and our AI post marketing survey (“PMS”), across India, Africa, and Latin America. We continue to evaluate to seek approval, and subsequently launch PulmoHeal^TM, with or without local partners, in various countries within the regions planned.

In January 2021 and subsequently in February 2021, the Company announced preliminary results for ARTI-19 trials for ARTIVeda^™. The interim results announced were, as previously disclosed above, based on 120 randomized patients across three sites in India. We reported positive topline results in April 2021, and we expect final data as soon as available. Upon completion of the trial results and obtaining regulatory approval for the use in India, it is the Company’s objective to file for Emergency Use Authorization (“EUA”) with regulatory authorities around the world, including India, the United States, the United Kingdom, countries in Africa and Latin America; discussions regarding EUA with several of these authorities have commenced. On August 24, 2021, the Company announced that PulmoHeal^TMand ArtiVeda^TM have proven to be effective against mild and moderate COVID-19 following the preplanned prospective analysis of the Company’s ARTI-19 clinical trial. As announced, the study report would serve as the basis for the Company’s regulatory submission for marketing approval of ArtiVeda^TM.

No adverse events were reported that required discontinuation of treatment. When ARTIVeda^™ was added to the standard of care (“SOC”), more patients recovered faster than SOC alone. Of the 39 patients, 31 patients (79.5%) being treated with ARTIVeda^™ became asymptomatic after 5-day of therapy. In comparison, only 12 of the 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (P=0.028, Fisher’s exact test). For the sicklier patients (WHO scale 4), the median time to becoming asymptomatic was only 5 days for the ARTIVeda + SOC group (N=18), as compared to 14 days for the SOC alone group (N=10) (P=0.004, Log-rank test). These data sets provide clinical support that targeting the TGF-β pathway with ARTIVeda^™may contribute to a faster recovery of patients with mild to moderate COVID-19. The trend was more pronounced with higher initial disease status. Log rank statistics: WHO-scale 2,3,4: p= 0.0369 /RR = 1.476 (0.8957-2.433), WHO-scale 3,4: p= 0.026/ RR = 1.581 (0.9094-2.747), WHO-scale 4: p= 0.0043/ RR = 2.038 (0.9961-4.168). RR = rate ratio for recovery. The Company has published the results of the trial in certain renowned publications.

In addition to ARTIVeda^™, the Company has also developed and launched ArtiHealth and the PMS, and when packaged with ARTIVeda^TM, are packaged as a product offering under the name PulmoHeal^™. PulmoHeal^™is a full evaluation package of drug and assessment platforms for COVID-19, and other respiratory disease patients. Windlas has launched ArtiHealth on Amazon.in, Flipkart, and 1mg.com. The platform has been powered by the Company’s AI supercomputing and AI platform in conjunction with IBM. Initially, the cough assessment will be powered by Salcit Pvt. Ltd.’s (“Salcit”) AI module. Per Salcit, their AI module has overall accuracy in predicting the pattern of the disease at 91.97%, sensitivity at 87.2%, and specificity at 93.69%.

Our artificial intelligence subsidiary, PointR, develops and deploys high performance cluster computers and AI technologies as a supercomputing grid that can be layered in and interconnected to create an all-point mesh to harvest operational data within manufacturing ~~plant,~~plants, hospitals, clinics, and phase I units. These grids provide real-time, localized decision-making, harvesting complex data from structured and unstructured sources. The deployment of this supercomputing grid enables data capture and insight extraction in real time in blocks which are chained into blockchain ledger records serving as immutable transactions for stakeholders such as regulatory agencies, caretakers, insurers, payers, and manufacturers. The PointR grid can integrate and fuse data from any type of sensors or collection devices. For example, the Vision platform is a network of activity detection cameras functionalized with AI algorithms to monitor, evaluate, and archive real time visual data as a series of metadata entries in a Blockchain ledger. In the pharmaceutical industry, PointR’s AI combined with Blockchain will be used in the entire life cycle of a drug: discovery, clinical trials and manufacturing. Leveraging its deep partnership with IBM, the PointR team will combine its own AI Vision technology with industry standard Blockchain to transform drug manufacturing and real-world evidence monitoring for clinical trials. The combined system has the potential to automatically record individual key steps in ~~cGMP~~Current Good Manufacturing Practice regulations enforced by the FDA (“CGMP”) for manufacturing operations including the flow of people, raw materials and operations in trusted perpetual blockchain ledgers that are indisputable. This has the potential to create much more efficient ~~GMP~~CGMP manufacturing operations while simultaneously improving reliability and data security. The Company is also developing AI driven telehealth and other applications, that would be used in health monitoring and supporting the Company’s various clinical programs. The PointR technology is planned to be transferred into Edgepoint. Edgepoint also plans to redeploy TrustPoint, a tested technology for ~~GMP~~CGMP drug manufacturing relieving human errors in supply chain and increasing compliance with warehouse operating procedures. For example, the warehouse module of TrustPoint will automatically create a shopping list from standard templates and alert supply chain personnel to collect and deliver a list of raw materials to manufacturing. To support the anti-viral drug program, Edgepoint is developing ~~an AI app to remotely monitor patients’ respiratory status just using a mobile phone.~~ArtiHealth. Protected by patents and partnership with IBM Watson Health Research ~~the app~~ArtiHealth allows patients to cough and speak into ~~a mobile phone app~~the ArtiHealth App that can be operated either by a nurse or by the end-user patient at home. ~~The app~~ArtiHealth is part of the company’s Telehealth platform to remotely monitor patient’s progression of disease. ~~Mateon’s~~The Company’s clinical trials of ~~the anti-viral agent ARTI-Shield~~ ARTIVeda^TMwill deploy ~~the AI app~~ArtiHealth to ~~COVID~~COVID-19 patients in the study to collect and score data by medical professionals. The data will be used by the AI to predict and diagnose patients as a de-novo software as a medical device. After regulatory approvals, ~~the app~~ArtiHealth will be bundled with ~~ARTI-Shield™~~ARTIVeda^TM to be prescribed by physicians. Patients will be able to self-monitor progression of their respiratory condition with the ~~AI app~~Edgepoint App as much as they check their temperature with a thermometer. ~~The app~~ArtiHealth virtualizes and expands the use of spirometers in the form of a software app.

~~For the past year and a half,~~Since April 2019, we have been operating under significant capital constraints, which has curtailed our ability to achieve meaningful progress in either of the Company’s other two clinical programs – one of which is developing OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and the other of which is developing CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. We believe that the merger of Oncotelic and ~~Mateon~~Oncotelic Inc. creates a combined company that has potential to generate shareholder value through a promising pipeline of next generation immunotherapies targeting several significant cancer markets where there is a lack of therapeutic options and lack of an effective immunotherapy ~~protocol.~~protocol

Research Service Agreement between Golden Mountain Partners LLC ~~(GMP)~~(“GMP”) and the Company.

When COVID-19 emerged in China, the Company and GMP contemplated a collaboration to develop drug candidates for COVID-19. Oncotelic Inc. and GMP entered into a research and services agreement (the “GMP Research Agreement”) on February 3, 2020 memorializing their collaborative efforts to develop and test COVID-19 antisense therapeutics (the “GMP Agreement Product”). On March 18, 2020, the Company reported the anti-viral activity of OT-101 – its lead drug candidate currently in phase 3 testing in pancreatic cancer and glioblastoma. In an in vitro antiviral testing performed by an independent laboratory, OT-101 has an 50% effective concentration ~~(EC50)~~(“EC50”) of 7.6 µg/mL and is not toxic at the highest dose of 1000 µg/mL giving a safety index ~~(SI)~~(“SI”) value of >130, which is considered highly active. On March 23, 2020, the Company and GMP entered into a supplement to the GMP Research Agreement (the “GMP Research Supplement”) to confirm the inclusion of OT-101 within the scope of the GMP Research Agreement as a GMP Agreement Product, pending positive confirmatory testing against COVID-19. On April 6, 2020, the Company announced that it had delivered the requisite testing results to GMP confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of greater than 500. Also, the Company has submitted a Pre-Investigational New Drug application package to the FDA. GMP paid the Company fees of $300,000 during the three months ended March 31, 2020 and $900,000 during the three months ended June 30, 2020 for the services rendered under the GMP Research Agreement. The Company also recorded approximately $40,000 for reimbursement of actual costs incurred. In consideration for the financial support provided by GMP for the research, pursuant to the terms of the GMP Research Agreement (as amended by the GMP Research Supplement) GMP is entitled to obtain certain exclusive rights to the use of the GMP Agreement Product in the COVID Field on a global basis, and an economic interest in the use of the GMP Agreement Product in the COVID Field, including ~~50/50~~up to an equal split of profit sharing. As described in the GMP Research Supplement, the Company intends to license or assign intellectual property rights, including the 2020 Patent Application and any other intellectual property rights owned or controlled by the Company relating to the GMP Agreement Product, OXi4503 and CA4P, to a joint venture company (the “Joint Venture ~~Transaction~~Company”) to be established jointly between Oncotelic Inc. and GMP (or its designee), as well as providing management services and other expertise to the ~~joint venture company.~~Joint Venture Company. GMP intends that it (or its designee, as the case may be) shall provide funding to the ~~joint venture company~~Joint Venture Company to support its development and commercial activities in the ~~joint venture company’s~~Joint Venture Company’s territories, and in each case, on terms to be agreed by the parties. GMP shall be entitled to use its governmental relations and local expertise in Greater China to assist with coordinating the research, development and commercialization of (i) the GMP Agreement Products in the COVID Field, (ii) the GMP Agreement Products in the OT101 Oncology Field, (iii) OXi4503; and (iv) CA4P, in each case in Greater China.

The ~~joint venture company~~Joint Venture Company is intended to be jointly owned ~~50% by Oncotelic and 50%~~ by GMP (or its designee), the Company and Dr. Vuong Trieu, the Company’s Chief Executive Officer (the “CEO”), and its principal activities shall be to research, develop, bring to market and commercialize: (i) the GMP Agreement Products in the COVID Field on a global basis, (ii) the GMP Agreement Products in the OT101 Oncology Field, ~~in the territory set forth above,~~ (iii) ~~OXi4503 in the territory set forth above;~~OXi4503; and (iv) CA4P, in ~~the territory set forth above. On April 6,~~each case in Greater China.

In June 2020, the Company announced that it had delivered the requisite testing results to GMP confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500. Also, the Company has submitted a Pre-Investigational New Drug application package to the Food and Drug Administration. GMP paid the Company fees of $300,000 during the three months ended March 31, 2020 and $900,000 during the three months ended June 30, 2020 for the services rendered under the agreement. The Company also recorded approximately $40,000 for reimbursement of actual costs incurred. The Company has received the total fees from GMP as of the date of this report.

~~In June 2020, Mateon~~ secured $2 million in debt financing, evidenced by a ~~one year~~one-year convertible note (the ~~“GMP Note”~~“GMP Note”) from GMP or its affiliate, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed ~~by Dr. Vuong Trieu,~~ the ~~Chief Executive Officer of Mateon.~~CEO. The GMP Note is convertible into ~~Mateon’s~~the Company’s Common Stock upon the GMP Note’s maturity one year from the date of the GMP Note, at ~~Mateon’s~~the Company’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the GMP Note’s maturity at the end of one year. Such financing will be utilized solely to fund the clinical trial.

The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $2 million. ~~In October 2020, the GMP paid approximately $0.5 million to~~As of June 30, 2021, the clinical ~~trial~~research organization ~~which~~has invoiced GMP’s affiliate for the entire $2 million, and the Company has accrued the $2 million as a ~~liability to the Company~~convertible debt, including accrued interest thereon, under the terms of the GMP Note.

On August 13, 2021 the Company, the CEO, and GMP executed a letter of intent and a non-binding term sheet (the “Term Sheet”), which Term Sheet included certain binding terms relating to a standstill agreement and the issuance of a convertible promissory note (as more fully described below). The Term Sheet sets forth the terms and conditions pursuant to which the Company and GMP will, subject to shareholder approval, form a joint venture (the “JV”) with the objective to develop the Company’s product portfolio. Pursuant to the Term Sheet, the Company will contribute its product portfolio to the JV in consideration for a 35% ownership stake in the JV. As set forth above, the Term Sheet sets forth certain binding terms regarding (i) a 45-day standstill by the Company, extendable for a further 30 days with mutual written consent by all parties, and (ii) the issuance by the Company of a convertible note for $1.5 million to GMP to fund the OT-101 clinical trial study close-out. Although no assurances can be given, the Company and GMP currently intend to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. The formation of the JV is not assured as the formation of the JV is subject to approval of the Company’s shareholders and the execution of definitive agreements, among other conditions.

In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID-19, bearing 2% annual interest. The GMP Note is convertible into the Company’s Common Stock upon the maturity of the GMP Note 2, being one year from the date of issuance of the GMP Note 2, at the Company’s Common Stock price on the date of conversion with no discount. GMP does not have the option to convert prior to the maturity of the GMP Note 2. Such financing will be utilized solely to fund the clinical trial.

As of September 30, 2021, GMP was invoiced by the clinical research organization for $0.5 million. GMP paid the clinical trial organization the first tranche of $0.5 million in October 2021.

OnIn August ~~19,~~ 2020, the Company executed a memorandum of understanding (the “MOU”) with Windlas ~~Biotech Private Limited (~~~~“Windlas~~”) for the development and commercialization of Artemisinin as a therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19. The development of Artemisinin against COVID-19 is dependent on the successful completion of ARTI-19 clinical trial “Artemisinin Intervention trial against COVID-19” (“ARTI-19 trial”), which is being initiated globally in Africa, India, and South America. Windlas will be our manufacturing partner for the clinical trial batches as well as commercial batches.

On In September 1, 2020, the Company executed the final MOU with Windlas regarding the development and commercialization of Artemisinin as therapeutic pharmaceutical, nutraceutical and herbal supplement against COVID-19.

The ARTI-19 trial has been cleared by India regulatory authorities ~~for initiation. The trial is now~~and registered under ~~CTRI and three~~CTRI. Three sites have been selected ~~their IRB~~for the ARTI-19 trial, the approval of the requisite Institutional Review Boards has been obtained, ~~their staffs have~~and the respective staff has been trained into the ~~protocol/EDC.~~protocol and electronic data capture systems. Additional sites will be added as the trial ~~progressed. Enrollment of~~progresses. 120 patients ~~has already commenced for the trial.~~

~~The Company and Windlas entered into a License, Development and Commercialization Agreement, dated November 10, 2020 (the “~~~~Commercialization Agreement~~~~”), which formalized the terms set forth~~were enrolled in the ~~MOU. Pursuant to~~ARTI-19 trial during the ~~Commercialization Agreement, Windlas shall be responsible~~year ended December 31, 2020. In January 2021 and subsequently in February 2021, the Company announced preliminary results for ~~developing, manufacturing,~~ARTIVeda^TM, and ~~supplying Artemisinin within~~final topline results in April 2021. As described above, ARTIVeda^TM is the Company’s lead Ayurvedic drug against COVID-19 in India and ~~eventually expanding worldwide, excluding China and its territories and~~being developed by the ~~Americas. Windlas will also be responsible to market Artemisinin and its variants~~Company in ~~India. Under the terms~~partnership with Windlas. We expect final data available 6-8 weeks thereafter. Upon completion of the ~~Commercialization Agreement, Windlas and~~trial results, it is the ~~Company will evenly split all profits derived from commercialization of Artemisinin within India. For all other territories, which excludes China and its territories and~~Company’s objective to file for EUA with regulatory authorities around the ~~Americas, the profit-split ratio is to be determined and negotiated on a country-by-country basis.~~

~~Oncotelic had entered into a license agreement in February 2018 (the “~~~~ATB Agreement~~~~”) with Autotelic BIO (“~~~~ATB~~~~”), a non-affiliated Korean Company. The ATB Agreement licensed the use of OT-101, in combination with Interleukin-2 (the “~~~~Combined Product”)~~, and granted to ATB an exclusive license under the Oncotelic technology to develop, make, have made, use, sell, offer for sale, import and export the Combined Product, and the Combined Product only, in the COVID-19 field, throughout the entire world, ~~(excluding~~including India, the United States, of America and Canada) as the territory, on the terms and subject to the conditions of the ATB Agreement. The ATB Agreement requires ATB to be responsible for the development of the Combined Product. Oncotelic was responsible to provide to ATB the technical know-how and other pertinent information on the development of the Combined Product. ATB paid Oncotelic a non-refundable milestone payment in consideration for the rights and licenses granted to ATB under the ATB Agreement, and ATB was to pay Oncotelic $500,000 within sixty days from the successful completion of the in vivo efficacy studies. This payment was made in June 2020 after the successful completion of the in-vivo study and the United Kingdom; discussions regarding EUA with several of these authorities have commenced. For more information, please see above under Company ~~recorded the revenue during the three months ended June 30, 2020.~~ Overview.

In addition, ATB is to pay Oncotelic: (i) $500,000 upon Oncotelic’s completion of the technology know how and Oncotelic’s technical assistance and regulatory consultation to ATB, as determined by the preparation of a Current Good Regulation Practices audit or certification by the Food and Drug Administration, with a mutual goal to obtain marketing approval of the Combined Product in the aforementioned territory; (ii) $1,000,000 upon receiving marketing approval of the Combined Product in Japan, China, Brazil, Mexico, Russia, or Korea; and (iii) $2,000,000 from receiving marketing approval of the Combined Product in Germany, France, Spain, Italy, or the United Kingdom. ATB paid the Company fees of $0.5 million during the three months ended June 30, 2020 for the successful completion of the in-vivo efficacy studies.

~~Beginning~~ ~~July~~April 2020, the Company ~~offered and sold certain units (“~~~~Units~~~~”) in a private placement through JH Darbie & Co., Inc. (“~~~~JH Darbie~~~~”), with each unit consisting of: (i) 25,000 shares of Edgepoint common stock, par value $0.01 per share (“~~~~Edgepoint Common Stock~~~~”), for a price of $1.00 per share of Edgepoint Common Stock; (ii) one convertible promissory note issued by the Company (the “~~~~Unit~~ ~~Note~~”), convertible into up to 25,000 shares of EdgePoint Common Stock at a conversion price of $1.00 per share, or up to 138,889 shares of the Company’s Common Stock, at a conversion price of $0.18 per share; and (iii) 100,000 warrants (the “~~Warrants~~~~”), consisting of (a) 50,000 warrants to purchase an equivalent number of shares of EdgePoint Common Stock at $1.00 per share (“~~~~Edgepoint Warrant~~~~”), and (b) 50,000 warrants to purchase an equivalent number of shares of Company Common Stock at $0.20 per share (“~~~~Mateon Warrant~~~~”) (the “~~~~JH Darbie Financing~~~~”). In total, the Company has issued and sold a total of 53 Units. In addition, 5.3 units were issued to JH Darbie as fees.~~

~~Thus far, the JH Darbie Financing has resulted in gross~~received loan proceeds of $2,650,000 to the Company. Placement agent fees of $339,200 were paid to JH Darbie pursuant to that certain Placement Agent Agreement, dated February 25, 2020 between the Company and JH Darbie (the “~~Darbie Placement Agreement~~”). In addition, the Company paid approximately $39,000 as legal costs for the transaction. Under the Darbie Placement Agreement, JH Darbie has the right to sell a minimum of 40 Units and a maximum of 100 Units on a best-efforts basis. The Company has had three tranches under the JH Darbie Financing; first tranche was in July 2020, the second tranche was in August 2020 and the third tranche in September 2020.

~~On April 21, 2020, the Company, entered into a Paycheck Protection Program Promissory Note (the “~~~~PPP Note~~~~”) with respect to a loan~~ in the amount of $250,000 (the “First PPP Loan”) ~~from Silicon Valley Bank (the “~~~~Lender~~~~”). The PPP Loan was obtained pursuant to~~under the Paycheck Protection Program ~~(the “~~(“PPP”) ofwhich was established under the Coronavirus Aid, Relief and Economic Security ~~Act (the “~~(“CARES ~~Act~~”) Act and is administered by the ~~U.S.~~ Small Business Administration (“SBA”). The PPP ~~Loan matures on April 21, 2022~~provides loans to qualifying businesses (“PPP Loans”) in amounts up to 2.5 times the average monthly payroll expenses and ~~bears interest at a rate of 1.00% per annum. The~~was designed to provide direct financial incentive to qualifying businesses to keep their workforce employed during the Coronavirus crisis. PPP ~~Loan is payable in 17 equal monthly payments commencing November 21, 2020. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties.~~

~~All or a portion of the PPP Loan may be forgiven~~Loans are uncollateralized and guaranteed by the SBA and forgivable after a “covered period” (8 weeks or 24 weeks) as long as the ~~Lender~~borrower maintained its payroll levels and uses the loan proceeds for eligible expenses, including payroll, benefits, mortgage interest, rent and utilities. The forgiveness amount would be reduced if the borrower terminated employees or reduced salaries and wages more than 25% during the covered period. Any unforgiven portion was payable over 2 years if issued before, or 5 years if issued after, June 5, 2020 at an interest rate of 1% with payments deferred until the SBA remits the borrowers loan forgiveness amount to the lender, or if the borrower did not apply for forgiveness, 10 months after the covered period. PPP loans provide for customary events of default, including payment defaults, breach of representations and warranties, and insolvency events and may be accelerated upon ~~application by~~occurrence of one or more of these events of default. Additionally, the PPP Loans do not include prepayment penalties.

The Company met the First PPP Loan forgiveness requirements and in August 2021 applied for forgiveness. Also, in August 2021, the Company ~~not later than December 31, 2020 upon documentation~~received the First PPP Loan forgiveness approval from the lender and wrote off the loan outstanding amount inclusive of ~~expenditures~~interest accrued, in ~~accordance with~~ the ~~SBA requirements.~~

~~On June 25, 2020,~~amount of $253,347. The Company recorded the ~~Company commenced a solicitation of shareholder consents (the “~~~~Consent Solicitation~~~~”), pursuant to a consent solicitation statement (the “~~~~Consent Solicitation Statement~~~~”), to~~amount forgiven as forgiveness income within the ~~holders (the “~~~~Stockholders~~”)other income (expense) section of its ~~Common Stock and Series A Convertible Preferred Stock.~~ statement of operations.

The ~~deadline for Stockholders~~SBA reserves the right to ~~respond to~~audit any PPP loan, regardless of size. These audits may occur after the Consent Solicitation Statement was August 10, 2020 at 5:00 PM. Pursuant to the Consent Solicitation Statement, the following actions were approved by the written consent of the requisite number of Stockholders:

~~The Company filed the Current Report on Form 8-K with the SEC to declare the voting results on August 14, 2020. As of November 5, 2020, the state of Delaware~~forgiveness has approved the name change of the Company to Oncotelic Therapeutics, Inc. The Company is awaiting confirmation of the same, as well as all the other actions, by the State of Delaware and the Financial Industry Regulatory Authority.

~~The Merger was treated as a “reverse merger” for accounting purposes.~~been granted. In accordance with the ~~reporting requirements,~~CARES Act, all borrowers are required to maintain their PPP loan documentation for six years after the ~~Company will be reporting historical~~loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.

In July 2021, the Company’s wholly owned subsidiary, PointR, received loan proceeds in the amount of $92,995 under the PPP (the “Second PPP Loan”). The Second PPP Loan was at terms similar to the First PPP Loan. The entire amount received was outstanding at September 30, 2021.

The preparation of financial ~~data~~statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of ~~Oncotelic for all periods prior to~~assets and liabilities and the disclosure of contingent assets and liabilities at the date of the ~~Merger,~~financial statements, as well as the reported revenues and ~~for~~expense during the ~~combined company for all periods after~~reporting periods. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time we make such estimates. Actual results and outcomes may differ materially from our estimates, judgments and assumptions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the ~~Merger. Accordingly, the following management discussion and analysis should be read together with the audited financial statements~~change in estimate. Our significant accounting policies are more fully described in Note 2 to our Unaudited Consolidated Financial Statements included elsewhere in ~~our Annual Report on Form 10-K filed with the SEC on May 14, 2020.~~this Quarterly Report.

We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. We believe the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments are the following:

The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three months ended September 30, 2021 and 2020, there were no impairment losses recognized for long-lived assets.

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”.

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

Research and development expense consist of costs we incur for the development of our investigational drugs and, to a lesser extent, for preclinical research activities. Research and development costs are expensed as incurred. Research and development expense include clinical trial costs, salaries and benefits of employees, including associated stock-based compensation, payments to clinical investigators, drug manufacturing costs, laboratory supplies and facility costs. Clinical trial costs are a significant component of our research and development expense, and these can be difficult to accurately estimate. Included in clinical trial costs are fees paid to other entities that conduct certain research and development activities on our behalf, such as clinical research organizations, or CROs. We estimate clinical trial expense based on the services performed pursuant to contracts with research institutions such as CROs and the actual clinical investigators. These estimates are based on actual time and expenses incurred by the CRO and the clinical investigators. Also included in clinical trial expense are costs based on the level of patient enrollment into the clinical trial and the actual services performed under the related clinical trial agreement. Changes in clinical trial assumptions, such as the length of time estimated to enroll all patients, rate of screening failures, patient drop-out rates, number and nature of adverse event reports and the total number of patients enrolled can impact the average and expected cost per patient and the overall cost of the clinical trial. Based on patient enrollment reports and services provided, we may periodically adjust estimates for the clinical trial costs. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed, the length of time for these services or the costs of these services, our actual expenses could differ from our estimates.

We record the estimated fair value of all share-based payments issued to employees and other service providers. Our share-based payments consist primarily of stock options. The valuation of stock options is an inherently subjective process, since market values are not available for any stock options in our equity securities. Market values are also not available on long-term, non-transferable stock options in other equity securities. With no market values on options to trade in our common stock and no comparable market values on any long-term non-transferable stock options, the process of valuing our stock options is even more uncertain and subjective. Accordingly, we use a Black-Scholes option pricing model to derive an estimated fair value of the stock options which we issue. The Black-Scholes option pricing model requires certain input assumptions, including the expected term of the options and the expected volatility of our common stock. Changes in these assumptions could have a material impact on the estimated fair value that we record for share-based payments that we issue. We determine the term of the options based on the simplified method, which averages the vesting period and the contractual life of the stock option. We determine the expected volatility based on the historical volatility of our common stock over a period commensurate with the option’s expected term. The Black-Scholes option pricing model also requires assumptions for risk-free interest rates and the expected dividend yield of our common stock, but we feel that these values are more objective and note that changes in these values do not have a significant impact on the estimated value of the options when compared to the volatility and term assumptions.

We are also required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. Accordingly, we perform a historical analysis of option awards that are forfeited prior to vesting, and record total stock option expense that reflects this estimated forfeiture rate.

Comparison of the Results of Operations for the Three Months Ended September 30, ~~2020~~2021 to the Three Months Ended September 30, ~~2019~~2020

A comparison of the Company’s operating results for the three months ended September 30, ~~2020~~2021 and ~~2019,~~2020, respectively, is as follows.

We recorded a net loss of approximately $1.9 million for the three months ended September 30, ~~2020 and 2019:~~

~~We recorded~~2021, compared to a net loss of approximately $2.0 million for the three months ended September 30, ~~2020, compared to a net~~2020. The decreased loss of approximately ~~$1.0 million for the same period of 2019. The increased loss of approximately $1.0~~$0.1 million for the three months ended September 30, ~~2020~~2021 as compared to the same period of ~~2019~~2020 was primarily due to higher ~~operational expenses of $0.7 million, higher interest expense~~other income recorded due to the PPP loan forgiveness of $0.3 million ~~primarily related to interest expense related to the debt raised by the company~~recorded in the second and third quarters of 2019, and loss on conversion of debt of $0.1 million, partially offset by change in value of derivatives of $0.1 million The financial information presented does not include any expenses for PointR operations for the three months ended September 30, ~~2019.~~2021 compared to no revenues in the same period of 2020; higher operating expenses of approximately $0.2 million and higher interest expense of $0.1 million.

Research and development (“R&D”) ~~expenses increased~~expense decreased by approximately ~~$0.6~~$0.3 million for the three months ended September 30, ~~2020~~2021 compared to the same period in ~~2019.~~2020. The ~~higher~~lower R&D ~~cost~~expense was primarily due to by higher ~~amortization~~personnel expense of ~~intangibles and depreciation on R&D Equipment of $0.2~~approximately $0.1 million and higher ~~personnel~~ costs related to clinical trial operations of ~~$0.4 million. The financial information presented does not include any R&D activity for PointR for~~approximately $0.2 million during the ~~period~~three months ended September 30, ~~2019.~~2020.

As a result of our ~~mergers with Oncotelic and PointR,~~Mergers, we expect to increase ~~research and development~~R&D activities, including the initiation of new clinical trials including those for COVID-19, and therefore believe that ~~research and development expenses~~R&D expense will increase for the remainder of ~~2020~~2021 compared to ~~research and development expenses~~R&D expense in ~~2019,~~2020, subject to our continuing ability to secure sufficient funding to continue planned operations.

General and administrative (“G&A”) ~~expenses~~expense increased by approximately ~~$0.1~~$0.5 million for the three months ended September 30, ~~2020~~2021 compared to the three months ended September 30, ~~2019,~~2020, primarily due to ~~increases~~an increase of approximately $0.6 million in stock compensation expense incurred in connection with recording stock based compensation on restricted stock units and stock options during the three months ended September 30, 2021, partially offset by lower legal and professional expenses of $0.1 ~~million due to increase in personnel costs.~~million.

As a result of our ~~mergers with Oncotelic and PointR,~~Mergers, we expect G&A ~~expenses~~expense to increase for the remainder of ~~2020~~2021 in order to support our anticipated additional business development, fundraising, investor relations and administrative activities, subject to our continuing ability to secure sufficient funding to continue planned operations.

During the three months ended September 30, 2021, we did not record a gain or loss on conversion of debt. During the same period in 2020, we recorded a loss on conversion of debt by Peak One of approximately ~~$88 thousand~~$89,000 related to the difference in fair value to the price at which the debt was converted.

We recorded the forgiveness of the First PPP Loan amount as other income of approximately $253,000 during the three months ended September 30, 2021. No similar ~~loss~~income was recorded during the same period ~~in 2019.~~ended September 30, 2020.

During the three months ended September, ~~30, 2020,~~2021, we recorded ~~a gain of~~ approximately ~~$50 thousand upon a~~$0.1 million change in value ~~upon conversion~~ of ~~the debt~~derivatives due to ~~liabilities as a derivative as well as new~~ debt converting to liabilities on the convertible promissory notes issued to our CEO, a bridge investor, Peak One, and TFK ~~our CEO and a bridge investor. No similar charge was~~(collectively, the “Convertible Notes”). The Company recorded approximately $50,000 change in value in the value of derivatives during the same period in ~~2019.~~2020. The Convertible Notes became convertible 180 days after issuance, and as such Peak One, TFK, the CEO and the bridge investor had the ability to convert that debt into equity at: (i) the variable conversion price of 65% of the Company’s lowest traded price after the first 180 days, or (ii) at the lower of $0.10 per share or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument which resulted in the recording of a derivative liability and change in value of the derivative.

~~During~~We recorded interest expense, including amortization of debt costs, of approximately $0.4 million for the three months ended September 30, ~~2020, we recorded~~2021 primarily in connection with increased debt raised from convertible notes and the JH Darbie Financing, as compared to $0.3 million for the same period of ~~interest expense, primarily on the~~2020, in connection with lower debt raised from convertible notes issued to Peak One, TFK, our CEO and a bridge investor, as well as the Fall 2019 Notes. This included normal and accelerated amortization of debt discounts and interest recorded on the Fall 2019 Notes. We recorded interest expense of $60 thousand during the same period of ~~2019~~2020. For more information on debt raised from convertible notes and the ~~same notes.~~JH Darbie Financing, see Note 5 and Note 6 of the Unaudited Consolidated Financial Statements of this Quarterly Report.

Comparison of the Results of Operations for the Nine Months Ended September 30, ~~2020~~2021 to the Nine Months Ended September 30, ~~2019~~2020

A comparison of the Company’s operating results for the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, respectively, is as follows.

	2020			2019			Variance			September 30, 2021			September 30, 2020			Variance
Revenue	$	1,740,855		$	-		$	1,740,855
Income:
Service revenue										$	-		$	1,740,855		$	(1,740,855	)
Total Income											-			1,740,855			(1,740,855	)

Operating expenses:
Operating expense:
Research and development		1,730,337			1,109,050			621,287			3,135,413			1,730,337			1,405,076
General and administrative		4,263,265			1,958,731			2,304,534			4,475,642			4,263,265			212,377
Total operating expense		5,993,602			3,076,781			2,925,281			7,611,055			5,993,602			1,617,453
Income (loss) from operations		(4,252,747	)		(3,076,781	)		(1,184,906	)
Loss from operations											(7,611,055	)		(4,252,747	)		(3,358,308	)
Other income (expense)
Loss on conversion of debt		(254,884	)		-			(254,884	)		(27,504	)		(254,884	)		237,380
PPP loan forgiveness											253,347			-			253,347
Change in the value of derivatives on debt		60,504			-			60,504			239,278			60,504			178,774
Interest expense, net		(1,615,233	)		(88,518	)		(1,526,715	)		(1,400,249	)		(1,615,233	)		214,983
Net income (loss)	$	(6,062,360	)	$	(3,156,299	)	$	(2,906,061	)
Net loss before non-controlling interests										$	(8,546,183	)	$	(6,062,360	)	$	(2,483,824	)

We recorded a net loss of approximately $8.5 million for the nine months ended September 30, ~~2020 and 2019:~~

~~We recorded~~2021, compared to a net loss of approximately $6.1 million for the nine months ended September 30, ~~2020, compared to a net loss of approximately $3.2 million for the same period in 2019.~~2020. The increased loss of approximately ~~$2.9~~$2.5 million for the nine months ended September, ~~30, 2020~~2021 as compared to the same period of ~~2019~~2020, was primarily due to lower service revenues of approximately ~~$2.9~~$1.7 million; higher operating expense of approximately $1.6 million, ~~of higher operational expenses related to Mateon, $1.5 million primarily related to~~partially offset by reduced interest expense, including acceleration of amortization of ~~normal and accelerated~~ debt issuance costs related to the debt ~~raised by the company in the second and third quarters of 2019 and a loss of $0.3 million of loss on non-cash conversion of debt; partially offset by the recording revenue~~ of approximately ~~$1.7~~$0.2 million, reduced change in value of derivatives of $0.2 million and ~~recording a non-cash~~lower loss on conversion of ~~value~~debt of ~~derivatives~~$0.2 million and by income recorded on the forgiveness of ~~$0.1 million~~the First PPP loan of approximately $0.3 million.

We did not record services revenue during the nine months ended September 30, ~~2020. The financial information presented does not include any expenses for PointR operations for the period ended September 30, 2019.~~

~~We recorded services revenue of $1.7 million during the nine months ended September 30, 2020~~2021 as compared to ~~no revenues~~$1.7 million during the same period ended ~~in 2019.~~September 30, 2020. The services revenue of $1.2 million was recorded from services provided to GMP during the ~~period~~nine months ended September 30, 2020 in connection with the development of OT-101 for COVID-19, and included reimbursement of costs incurred of approximately ~~$41 thousand. We also recorded~~$41,000, and $0.5 million ~~of revenues~~ from ~~ATB upon the successful completion of the in-vivo efficacy studies based on the ATB Agreement.~~Autotelic.

Research and development (“R&D ~~expenses marginally~~”) expense increased by approximately ~~$0.6~~$1.4 million for the nine months ended September 30, ~~2020~~2021 compared to the same period in ~~2019.~~2020. The ~~increase in costs was primarily due~~higher expense related to ~~increase in~~clinical trials of approximately $1.6 million, offset by lower personnel overhead costs of ~~$0.5~~approximately $0.1 million and partially offset by lower operational costs of approximately $0.1 million of legal and professional costs. The increase in personnel costs is to support the current ongoing clinical trials for OT-101 and Artemisinin for the COVID-19 pandemic as well as inclusion of personnel from PointR post the merger.million.

As a result of our ~~mergers with Oncotelic and PointR,~~Mergers, we expect to increase research and development activities, including the initiation of new clinical trials including those for COVID-19, and therefore believe that ~~research and development expenses~~R&D expense will increase for the remainder of ~~2020~~2021 compared to ~~research and development expenses~~R&D expense in ~~2019,~~2020, subject to our continuing ability to secure sufficient funding to continue planned operations.

General and administrative (“G&A ~~expenses~~”) expense increased by approximately ~~$2.3~~$0.2 million for ~~the~~ nine months ended September 30, ~~2020~~2021 compared to the nine months ended September 30, ~~2019,~~2020, primarily due ~~to an increase of approximately $1.8 million of non-cash~~higher stock based compensation ~~expense,~~recorded upon issuance of restricted stock units and stock options of approximately $0.5 million and higher ~~personnel~~operational costs of ~~$0.4~~$0.1 million, and partially offset by lower compensation costs of approximately $0.1 million ~~due to increase in~~and lower legal and professional ~~and other operational expenses.~~costs of approximately $0.4 million.

During the nine months ended September 30, ~~2020,~~2021, we recorded a loss on conversion of debt by ~~Peak One and~~ TFK of approximately ~~$0.3 million~~$27 thousand related to the difference in fair value to the price at which the debt was ~~converted.~~converted, compared to a loss of $0.3 million during the same period in 2020 upon the conversion of debt by Peak One.

We recorded the forgiveness of the First PPP Loan as income of approximately $250,000 during the nine months ended September 30, 2021. No similar ~~loss~~income was recorded during the same period ~~in 2019.~~ended September 30, 2020.

During ~~the~~ nine months ended September 30, ~~2020,~~2021, we recorded ~~a gain of~~ approximately ~~$60 thousand upon a~~$0.2 million change in value upon conversion of the debt to liabilities as a derivative ~~as well as new debt converting to liabilities~~ on the convertible notes ~~issued to~~of our CEO, Peak One, TFK, ~~our CEO~~ and a bridge investor. ~~No similar charge was~~The Company recorded approximately $61,000 change in value during the same period in ~~2019.~~2020. The convertible notes became convertible 180 days after issuance, and as such Peak One, TFK, the CEO and the bridge investor had the ability to convert that debt into equity at: (i) the variable conversion price of 65% of the Company’s lowest traded price after the first 180 days, or (ii) at the lower of $0.10 per share or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument which resulted in the recording of a derivative liability and change in value of the derivative.

~~During the~~We recorded interest expense, including amortization of debt costs, of approximately $1.4 million for nine months ended September 30, ~~2020, we recorded~~2021 primarily in connection with debt raised from convertible notes and the JH Darbie Financing, as compared to $1.6 million of interest expense on the convertible notes issued to Peak One, TFK, our CEO and a bridge investor, as well as the Fall 2019 Notes. This included normal amortization of debt discounts, recording of initial fair value of conversion of the notes from Peak One, TFK and the bridge investor and the acceleration of amortization of debt discounts upon conversion of the Peak One and TFK Notes. We recorded approximately $88,000 of interest expense duringfor the same period of 2020, in connection with amortization of higher debt costs on debt raised from convertible notes during 2019.

	*September 30, 2020* *(Unaudited)*			December 31, 2019			September 30, 2021			December 31, 2020
Cash	$	1,362		$	82		$	78		$	474
Working capital		(8,253	)		(6,510	)		(14,612	)		(10,567	)
Stockholders’ Equity		14,885			16,902			8,390			12,481

The Company has experienced net losses every year since inception and as of September 30, ~~2020~~2021 had an accumulated deficit of approximately ~~$18.2~~$29.2 million. As of September 30, ~~2020,~~2021, the Company had less than approximately ~~$1.4~~$0.1 million in cash, and current liabilities of approximately ~~$8.8~~$14.8 million. Of the approximately $14.8 million ~~of which~~in current liabilities, approximately ~~$1.3~~$2.0 million ~~are net assumed liabilities of Mateon as part~~was debt for conducting clinical trials for OT-101 from GMP, and $2.6 million related to contingent liability to issue Common Stock of the ~~merger. While~~Company to PointR shareholders upon achievement of certain milestones (see Note 1 of our Annual Report on Form 10K for the year ended December 31, 2020 filed with the SEC on April 15, 2021). The Company ~~expects~~does not expect to generate any meaningful revenue from ~~services and or licensing milestones~~product sales in the near future ~~the Company~~and expects to incur ~~significant~~ additional operating losses over the next several years, primarily as a result of the Company’s plans to continue clinical trials for its investigational ~~drugs, including for COVID-19.~~drugs. The Company’s limited capital resources, history of recurring losses and uncertainties as to whether the Company’s operations will become profitable raise substantial doubt about its ability to continue as a going concern. The financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The principal source of the Company’s working capital deficit to date has been the ~~sale~~issuance of ~~equity securities~~convertible notes, a substantial part of which has been provided by officers and ~~raising debt.~~certain insiders. The Company will need to raise additional capital in order to fund its operations and continue development of product candidates. The Company is evaluating the options to further the development of ~~Oncotelic’s~~the Company’s lead product candidate, OT-101 for both cancer and COVID-19, Artemisinin for COVID-19, developing AI technologies to support the COVID-19 therapies; in addition to evaluating the development pathway of its product candidates; OXi4503 and/or CA4P. ~~Since April 2019, the Company has raised $4,269,800, net of cash discounts of $450,200, through the JH Darbie Financing, sale of convertible debentures and notes.~~

The Company anticipates raising substantial additional capital through the sale of equity securities and/or debt, but no other financing arrangements are in place at this time.

If the Company is unable to access additional funds when needed, it may not be able to continue the development of these investigational drugs and the Company could be required to delay, scale back or eliminate some or all of its development programs and operations. Any additional equity financing, if available, would be dilutive to the current stockholders and may not be available on favorable terms. Additional debt financing, if available, may involve restrictive covenants and could also be dilutive. The Company’s ability to access capital is not assured and, if access is not achieved on a timely basis, would materially harm the Company’s financial condition, the value of its Common Stock and its business prospects.

Net cash ~~generated~~used in operating activities was approximately $3.4 million for the nine months ended September 30, 2021. This was due to the net loss of approximately $8.5 million, primarily offset by non-cash amortization of debt discounts and deferred financing costs of $1.1 million, non-cash stock compensation costs on fair value of the warrants issued during the nine months ended September 30, 2021 of $2.1 million, stock compensation cost recorded on fair value of restricted stocks of approximately $0.2 million, stock compensation on stock options granted during the three months ended September 30, 2021 of approximately $0.3 million; and changes in operating assets and liabilities of approximately $1.7 million.

Net cash used in operating activities was approximately $1.3 million for the nine months ended September 30, 2020. This was due to the net loss of approximately $6.1 million, which was partially offset by non-cash charges of approximately $4.0 million, non-cash loss on conversion of debt and change in value of derivatives of approximately $0.3 million and changes in operating assets and liabilities of approximately $0.5 million.

~~Net cash used in operating activities was $1.3 million for~~Financing Activities

For the nine months ended September 30, ~~2019, due to the~~2021, net ~~loss of approximately $3.2 million offset~~cash provided by non-cash charges of approximately $0.5 million, non-cash issuance of common shares in satisfaction of accounts payable of approximately $0.4 million and changes in operating assets and liabilities of approximately $1.0 million.

Net cash generated from investing activities was $0 for the nine months ended September 30, 2020 as compared to $0.2 million for the same period of 2019. Cash generated during the nine months ended September 30, 2019 was due to the cash acquired from the Oncotelic Merger.

~~Net cash generated from~~ financing activities was ~~$2.6~~approximately $3.0 million, ~~during~~due to a receipt of cash from the ~~nine months ended September 30, 2020 as compared to $1.2~~JH Darbie Financing of $1.6 million, ~~during~~sale of equity of $0.1 million, proceeds of a convertible note of $0.3 million from Geneva and convertible notes and short-term loans from certain related parties, the ~~nine months ended September 30, 2019.~~CFO and bridge investors of $1.0 million, and approximately $0.1 million from the PPP, partially offset by repayments of debt of approximately $0.2 million.

~~During~~For the nine months ended September 30, 2020, net cash provided by financing activities ~~was~~$2.6 million which primarily ~~from~~was $2.3 million of cash generated from the JH Darbie Financing, net of amortized costs, $250,000 under the PPP, ~~administered by the SBA to support small businesses impacted by the COVID-19 pandemic,~~ and $70,000 from receipt of a ~~short term~~short-term loan from the Company’s CEO.

For the nine months ended September 30, 2019, net cash provided by financing activities was primarily from $0.9 million from notes payable, $0.1 million from a note payable from a related party and $83,000 from the sale of Oncotelic Common Stock.

We do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.

~~There~~Our current drug development programs are based on a series of compounds called combretastatins, which we have ~~been no changes~~exclusively licensed from Arizona State University, or ASU. If our current drug candidates are approved, we will be required to ~~our critical accounting policies and significant judgments and estimates from our Financial Results incorporated with our Annual Report~~pay low to mid-single-digit royalties on ~~form 10-K filed~~future net sales of products associated with the ~~SEC~~ASU patent rights until these patent rights expire.

We also have an exclusive license from Bristol-Myers Squibb, or BMS, for certain patent rights to particular combretastatins, including CA4P. If CA4P is approved, we will be required to pay low-single-digit royalties on ~~May 14, 2020 other than those that have been included in Note 2 to this quarterly report on form 10Q.~~future net sales of products associated with the BMS patent rights until these patent rights expire.

~~Any new and recently adopted accounting pronouncements are more fully described in Note 2 to our unaudited condensed consolidated financial statements included in this Quarterly Report.~~

AsOur cash is maintained in U.S. dollar accounts. We have adopted a ~~smaller reporting company,~~policy for the cash that we hold, and also for any cash equivalents and investments that we may hold, the primary objective of which is to preserve principal, while also maintaining liquidity to meet our operating needs and maximize yields to the extent possible. Although our investments can be subject to credit risk, we follow procedures to limit the amount of credit exposure in any single issue, issuer or type of investment. Our investments are ~~not required~~also subject to ~~provide~~interest rate risk and would be likely to decrease in value if market interest rates increase. However, due to the ~~information required by this Item.~~generally conservative nature of our investments and relatively short duration, we believe that interest rate risk is mitigated.

Although we may from time to time manufacture drugs and conduct preclinical or clinical trials outside of the United States, we believe our exposure to foreign currency risk to be immaterial.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the ~~Securities~~ Exchange Act ~~of 1934, as amended (the “~~~~Exchange Act~~~~”),~~ is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”) conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our CEO and our CFO each concluded that our disclosure controls and procedures are not effective to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act, (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) is accumulated and communicated to our management, including our CEO and our CFO, as appropriate to allow timely decisions regarding required disclosure.

Management conducted an assessment of the effectiveness of our internal control over financial reporting as of September 30, ~~2020~~2021 based on the framework established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that the Registrant’s internal control over financial reporting as of ~~September~~June 30, ~~2020~~2021 was not effective as a result of certain material weaknesses.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses which are observed in many small companies with a small number of accounting and financial reporting staff:

Management ~~has~~had been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. ~~The~~However, due to current resource restrictions, management has put the remediation plan on hold. Once the Company has the required resources, the remediation actions shall be planned and will include:

During the nine months ended September 30, ~~2020,~~2021, we continued to execute upon our planned remediation actions which are all intended to strengthen our overall control environment. We ~~added two new directors~~have put those plans on hold for the time being as we gather required resources to reinitiate the efforts. We are evaluating hiring an external firm to help us with the remediation efforts. While we have made progress in our ~~Board~~planned remediation efforts and we expect the Company to complete its planned execution of ~~Directors and re-established our Audit Committee. During~~internal controls over financial reporting during the ~~fiscal~~ year ended December 31, ~~2019, and as a result of the Merger,~~2021, we ~~have consolidated all accounting functions~~may not be able to ~~the Company headquarters and all record keeping has been migrated into the same accounting software. We have recruited a third party firm to assist us~~achieve our objectives in ~~the evaluation of~~completely remediating our financial reporting capabilities as well as advise on complex accounting matters, including revenue recognition under ASC 606, goodwill impairment, fair value measurements etc. We are also in discussions with another third party to assist us in strengthening our internal control processes and evaluation processes.existing weaknesses.

We are committed to maintaining a strong internal control environment and believe that these remediation efforts will represent significant improvements in our control environment. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

In addition to the risk ~~factors~~factor described below, for information about the risks and uncertainties related to our business, please see the risk factors described in our ~~annual report~~Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020 filed on April 15, 2021 as well as risk factors described in our quarterly filings on form 10-Q and our Current Reports on form 8-Ks. The risks described below and in our Form 10-K, form 10-Qs and form 8-Ks are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

The risks arising with respect to the historic Oncotelic business and operations may be different from what we anticipate, which could lead to significant, unexpected costs and liabilities and could materially and adversely affect our business going forward.

It is possible that we may not have fully anticipated the extent of the risks associated with the Merger. After the Merger, Oncotelic’s historic business was combined with Mateon and prior to the Merger, Oncotelic had a significant operating history. As a consequence, we may be subject to claims, demands for payment, regulatory issues, costs and liabilities that were not and are not currently expected or anticipated. The risks involved with taking over a business with a significant operating history and the costs and liabilities associated with these risks may be greater than we anticipate. We may not be able to contain or control the costs or liabilities associated with Oncotelic’s historic business, which could materially and adversely affect our business, liquidity, capital resources or results of operation.

~~Our historical results of operation may not fully reflect the underlying performance of our business and period-to-period comparisons of our operating results may not be meaningful.~~

For accounting purposes, the Merger between Mateon and Oncotelic is treated as a “reverse merger” under U.S. GAAP and Oncotelic is considered the accounting acquirer. Oncotelic’s historical results of operations will replace the Mateon’s historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the Company’s financial statements will reflect the results of operations of the combined Company. Accordingly, the financial statements for the Company included in this Quarterly Report for periods prior to the Merger are not the same as the Company’s prior reported filings with the SEC, which were derived from the operations of Mateon. As a result, period-to-period comparisons of our operating results may not be meaningful. The results of any one quarter should not be relied upon as an indication of future performance.

Our business may suffer from the severity or longevity of the COVID-19 Global Outbreak.

The COVID-19 is currently impacting countries, communities, supply chains and markets, as well as the global financial markets. To date, COVID-19 has not had a material impact on the Company, other than as set forth above. However, the Company cannot predict whether ~~COVID- 19~~COVID-19 will have a material impact on our financial condition and results of operations due to understaffing, disruptions in government spending, among other factors. In addition, at this time we cannot predict the impact of COVID-19 on our ability to obtain financing necessary for the Company to fund its working capital requirements. In most respects, it is too early in the COVID-19 pandemic to be able to quantify or qualify the longer-term ramifications on our business, our customers and/or our potential investors.

There is no guaranty that the Company will enter into definitive agreements for the formation of a joint venture (the “Joint Venture”) with Golden Mountain Partners, LLC (“GMP”), or that the Company will benefit from entering into the Joint Venture with GMP.

As of the date of this Quarterly Report, definitive agreements have not been executed necessary to form the Joint Venture, as discussed in that certain Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on August 17, 2021 (the “Current Report”). Therefore, no assurances can be given that the Company will receive any of the benefits set in the Current Report regarding the Joint Venture, or that the Joint Venture will be formed at all. If the Joint Venture is formed, and definitive agreements are executed, no assurances can be given that: (i) the Joint Venture will consummate an initial public offering, (ii) the Joint Venture will obtain the value anticipated by management; or (iii) the Company will realize a return on its investment in the Joint Venture.

~~During~~In January 2021, the ~~three months ended March 31, 2020, we~~Company issued ~~2,012,145~~657,000 shares of ~~our~~its Common Stock to ~~Peak One for $150,000 upon~~TFK in connection with the partial conversion of their ~~debt of $400,000. Also, during~~convertible promissory notes. For more information regarding the ~~three months ended June 30, 2020, we~~convertible promissory note issued ~~569,800~~to TFK, see Note 5 to the Unaudited Consolidated Financial Statements included in this Quarterly Report.

In March 2021, the Company converted 278,188 shares of ~~our~~the Company’s Series A Preferred Stock into 278,187,847 shares of its Common Stock pursuant to ~~Peak One~~the terms of the Merger Agreement and PointR Merger Agreement. For more information regarding the Mergers, see Note 1 to our Annual Report on form 10-K for ~~$50,000 upon~~ the ~~full conversion of their debt of $200,000 under~~year ended December 31, 2020 filed with the ~~first tranche of their debt.~~ SEC on April 15, 2021).

In ~~addition, during~~May 2021, the ~~three months ended September 30, 2020, we~~Company issued ~~1,000,000~~250,000 shares of ~~our Common Stock to Peak One for $100,000 upon the partial conversion of their debt of $200,000 under the second tranche of their debt. After the conversion, the remaining debt owed~~its common stock to Peak One as compensation in connection with the EPL. These shares were subsequently registered by the filing of ~~September 30, 2020 is $100,000.~~our Registration Statement on Form S-1 with the SEC.

~~During~~In May and June 2021, the ~~three months ended March 31, 2020, we~~Company entered into Securities Purchase Agreement with Geneva Roth Remark Holdings Inc., whereby the Company issued ~~1,950,000~~two convertible notes in the aggregate principal amount of $307,500 convertible into shares of ~~our~~common stock of the Company. Such unsecured convertible notes may be converted into shares of the Company’s common stock upon the conversion of the unsecured convertible note.

In July 2021, the Company issued 1,257,952 shares of Common Stock to ~~TFK for $133,430~~its employees in lieu of fully vested restricted stock units under the 2015 Equity Incentive Plan. The Company recorded a stock-based compensation cost of $226,431 related to such issuance.

In August 2021, the Company issued Note Purchase Agreements with Autotelic Inc., the CFO, and certain other accredited investors. Under the terms of the Note Purchase Agreements, the Company issued an aggregate of $698,500 in debt in the form of unsecured convertible promissory notes. Such Notes were issued against some of the short-term debt due as of June 30, 2021. Such unsecured convertible notes may be converted into shares of the Company’s common stock upon the ~~partial~~ conversion of ~~their~~the unsecured convertible note.

In September 2021, the Company issued 310,000 shares of Common Stock to Equity NY in connection with certain services rendered by them and recorded a non-cash expense of $23,641.

In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note from GMP, to fund the same clinical trial evaluating OT-101 against COVID-19. The GMP Note is convertible into the Company’s Common Stock upon the maturity one year from the date of ~~$200,000. After~~ the GMP Note, at the Company’s Common Stock price on the date of conversion with no discount.

In October 2021, the ~~remaining debt owed~~Company entered into an Unsecured Convertible Note Purchase Agreement with GMP, pursuant to ~~TFK, as~~which the Company issued a convertible promissory note in the aggregate principal amount of ~~March 31, 2020~~$0.5 million which is ~~$66,570.~~convertible into shares of the Company’s Common Stock at either the earlier of (a) the one-year anniversary of the date of the October Purchase Agreement, or (b) the acceleration of the maturity of the October 2021 Note by GMP upon occurrence of an Event of Default. The October Purchase Agreement requires the Company to use of the proceeds received under the October 2021 Note to support the clinical development of OT-101, including payroll and has been made in continuation of the relationship between the Company and GMP.

~~None.~~In August 2021, the Company, Golden Mountain Partners, LLC, and Vuong Trieu, the Company’s Chief Executive Officer signed a letter of intent and a term sheet (the “Term Sheet”) pursuant to which the Company is to receive a loan of $1.5 million in exchange for the issuance of a convertible promissory note, which may be convertible into shares of the Company’s Common Stock upon certain terms and conditions as to be negotiated by the parties at a later date.

In reviewing the agreements included as exhibits to this Quarterly Report, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Quarterly Report and the Company’s other public filings, which are available without charge through the SEC’s website at http://www.sec.gov.

The following exhibits are included as part of this Quarterly ~~Report:~~Report. A more complete list of previously filed Exhibits can be found with our Annual Report on Form 10K filed with the SEC on April 15, 2021:

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None		~~MATN~~OTLC		N/A

Large accelerated filer	~~[ ]~~☐	Accelerated filer	~~[ ]~~☐

Non-accelerated filer	~~[X]~~☒	Smaller reporting company	~~[X]~~☒

		Emerging growth company	~~[ ]~~☐

		Page

PART I. FINANCIAL INFORMATION

ITEM 1.	Financial Statements (unaudited)	3

	Consolidated Balance Sheets as of September 30, ~~2020~~2021 and December 31, ~~2019~~2020	3

	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, ~~2020~~2021 and ~~2019~~2020	4

	Consolidated Statements of Changes in Stockholders’ Equity for the Three Months and Nine Months Ended September 30, ~~2020~~2021 and ~~2019~~2020	5

	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, ~~2020~~2021 and ~~2019~~2020	7

	Notes to Consolidated Financial Statements	8

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3438

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	4353

ITEM 4.	Controls and Procedures	4353

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings	4554

ITEM 1A.	Risk Factors	4554

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4655

ITEM 3.	Defaults Upon Senior Securities	4655

ITEM 4.	Mine Safety Disclosures	4655

ITEM 5.	Other Information	4656

ITEM 6.	Exhibits, Financial Statement Schedules	4656

SIGNATURES		5357

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2020			2019			2020			2019

Service Revenue	$	-		$	-		$	1,740,855		$	-

Operating expenses:
Research and development		936,196			343,789			1,730,337			1,109,050
General and administrative		680,077			586,924			4,263,265			1,958,731
Total operating expenses		1,616,273			930,713			5,993,602			3,067,781

Loss from operations		(1,616,273	)		(930,713	)		(4,252,747	)		(3,067,781	)
Other expense:
Interest expense, net		(331,459	)		(60,413	)		(1,615,233	)		(88,518	)
Change in fair value of derivative on debt		49,992			-			60,504			-
Loss on debt conversion		(88,817	)		-			(254,884	)		-
Total other expense		(370,284	)		(60,413	)		(1,809,612	)		(88,518	)
Net Loss	$	(1,986,557	)	$	(991,126	)	$	(6,062,360	)	$	(3,156,299	)

Basic & diluted net loss per share attributable to common stock	$	(0.02	)	$	(0.01	)	$	(0.07	)	$	(0.06	)
Basic & diluted weighted average common stock outstanding		88,964,549			74,526,579			87,474,986			52,131,543

									Additional
	Preferred Stock				Common Stock				Paid-in			Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity

Balance at January 1, 2019		-	$	-		6,843,802	$	68,438	$	7,886,598		$	(5,490,277	)	$	2,464,759

Common shares issued for cash		-		-		20,750		208		82,792			-			83,000
Common shares issued for services		-		-		91,844		918		417,218			-			418,136
Stock-based compensation		-		-		-		-		268,259			-			268,259
Common shares issued for settlement of accounts payable to related party		-		-		80,772		808		237,282			-			238,090
Net loss		-		-		-		-		-			(976,063	)		(976,063	)
Balance at March 31, 2019		-		-		7,037,168		70,372		8,892,149			(6,466,340	)		2,496,181

Recapitalization under reverse merger		193,713		1,937		75,232,798		752,328		2,972,606			881			3,727,752
Stock-based compensation		-		-		-		-		72,415			-			72,415
Beneficial Conversion Feature on convertible debt and restricted common shares		-		-		1,050,000		10,500		498,640			-			509,140
Common shares issued in conversion of warrants		-		-		150,000		1,500		(1,380	)		-			120
Net loss		-		-		-		-		-			(1,189,110	)		(1,189,110	)
Balance as of June 30, 2019		193,713		1,937		83,469,966		834,700		12,434,430			(7,654,569	)		5,616,498

Beneficial conversion feature on convertible debt		-		-		-		-		175,000			-			175,000
Net loss		-		-		-		-		-			(991,126	)		(991,126	)
Balance as of September 30, 2019		193,713	$	1,937		83,469,966	$	834,700	$	12,609,430		$	(8,645,695	)	$	4,800,372


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2021			2020			2021			2020

Service Revenue	$	-		$	-		$	-		$	1,740,855
Total Revenue		-			-			-		$	1,740,855
Operating expenses:
Research and development		621,927			936,196			3,135,413		$	1,730,337
General and administrative		1,187,035			680,077			4,475,642			4,263,265
Total operating expenses		1,808,962			1,616,273			7,611,055			5,993,602

Loss from operations		(1,808,962	)		(1,616,273	)		(7,611,055	)		(4,252,747	)
Other income (expense):
Interest expense, net		(445,363	)		(331,459	)		(1,400,249	)		(1,615,233	)
PPP loan forgiveness		253,347			-			253,347			-
Change in fair value of derivative on debt		145,449			49,992			239,278			60,504
Loss on debt conversion		-			(88,817	)		(27,504	)		(254,884	)
Total other income (expense)		(46,567	)		(370,284	)		(935,128	)		(1,809,612	)
Net loss before non-controlling interests		(1,855,529	)		(1,986,557	)		(8,546,183	)		(6,062,360	)
Net loss attributable to non-controlling interests		(293,001	)		-			(949,295	)		-
Net loss attributable to Oncotelic Therapeutics, Inc.	$	(1,562,528	)	$	(1,986,557	)	$	(7,596,888	)	$	(6,062,360	)

Basic net loss per share attributable to common stock	$	(0.00	)	$	(0.02	)	$	(0.03	)	$	(0.07	)
Basic weighted average common stock outstanding		370,443,893			88,964,549			279,358,671			87,474,986

●	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

●	Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.

●	Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

	Carrying		Fair Value Measurement Using
At September 30, 2020	Value		Level 1		Level 2		Level 3		Total

Restricted Cash – CDs at Bank	$	20,000	$	20,000	$	-	$	-	$	20,000
	$	20,000	$	-	$	-	$	-	$	20,000

~~Expected Term~~	~~1.5 years~~
~~Expected volatility~~	~~184.7%-191.9~~	%
~~Risk-free interest rates~~	~~0.13%-0.15~~	%
~~Dividend yields~~	~~0.00~~	%

For the years ended December 31,

Remainder of 2020	$	68,860
2021		275,440
2022		275,440
2023		275,440
2024		275,440
	$	1,170,620

	September 30, 2020		December 31, 2019

Accounts payable – related party	$	385,002	$	601,682

		September 30, 2021		December 31, 2020

Accounts payable – related party	$	425,740	$	391,631

	December 31, 2019

10% Convertible note payable, due April 23, 2022 – Peak One	$	115,623
10% Convertible note payable, due June 12, 2022 – Peak One		(81,735	)
10% Convertible note payable, due April 23, 2022 - TFK		115,623
10% Convertible note payable, due April 23, 2022 – Related Party		(12,663	)
10% Convertible note payable, due April 23, 2022 – Bridge Investor		(2,748	)
10% Convertible note payable, due August 6, 2022 – Bridge Investor		26,824
		160,924

Fall 2019 Notes
5% Convertible note payable – Stephen Boesch		187,785
5% Convertible note payable – Vuong Trieu*		187,785
5% Convertible note payable – Sanjay Jha (Through his family trust)		187,785
5% Convertible note payable – CEO, CTO & CFO		77,620
5% Convertible note payable – Bridge Investors		159,025
		800,000
Total of notes and other debt	$	960,924

	September 30, 2021		December 31, 2020

Related parties convertible note, 5% coupon August 2022	$	251,952	$	-
CFO convertible note, 5% coupon August 2022		75,586
Accredited investors convertible note, 5% coupon August 2022		376,416		-
	$	703,954	$	-

	■	25,000 shares of ~~Edgepoint~~Edge Point Common ~~Stock~~stock for a price of ~~$1.00~~$1.00 per share of ~~Edgepoint~~Edge Point Common ~~Stock.~~stock.
	■	One convertible promissory note, convertible ~~into~~ up to 25,000 shares of ~~Edgepoint~~Edge Point Common ~~Stock,~~stock, at a conversion price of ~~$1.00~~$1.00 per share or up to 138,889 shares of the Company’s ~~Common Stock,~~common stock, at a conversion price of ~~$0.18~~$0.18 per share.
	■	50,000 warrants to purchase an equivalent number of shares of ~~Edgepoint~~Edge Point Common ~~Stock~~stock at ~~$1.00~~$1.00 per share or an equivalent number of shares of the Company’s ~~Common Stock~~common stock at ~~$0.20~~ $0.20 per share with a ~~three-year~~three-year expiration date.

	■	Term: Through June 30, ~~2021.~~2021 (extended to March 31, 2022).
	■	Coupon: ~~16%~~16%.
	■	Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common ~~Stock.~~Stock.
	■	The conversion price is initially set at ~~$0.18~~$0.18 per share for the Company’s Common Stock or ~~$1.00~~$1.00 for Edgepoint Common Stock, subject to adjustment.

Expected Term	1.5 years
Expected volatility	152.3%-164.8	%
Risk-free interest rates	0.09%-0.11	%
Dividend yields	0.00	%

Expected Term	1-2 years
Expected volatility		94.4%-130.0	%
Risk-free interest rates		0.08%-0.25	%
Dividend yields		0.00	%

Milestones	Transaction Value		Actions

Tranche 1	$	1,000,000	Upon the earlier to occur of: (i) the Company receiving an investment of at least $20 million, and (ii) the uplisting of the Company’s common stock to any NASDAQ market or the New York Stock Exchange.

Tranche 2	$	2,000,000	Upon approval by the United States Food and Drug Administration of the Company’s 505(b)2 application for purposes of treating PD.

Tranche 3	$	2,000,000	Upon first patient in (“FPI”) for any clinical trial supporting the use of AL-101 for the treatment of PD or ED.

Tranche 4	$	2,500,000	Upon FPI for phase 2 clinical trials supporting the use of AL-101 to treat FSD.

Tranche 5	$	2,500,000	Upon FPI for phase 3 clinical trials supporting the use of AL-101 to treat FSD

Tranche 6	$	10,000,000	Upon Marketing approval for the use of AL-101 to treat PD.

Tranche 7	$	10,000,000	Upon Marketing approval for the use of AL-101 to treat ED.

Tranche 8	$	10,000,000	Upon Marketing approval for the use of AL-101 to treat FSD

Tranche 9	$	10,000,000	Upon the earlier of: (i) the Company entering into a licensing agreement with a third party for the use of AL-101 for the treatment of PD, ED or FSD with an aggregate licensing value of at least $50 million; and (ii) the Company’s gross revenue derived from sales of AL-101 for the treatment of PD, ED or FSD reaches at least $50.0 million.

				Weighted
				Average
	Shares			Exercise Price
Outstanding at December 31, 2019		6,145,044		$	0.75
Expired or canceled		(15,040	)		2.72
Outstanding at September 30, 2020		6,130,004		$	0.75

Expected Term	1 year
Expected volatility		97.3 – 110.0	%
Risk-free interest rates		0.05	%
Dividend yields		0.00	%

				Weighted-
				Average
As of September 30, 2020	Shares			Exercise Price

Outstanding at December 31, 2019		19,515,787		$	0.60
Issued during the nine months ended September 30, 2020		16,665,000			0.20
Expired or cancelled		(18,028,287	)		0.63
Outstanding at September 30, 2020		18,152,500		$	0.20

				Weighted-
As of December 31, 2019				Average
	Shares			Exercise Price

Outstanding at December 31, 2018		24,380,893		$	1.05
Expired or cancelled		(4,865,106	)		2.82
Outstanding at December 31, 2019		19,515,787		$	0.60

				Weighted-
				Average
For the year ended December 31, 2020	Shares			Exercise Price

Outstanding at January 1, 2020		19,515,787		$	0.60
Issued during the year ended December 31, 2020		17,215,000			0.20
Expired or cancelled		(18,028,287	)		0.63
Outstanding at December 31, 2020		18,702,500		$	0.20

		Outstanding and exercisable
				Weighted-		Weighted-
				Average		Average
		Number		Remaining Life		Exercise		Number
Exercise Price		Outstanding		in Years		Price		Exercisable

$	0.20		1,487,500		2.75	$	0.20		1,487,500
	0.20		2,915,000		3.00		0.20		-
	0.20		13,750,000		2.75		0.20		13,750,000

			18,152,500		2.75	$	0.20		15,237,500

		Outstanding and exercisable
			Weighted-		Weighted-
			Average		Average
		Number	Remaining Life		Exercise	Number
	Exercise Price	Outstanding	in Years		Price	Exercisable

$	0.20	1,487,500	2.08	$	0.20	1,487,500
	0.20	41,250,000	2.15		0.20	41,250,000
		42,737,500	2.15	$	0.20	42,737,500

	September 30, 2021			December 31, 2020
Deferred tax assets:
Stock-based compensation	$	1,164		$	1,164
Assets		5,887			6,227
Liability accruals		316			173
R&D Credit		4,784			4,760
Capital Loss		528			528
Deferred state tax		(2,200	)		(2,086	)
Net operating loss carry forward		57,154			56,090
Total gross deferred tax assets		67,633			66,856
Less - valuation allowance		(67,633	)		(66,856	)
Net deferred tax assets	$	-		$	-

Executive	Title	Restricted Stock (Shares)		Stock Options (Shares)
Vuong Trieu	Chief Executive Officer		209,302		313,953
Chulho Park	Chief Technology Officer		162,791		244,186
Amit Shah	Chief Financial Officer		148,837		223,256

●	our ability to successfully commercialize our products and services on a large enough scale to generate profitable operations;
●	our ability to maintain and develop relationships with customers and suppliers;
●	our ability to successfully integrate acquired businesses or new products, or to realize anticipated synergies in connection with acquisitions of businesses or products;
●	expectations concerning our ability to raise additional funding and to continue as a going concern;
●	our ability to successfully implement our business plan; ~~and~~
●	our ability to avoid, or to adequately address any intellectual property claims brought by third parties; and
●	the anticipated impact of any changes in industry regulation.

	~~(1)~~	~~changing the name of the Company to “Oncotelic Therapeutics, Inc.” and to changing the Company’s ticker symbol (the “~~~~Name Change~~~~”);~~

	~~(2)~~	amending the Company’s Amended and Restated 2015 Equity Incentive Plan to increase the number of shares of Common Stock available for issuance from 7.25 million shares to 27.25 million shares, and increasing the maximum number of stock awards that may be issued in any fiscal year from 500,000 to 1,000,000 shares (the “~~Plan Amendment~~~~”);~~

	~~(3)~~	~~increasing the authorized number of shares of Common Stock from 150,000,000 to 750,000,000 (the “~~~~Capital Increase~~~~”); and~~

	~~(4)~~	~~amending and restating the certificate of incorporation for the Company to give effect to the Name Change, Capital Increase and forum selection provision.~~

	Nine months ended September 30,
	2020			2019
Net cash used in operating activities	$	(1,344,317	)	$	(1,336,295	)
Net cash provided by investing activities		-			182,883
Net cash provided by financing activities		2,624,541			1,162,120
Increase in cash	$	1,280,224		$	13,708

	Nine month ended Sept. 30,
	2021			2020
Net cash provided by (used in) operating activities	$	(3,367	)	$	(1,324	)
Net cash provided by financing activities		2,971			2,624
Increase (decrease) in cash	$	(396	)	$	1,300

●	Lack of formal policies and procedures;
●	Lack of a functioning audit committee and independent directors on the Company’s board of directors to oversee financial reporting responsibilities;
●	Inadequate or lack of segregation of duties;
●
●	Lack of dedicated resources and experienced personnel to design and implement internal control procedures to support financial reporting objectives;
●
●	Lack of qualified accounting personnel to prepare and report financial information in accordance with GAAP; and
●
●	Lack of risk assessment procedures on internal controls to detect financial reporting risks on a timely manner.

●	Continue to search for, evaluate and recruit qualified independent outside directors;
●	Hire qualified accounting personnel to prepare and report financial information in accordance with GAAP;
●
●	Identify gaps in our skills base and the expertise of our staff required to meet the financial reporting requirements of a public company; and
●
●	Continue to develop policies and procedures on internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.

●	Hire personnel internally or consultants to assist in developing policies and procedures on internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.